{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyMupfAIKYMd5O9BlCPBCP/q",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/mamantaroking/Dashboard-for-Duopharma/blob/main/scraping_scripts.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pip install selenium requests pandas numpy pdfplumber beautifulsoup4"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XEDUSvEbPsls",
        "outputId": "9c1c859b-645e-421d-b5ba-4d745f4b86c0"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: selenium in /usr/local/lib/python3.10/dist-packages (4.27.1)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (2.32.3)\n",
            "Requirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (2.2.2)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (1.26.4)\n",
            "Requirement already satisfied: pdfplumber in /usr/local/lib/python3.10/dist-packages (0.11.5)\n",
            "Requirement already satisfied: beautifulsoup4 in /usr/local/lib/python3.10/dist-packages (4.12.3)\n",
            "Requirement already satisfied: urllib3<3,>=1.26 in /usr/local/lib/python3.10/dist-packages (from urllib3[socks]<3,>=1.26->selenium) (2.2.3)\n",
            "Requirement already satisfied: trio~=0.17 in /usr/local/lib/python3.10/dist-packages (from selenium) (0.28.0)\n",
            "Requirement already satisfied: trio-websocket~=0.9 in /usr/local/lib/python3.10/dist-packages (from selenium) (0.11.1)\n",
            "Requirement already satisfied: certifi>=2021.10.8 in /usr/local/lib/python3.10/dist-packages (from selenium) (2024.12.14)\n",
            "Requirement already satisfied: typing_extensions~=4.9 in /usr/local/lib/python3.10/dist-packages (from selenium) (4.12.2)\n",
            "Requirement already satisfied: websocket-client~=1.8 in /usr/local/lib/python3.10/dist-packages (from selenium) (1.8.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests) (3.10)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas) (2024.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.10/dist-packages (from pandas) (2024.2)\n",
            "Requirement already satisfied: pdfminer.six==20231228 in /usr/local/lib/python3.10/dist-packages (from pdfplumber) (20231228)\n",
            "Requirement already satisfied: Pillow>=9.1 in /usr/local/lib/python3.10/dist-packages (from pdfplumber) (11.0.0)\n",
            "Requirement already satisfied: pypdfium2>=4.18.0 in /usr/local/lib/python3.10/dist-packages (from pdfplumber) (4.30.1)\n",
            "Requirement already satisfied: cryptography>=36.0.0 in /usr/local/lib/python3.10/dist-packages (from pdfminer.six==20231228->pdfplumber) (43.0.3)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.10/dist-packages (from beautifulsoup4) (2.6)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas) (1.17.0)\n",
            "Requirement already satisfied: attrs>=23.2.0 in /usr/local/lib/python3.10/dist-packages (from trio~=0.17->selenium) (24.3.0)\n",
            "Requirement already satisfied: sortedcontainers in /usr/local/lib/python3.10/dist-packages (from trio~=0.17->selenium) (2.4.0)\n",
            "Requirement already satisfied: outcome in /usr/local/lib/python3.10/dist-packages (from trio~=0.17->selenium) (1.3.0.post0)\n",
            "Requirement already satisfied: sniffio>=1.3.0 in /usr/local/lib/python3.10/dist-packages (from trio~=0.17->selenium) (1.3.1)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from trio~=0.17->selenium) (1.2.2)\n",
            "Requirement already satisfied: wsproto>=0.14 in /usr/local/lib/python3.10/dist-packages (from trio-websocket~=0.9->selenium) (1.2.0)\n",
            "Requirement already satisfied: pysocks!=1.5.7,<2.0,>=1.5.6 in /usr/local/lib/python3.10/dist-packages (from urllib3[socks]<3,>=1.26->selenium) (1.7.1)\n",
            "Requirement already satisfied: cffi>=1.12 in /usr/local/lib/python3.10/dist-packages (from cryptography>=36.0.0->pdfminer.six==20231228->pdfplumber) (1.17.1)\n",
            "Requirement already satisfied: h11<1,>=0.9.0 in /usr/local/lib/python3.10/dist-packages (from wsproto>=0.14->trio-websocket~=0.9->selenium) (0.14.0)\n",
            "Requirement already satisfied: pycparser in /usr/local/lib/python3.10/dist-packages (from cffi>=1.12->cryptography>=36.0.0->pdfminer.six==20231228->pdfplumber) (2.22)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import logging\n",
        "from selenium import webdriver\n",
        "from selenium.webdriver.common.by import By\n",
        "from selenium.webdriver.support.ui import WebDriverWait\n",
        "from selenium.webdriver.support import expected_conditions as EC\n",
        "from selenium.webdriver.firefox.service import Service\n",
        "from selenium.webdriver.common.action_chains import ActionChains\n",
        "from selenium.common.exceptions import StaleElementReferenceException\n",
        "from urllib.parse import urljoin, quote\n",
        "from bs4 import BeautifulSoup\n",
        "import requests\n",
        "import pandas as pd\n",
        "import numpy as np\n",
        "import time\n",
        "import re\n",
        "import sys\n",
        "import os\n",
        "import json\n",
        "import io\n",
        "import pdfplumber"
      ],
      "metadata": {
        "id": "dlGLdunWPlbf"
      },
      "execution_count": 1,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **NPRA**"
      ],
      "metadata": {
        "id": "UMsqsb1CZMVF"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Functions"
      ],
      "metadata": {
        "id": "LQLPeNbHaGwq"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def replace_newlines_with_spaces(df):\n",
        "    return df.replace([r'\\r', r'\\n'], ' ', regex=True)"
      ],
      "metadata": {
        "id": "TfUocO-mZYri"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "# function used to filter the kategori/category and status\n",
        "# columns based on their dca number\n",
        "def filter_dataframe(df, dca):\n",
        "    df_filtered = pd.DataFrame()\n",
        "\n",
        "    # DCA382 is separated because of the space (' ')\n",
        "    # replacing newline (\\n) between PRESCRIPTION- and FULL\n",
        "\n",
        "    if dca == 382:\n",
        "        if 'Kategori' in df.columns or 'Status' in df.columns:\n",
        "            df_filtered = df[\n",
        "                df['Kategori'] == 'PRESCRIPTION- FULL'\n",
        "            ]\n",
        "            df_filtered = df_filtered[\n",
        "                df_filtered['Status'] == 'NEW PRODUCT APPROVED'\n",
        "                ]\n",
        "\n",
        "        '''if 'Status' in df.columns:\n",
        "            df_filtered = df_filtered[\n",
        "                df_filtered['Status'] == 'NEW PRODUCT APPROVED'\n",
        "            ]'''\n",
        "\n",
        "    elif dca == 353:\n",
        "        if 'Status' in df.columns:\n",
        "            df_filtered = df[\n",
        "                df['Status'].isin(\n",
        "                    [\n",
        "                        'New Registration Approval',\n",
        "                        'New Product Registration',\n",
        "                        'NEW PRODUCT REGISTRATION',\n",
        "                        'New Registration',\n",
        "                        'New Product Approved',\n",
        "                        'New Registrati on Approval',\n",
        "                        'New Registrati on',\n",
        "                        'NEW PRODUCT'\n",
        "                    ]\n",
        "                )\n",
        "            ]\n",
        "\n",
        "            df_filtered = df_filtered[[\n",
        "                'Bil.',\n",
        "                'No. Rujukan',\n",
        "                'No. Pendaftaran MAL',\n",
        "                'Nama Produk',\n",
        "                'Pemegang',\n",
        "                'Pengilang',\n",
        "                'Tarikh Daftar',\n",
        "                'Tarikh Luput',\n",
        "                'Status',\n",
        "            ]]\n",
        "\n",
        "    # Same as DCA382\n",
        "    elif dca < 363 and dca > 353:\n",
        "        if 'Kategori' in df.columns or 'Status' in df.columns:\n",
        "            df_filtered = df[\n",
        "                df['Kategori'].isin(\n",
        "                    [\n",
        "                        'PRESCRIPTION- FULL',\n",
        "                        'PRESCRIPTI ON-FULL',\n",
        "                        'PRESCRIPTION-FULL'\n",
        "                    ]\n",
        "                )\n",
        "            ]\n",
        "\n",
        "            df_filtered = df_filtered[\n",
        "                df_filtered['Status'] == 'NEW PRODUCT APPROVED'\n",
        "            ]\n",
        "\n",
        "        '''if 'Status' in df.columns:\n",
        "            df_filtered = df_filtered[\n",
        "                df_filtered['Status'] == 'NEW PRODUCT APPROVED'\n",
        "            ]'''\n",
        "\n",
        "    # Same reason to previous condition but with more variations\n",
        "    # There're 4 keywords: New Registration Approval/Approved,\n",
        "    # New Product Approved, New Product Registration\n",
        "    #  and New Registration\n",
        "    elif dca < 354 or dca == 33 and dca != 353:\n",
        "        if 'Status' in df.columns:\n",
        "            df_filtered = df[\n",
        "                df['Status'].isin(\n",
        "                    [\n",
        "                        'New Registration Approval',\n",
        "                        'New Product Registration',\n",
        "                        'NEW PRODUCT REGISTRATION',\n",
        "                        'New Registration',\n",
        "                        'New Product Approved',\n",
        "                        'New Registrati on Approval',\n",
        "                        'New Registrati on'\n",
        "                    ]\n",
        "                )\n",
        "            ]\n",
        "\n",
        "        # No filtering applied if neither column is found\n",
        "        else:\n",
        "            print(\"Status is not in the DataFrame.\")\n",
        "            df_filtered = df\n",
        "\n",
        "    # To filter the rest of the dca files\n",
        "    else:\n",
        "        if 'Kategori' in df.columns:\n",
        "            df_filtered = df[\n",
        "                df['Kategori'] == 'PRESCRIPTION-FULL'\n",
        "            ]\n",
        "\n",
        "        elif 'Category' in df.columns:\n",
        "            df_filtered = df[\n",
        "                df['Category'] == 'PRESCRIPTION-FULL'\n",
        "            ]\n",
        "\n",
        "        # No filtering applied if neither column is found\n",
        "        else:\n",
        "            print(\"Neither 'Kategori' nor 'Category' is in the DataFrame.\")\n",
        "            df_filtered = df\n",
        "\n",
        "        if 'Status' in df.columns:\n",
        "            df_filtered = df_filtered[\n",
        "                df_filtered['Status'] == 'NEW PRODUCT APPROVED'\n",
        "            ]\n",
        "\n",
        "    return df_filtered\n"
      ],
      "metadata": {
        "id": "xLNNI24GaMBy"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "# function that takes url, and columns to extract\n",
        "# the pdf file into a pandas dataframe\n",
        "def process_new_entry(url, columns, text):\n",
        "    print(f\"Processing new entry: {url}\")\n",
        "    try:\n",
        "        # Get the PDF from the NPRA url into session\n",
        "        response = requests.get(url)\n",
        "        pdf_file = io.BytesIO(response.content)\n",
        "\n",
        "        # Using pdfplumber open the pdf file\n",
        "        #  and create the pdf dataframe\n",
        "        pdf = pdfplumber.open(pdf_file)\n",
        "        df = pd.DataFrame(columns=columns)\n",
        "\n",
        "        # Determine the number of pages in the PDF\n",
        "        size = len(pdf.pages)\n",
        "\n",
        "        # Using a for loop to iterate through each page\n",
        "        # of the pdf to extract the data\n",
        "        # within each page into a pandas dataframe\n",
        "        for i in range(size):\n",
        "            # set the current page of the pdf\n",
        "            page = pdf.pages[i]\n",
        "\n",
        "            # Extract table from the current page\n",
        "            tables = page.extract_table()\n",
        "\n",
        "            if tables:\n",
        "                # Insert the extracted data from the\n",
        "                # current page into a new dataframe\n",
        "                each_page_data = pd.DataFrame(\n",
        "                    tables,\n",
        "                    columns=columns\n",
        "                )\n",
        "\n",
        "                # print(f\"Appending data with shape: {each_page_data.shape}\")\n",
        "\n",
        "                # Concatenate the dataframe containing extracted\n",
        "                # data from the current page with pdf dataframe\n",
        "                df = pd.concat(\n",
        "                    [df, each_page_data],\n",
        "                    ignore_index=True\n",
        "                )\n",
        "                df['DCA Number'] = text\n",
        "\n",
        "\n",
        "        # Return pdf dataframe\n",
        "        return df\n",
        "\n",
        "    # Print exception in case an error occure\n",
        "    except Exception as e:\n",
        "        print(f\"An error occurred: {e}\")\n"
      ],
      "metadata": {
        "id": "68sWTLMHaTYv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Scraping Scripts\n",
        "\n"
      ],
      "metadata": {
        "id": "dNnIkKDSaWN3"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### *Fully automatic – All in one*"
      ],
      "metadata": {
        "id": "cdGz9H6IclGV"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "    ### *Fully automatic  All in one*"
      ],
      "metadata": {
        "id": "ON9YMMGibC66"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# The main function of the program\n",
        "def main():\n",
        "    # URL of the webpage to scrape (NPRA)\n",
        "    base_url = \"https://www.npra.gov.my/index.php/en/informationen/new-products-indication/new-products-approved-quest3.html\"\n",
        "    response = requests.get(base_url)\n",
        "\n",
        "    # Initialize beautiful soup to grab all 'a' component\n",
        "    # that contains the HREF link for the pdf files\n",
        "    if response.status_code == 200:\n",
        "        soup = BeautifulSoup(\n",
        "            response.text, 'html.parser'\n",
        "        )\n",
        "        links = soup.find_all('a')\n",
        "        # Define array that can store multiple dataframes\n",
        "        # for concatenation at the end of the program\n",
        "        dfs = []\n",
        "\n",
        "        # Define dataframe columns for DCA354 and later\n",
        "        newer_columns = [\n",
        "            'Bil.',\n",
        "            'No. Rujukan',\n",
        "            'No. Pendaftaran MAL',\n",
        "            'Nama Produk',\n",
        "            'Pemegang',\n",
        "            'Pengilang',\n",
        "            'Status',\n",
        "            'Kategori',\n",
        "            'Tarikh Daftar',\n",
        "            'Tarikh Luput',\n",
        "        ]\n",
        "\n",
        "        # Define dataframe columns for DCA353 and prior\n",
        "        older_columns = [\n",
        "            'Bil.',\n",
        "            'No. Rujukan',\n",
        "            'No. Pendaftaran MAL',\n",
        "            'Nama Produk',\n",
        "            'Pemegang',\n",
        "            'Pengilang',\n",
        "            'Tarikh Daftar',\n",
        "            'Tarikh Luput',\n",
        "            'Status',\n",
        "        ]\n",
        "\n",
        "        column_355 = [\n",
        "            'Bil.',\n",
        "            'No. Pendaftaran MAL',\n",
        "            'Nama Produk',\n",
        "            'Pemegang',\n",
        "            'Pengilang',\n",
        "            'Status',\n",
        "            'Kategori',\n",
        "            'Tarikh Daftar',\n",
        "            'Tarikh Luput',\n",
        "        ]\n",
        "\n",
        "        column_353 = [\n",
        "            'Bil.',\n",
        "            'No. Rujukan',\n",
        "            'No. Pendaftaran MAL',\n",
        "            'Nama Produk',\n",
        "            'Pemegang',\n",
        "            'Pengilang',\n",
        "            'Status',\n",
        "            'Tarikh Daftar',\n",
        "            'Tarikh Luput',\n",
        "        ]\n",
        "\n",
        "\n",
        "        # try:\n",
        "        # For loop to iterate through the individual\n",
        "        # 'a' components to get the href links\n",
        "        for link in links:\n",
        "            # Find the href arguement to get the pdf urls\n",
        "            href = link.get('href')\n",
        "            text = link.text.strip()\n",
        "\n",
        "            # Match the DCA number and convert into Integer\n",
        "            if href and re.match(r'^DCA\\s*\\d+', text):\n",
        "                dca_number = int(\n",
        "                    re.search(r'\\d+', text).group()\n",
        "                )\n",
        "                print(text)\n",
        "\n",
        "                # Piece together the base url and the\n",
        "                # HREF url to get access to the pdf file\n",
        "                full_url = urljoin(base_url, href)\n",
        "                encoded_url = quote(\n",
        "                    full_url, safe=':/?=&%'\n",
        "                )\n",
        "                print(encoded_url)\n",
        "\n",
        "                # Only loop between 354 and above\n",
        "                if dca_number == 353:\n",
        "                    df = process_new_entry(\n",
        "                        encoded_url,\n",
        "                        column_353,\n",
        "                        text\n",
        "                    )\n",
        "\n",
        "                elif dca_number == 355:\n",
        "                    df = process_new_entry(\n",
        "                        encoded_url,\n",
        "                        column_355,\n",
        "                        text\n",
        "                    )\n",
        "\n",
        "\n",
        "                elif dca_number >= 354:\n",
        "                    df = process_new_entry(\n",
        "                        encoded_url,\n",
        "                        newer_columns,\n",
        "                        text\n",
        "                    )\n",
        "\n",
        "                # only loop between 353 and below\n",
        "                elif dca_number < 354:\n",
        "                    df = process_new_entry(\n",
        "                        encoded_url,\n",
        "                        older_columns,\n",
        "                        text\n",
        "                    )\n",
        "\n",
        "                if df is not None:\n",
        "                    df = df.reset_index(drop=True)\n",
        "\n",
        "                    # Apply function to replace\n",
        "                    # newlines with spaces\n",
        "                    df = replace_newlines_with_spaces(df)\n",
        "\n",
        "                    # Apply function that filters the\n",
        "                    # dataframes for specific keywords\n",
        "                    df = filter_dataframe(df, dca_number)\n",
        "\n",
        "                    print(f\"Final DataFrame shape for {text}: {df.shape}\")\n",
        "\n",
        "                    # Add in the extracted pdf into the array\n",
        "                    dfs.append(df)\n",
        "\n",
        "        # Concatenate all pdf dataframes into one big df\n",
        "        df = pd.concat(dfs, ignore_index=True)\n",
        "        print(\"Concatenating complete!\")\n",
        "\n",
        "        # Add regs admin and country column\n",
        "        df.insert(0, 'Regulatory Admin', 'NPRA')\n",
        "        df.insert(1, 'Country Name', 'Malaysia')\n",
        "        df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "        # Save csv file\n",
        "        df.to_csv(\"Filtered_DCA.csv\", index=False)\n",
        "        print('Saving successful!')\n",
        "\n",
        "        # Raise exceptions if an error occured\n",
        "        '''except Exception as e:\n",
        "            print(f\"An error occurred: {e}\")\n",
        "        except IndexError as e:\n",
        "            print(f\"IndexError occurred: {e}\")\n",
        "        except ValueError as e:\n",
        "            print(f\"ValueError occurred: {e}\")'''\n",
        "\n",
        "    else:\n",
        "        print(f\"Failed to retrieve the webpage. Status code: {response.status_code}\")\n",
        "\n",
        "# Main function trigger\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "id": "mvzByf7xabeW"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### *Auto only one - For latest data only*"
      ],
      "metadata": {
        "id": "c4s_w8bfbMjn"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "# The main function of the program\n",
        "def main():\n",
        "    # URL of the webpage to scrape (NPRA)\n",
        "    base_url = \"https://www.npra.gov.my/index.php/en/informationen/new-products-indication/new-products-approved-quest3.html\"\n",
        "    response = requests.get(base_url)\n",
        "\n",
        "    # Initialize beautiful soup to grab all 'a' component\n",
        "    # that contains the the HREF link for the pdf files\n",
        "    if response.status_code == 200:\n",
        "        soup = BeautifulSoup(\n",
        "            response.text, 'html.parser'\n",
        "        )\n",
        "        links = soup.find_all('a')\n",
        "        print(links)\n",
        "        # Define array that can store multiple dataframes\n",
        "        # for concatenation at the end of the program\n",
        "        dfs = []\n",
        "\n",
        "        # Define dataframe columns for DCA354 and later\n",
        "        newer_columns = [\n",
        "            'Bil.',\n",
        "            'No. Rujukan',\n",
        "            'No. Pendaftaran MAL',\n",
        "            'Nama Produk',\n",
        "            'Pemegang',\n",
        "            'Pengilang',\n",
        "            'Status',\n",
        "            'Kategori',\n",
        "            'Tarikh Daftar',\n",
        "            'Tarikh Luput',\n",
        "        ]\n",
        "\n",
        "\n",
        "        try:\n",
        "            # For loop to iterate through the individual\n",
        "            # 'a' components to get the href links\n",
        "            for link in links:\n",
        "                # Find the href arguement to get the pdf urls\n",
        "                href = link.get('href')\n",
        "                text = link.text.strip()\n",
        "\n",
        "                # Match the DCA number and convert into Integer\n",
        "                if href and re.match(r'^DCA\\s*\\d+', text):\n",
        "                    dca_number = int(\n",
        "                        re.search(r'\\d+', text).group()\n",
        "                    )\n",
        "                    print(text)\n",
        "\n",
        "                    # Piece together the base url and the\n",
        "                    # HREF url to get access to the pdf file\n",
        "                    full_url = urljoin(base_url, href)\n",
        "                    encoded_url = quote(\n",
        "                        full_url, safe=':/?=&%'\n",
        "                    )\n",
        "                    print(encoded_url)\n",
        "\n",
        "\n",
        "                    # Scrape the data\n",
        "                    df = process_new_entry(\n",
        "                        encoded_url,\n",
        "                        newer_columns,\n",
        "                        text\n",
        "                    )\n",
        "\n",
        "\n",
        "                    if df is not None:\n",
        "                        df = df.reset_index(drop=True)\n",
        "\n",
        "                        # Apply function to replace\n",
        "                        # newlines with spaces\n",
        "                        df = replace_newlines_with_spaces(df)\n",
        "\n",
        "                        # Apply function that filters the\n",
        "                        # dataframes for specific keywords\n",
        "                        df = filter_dataframe(df, dca_number)\n",
        "\n",
        "                        print(\n",
        "                            f\"Final DataFrame shape for {text}: {df.shape}\"\n",
        "                        )\n",
        "\n",
        "                        # Add in the extracted pdf into the array\n",
        "                        dfs.append(df)\n",
        "\n",
        "                        break\n",
        "\n",
        "            # Concatenate all pdf dataframes into one big df\n",
        "            df = pd.concat(dfs, ignore_index=True)\n",
        "            print(\"Concatenating complete!\")\n",
        "\n",
        "            # Add regs admin and country column\n",
        "            df.insert(0, 'Regulatory Admin', 'HSA')\n",
        "            df.insert(1, 'Country Name', 'Singapore')\n",
        "            df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "            # Save csv file\n",
        "            df.to_csv(\"Filtered_DCA.csv\", index=False)\n",
        "            print('Saving successful!')\n",
        "\n",
        "        # Raise exceptions if an error occured\n",
        "        except Exception as e:\n",
        "            print(f\"An error occurred: {e}\")\n",
        "        except IndexError as e:\n",
        "            print(f\"IndexError occurred: {e}\")\n",
        "        except ValueError as e:\n",
        "            print(f\"ValueError occurred: {e}\")\n",
        "\n",
        "    else:\n",
        "        print(f\"Failed to retrieve the webpage. Status code: {response.status_code}\")\n",
        "\n",
        "# Main function trigger\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "id": "3iVxC1KubQkc"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### *Manual - Only one*"
      ],
      "metadata": {
        "id": "l5tlZW3cbjUf"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Working with style(filter) (Use DCA357)\n",
        "import pdfplumber\n",
        "import pandas as pd\n",
        "\n",
        "# Open pdf with pdfplumber\n",
        "# pdf = pdfplumber.open(\"DCA357.pdf\")\n",
        "pdf = pdfplumber.open(\"DCA353.pdf\")\n",
        "\n",
        "dca = 353\n",
        "\n",
        "columns = [\n",
        "            'Bil.',\n",
        "            'No. Rujukan',\n",
        "            'No. Pendaftaran MAL',\n",
        "            'Nama Produk',\n",
        "            'Pemegang',\n",
        "            'Pengilang',\n",
        "            'Status',\n",
        "            'Tarikh Daftar',\n",
        "            'Tarikh Luput',\n",
        "        ]\n",
        "\n",
        "df = pd.DataFrame(columns=columns)\n",
        "\n",
        "# Determine the number of pages in the PDF\n",
        "size = len(pdf.pages)\n",
        "\n",
        "# Using a for loop to iterate through each page\n",
        "# of the pdf to extract the data\n",
        "# within each page into a pandas dataframe\n",
        "for i in range(size):\n",
        "    # set the current page of the pdf\n",
        "    page = pdf.pages[i]\n",
        "\n",
        "    # Extract table from the current page\n",
        "    tables = page.extract_table()\n",
        "\n",
        "    if tables:\n",
        "        # Insert the extracted data from the\n",
        "        # current page into a new dataframe\n",
        "        each_page_data = pd.DataFrame(\n",
        "            tables,\n",
        "            columns=columns\n",
        "        )\n",
        "\n",
        "        # print(f\"Appending data with shape: {each_page_data.shape}\")\n",
        "\n",
        "        # Concatenate the dataframe containing extracted\n",
        "        # data from the current page with pdf dataframe\n",
        "        df = pd.concat(\n",
        "            [df, each_page_data],\n",
        "            ignore_index=True\n",
        "        )\n",
        "        df['DCA Number'] = dca\n",
        "\n",
        "# print(df.head())\n",
        "# print(df.columns)\n",
        "# print(df.columns.levels)\n",
        "\n",
        "# Reset the column names to a single level\n",
        "# df.columns = df.columns.get_level_values(0)\n",
        "df = replace_newlines_with_spaces(df)  # Apply the function here\n",
        "df = filter_dataframe(df, dca)  # Filter df to only include required keyword\n",
        "\n",
        "# Filter the dataframe\n",
        "# df = df[df['Catatan'] == 'New\\nRegistration\\nApproval']\n",
        "# df = df[df['Status'] == 'NEW PRODUCT\\nAPPROVED']\n",
        "df.to_csv('DCA353.csv', index=False)"
      ],
      "metadata": {
        "id": "-7hOGYfrbmpm"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Pdfplumber Visual"
      ],
      "metadata": {
        "id": "DDb0rQYYcvUD"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "pdf = pdfplumber.open(\"DCA354.pdf\")\n",
        "page0 = pdf.pages[0]\n",
        "vis = page0.to_image()\n",
        "vis.debug_tablefinder({})"
      ],
      "metadata": {
        "id": "74Dfxo_sc0jv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **HSA**"
      ],
      "metadata": {
        "id": "Laaq_fvuTsU2"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "For Scraping NDA"
      ],
      "metadata": {
        "id": "DAlETStXWhud"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from bs4 import BeautifulSoup\n",
        "import requests\n",
        "import pandas as pd\n",
        "\n",
        "# 1st base url configuration\n",
        "url1 = \"https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---\"\n",
        "# 2nd base url configuration\n",
        "url2 = 'https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-'\n",
        "# headers for beautifulsoup\n",
        "headers = {\n",
        "    'User-Agent': \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/42.0.2311.135 Safari/537.36 Edge/12.246\"}\n",
        "\n",
        "# Define columns\n",
        "column_def = [\n",
        "    'Product Name',\n",
        "    'Active Ingredient(s)',\n",
        "    'Application Type',\n",
        "    'Product Registrant',\n",
        "    'Approval Date',\n",
        "    'Registration Number'\n",
        "]\n",
        "\n",
        "\n",
        "# Function to generate all the different variations\n",
        "# in the urls based on the date (years and months)\n",
        "def generate_url_variations(start_year, end_year):\n",
        "\n",
        "    # List of months in whole spelling\n",
        "    full_months = [\n",
        "        'january',\n",
        "        'february',\n",
        "        'march',\n",
        "        'april',\n",
        "        'may',\n",
        "        'june',\n",
        "        'july',\n",
        "        'august',\n",
        "        'september',\n",
        "        'october',\n",
        "        'november',\n",
        "        'december'\n",
        "    ]\n",
        "\n",
        "    # List of months in 3 letter spellings\n",
        "    short_months = [\n",
        "        'jan',\n",
        "        'feb',\n",
        "        'mar',\n",
        "        'apr',\n",
        "        'may',\n",
        "        'jun',\n",
        "        'jul',\n",
        "        'aug',\n",
        "        'sep',\n",
        "        'oct',\n",
        "        'nov',\n",
        "        'dec'\n",
        "    ]\n",
        "\n",
        "    # List array to house all the urls\n",
        "    urls = []\n",
        "\n",
        "    # Start loop to iterate through the years\n",
        "    # Start year = 2016, end yer = 2024\n",
        "    for year in range(start_year, end_year + 1):\n",
        "\n",
        "        # Start loop for 3 letter spelling months\n",
        "        for month in short_months:\n",
        "            # For year 2019 and earlier\n",
        "            if year < 2019:\n",
        "                urls.append(f\"{url2}{month}-{year}\")\n",
        "\n",
        "            # For year 2019\n",
        "            elif year == 2019:\n",
        "                if month == 'jan' or month == 'feb' or month == 'mar' or month == 'apr':\n",
        "                    urls.append(f\"{url2}{month}-{year}\")\n",
        "                elif month == 'jul':\n",
        "                    pass\n",
        "                else:\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            # For year 2020\n",
        "            elif year == 2020:\n",
        "                if month == 'jun' or month == 'jul':\n",
        "                    pass\n",
        "                else:\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            # For year 2021\n",
        "            elif year == 2021:\n",
        "                if month == 'jan' or month == 'feb' or month == 'mar' or month == 'apr':\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            # For year 2022\n",
        "            elif year == 2022:\n",
        "                if month == 'feb':\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            # For year 2023\n",
        "            elif year == 2023:\n",
        "                if month == 'sep':\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            else:\n",
        "                break\n",
        "        # End loop for short spelling months\n",
        "\n",
        "        # Start loop for whole spelliog months\n",
        "        for month in full_months:\n",
        "\n",
        "            # For year 2019\n",
        "            if year == 2019:\n",
        "                if month == 'july':\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "                else:\n",
        "                    pass\n",
        "\n",
        "            # For year 2020\n",
        "            elif year == 2020:\n",
        "                if month == 'june' or month == 'july':\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "                else:\n",
        "                    pass\n",
        "\n",
        "            # For year 2021\n",
        "            elif year == 2021:\n",
        "                if month == 'january' or month == 'february' or month == 'march' or month == 'april':\n",
        "                    pass\n",
        "                else:\n",
        "                    urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            # For year 2022 and later\n",
        "            elif year > 2021:\n",
        "                urls.append(f\"{url1}{month}-{year}\")\n",
        "\n",
        "            else:\n",
        "                pass\n",
        "\n",
        "        # End for loop for whole month spellings\n",
        "    # End loop for years\n",
        "\n",
        "    return urls\n",
        "\n",
        "\n",
        "# Function definition to scrape the tables\n",
        "def scraping(url):\n",
        "\n",
        "    # Get response from the url\n",
        "    r = requests.get(url=url, headers=headers)\n",
        "\n",
        "    # Initialize soup\n",
        "    soup = BeautifulSoup(r.content, \"html.parser\")\n",
        "\n",
        "    # Define output array\n",
        "    output_list = []\n",
        "\n",
        "    # Start loop to find all table element\n",
        "    for table_element in soup.findAll('tbody'):\n",
        "\n",
        "        # Start loop to find all rows in table element\n",
        "        for row in table_element.findAll('tr'):\n",
        "            columns = row.findAll('td')  # find columns\n",
        "\n",
        "            # if there is more than one column\n",
        "            if len(columns) > 1:\n",
        "\n",
        "                # Get the text from the second column\n",
        "                selected_column = columns[1].get_text(strip=True)\n",
        "\n",
        "                # Add text into the output array\n",
        "                output_list.append(selected_column)\n",
        "                print(output_list)\n",
        "        # Enf loop to find rows\n",
        "    # End loop to find tables\n",
        "\n",
        "    # Transpose the array so the rows become columns\n",
        "    reshaped_list = [\n",
        "        output_list[i:i + 6] for i in range(0, len(output_list), 6)\n",
        "    ]\n",
        "    df = pd.DataFrame(reshaped_list, columns=column_def)\n",
        "\n",
        "    print(df)\n",
        "    print(url)\n",
        "    return df\n",
        "\n",
        "\n",
        "# The main function\n",
        "def main():\n",
        "    # Generates the URLs that will be used for scraping\n",
        "    urls = generate_url_variations(2016, 2024)\n",
        "\n",
        "    # Array to store the returned dataframes from scraping\n",
        "    all_data = []\n",
        "\n",
        "    # Iterate through the urls list\n",
        "    for url in urls:\n",
        "        try:\n",
        "            # Get the dataframes from scraping\n",
        "            df = scraping(url)\n",
        "\n",
        "            # Append the returned dataframe into the list\n",
        "            all_data.append(df)\n",
        "        except Exception as e:\n",
        "            print(f\"Failed to scrape {url}: {e}\")\n",
        "\n",
        "    # Concatenated all the dataframes in the list into one\n",
        "    concatenated_df = pd.concat(\n",
        "        all_data,\n",
        "        ignore_index=True\n",
        "    )\n",
        "\n",
        "    # Add regs admin and country column\n",
        "    concatenated_df.insert(0, 'Regulatory Admin', 'HSA')\n",
        "    concatenated_df.insert(1, 'Country Name', 'Singapore')\n",
        "    concatenated_df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "    # Save to csv\n",
        "    concatenated_df.to_csv(\n",
        "        'hsa_combined_nda.csv',\n",
        "        index=False\n",
        "    )\n",
        "\n",
        "# Main function trigger\n",
        "if __name__ == '__main__':\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "id": "JMd4U50pKTfW",
        "outputId": "0b7e57dc-1963-4a05-eb3b-952032bd4cd5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "['VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TABLET 7MG/ 5MG & 14MG/ 10MG', 'Amlodipine and Perindopril Arginine', 'NDA-2: New dosage form, indication, dosing regimenNDA-3: New strength', 'SERVIER (S) PTE LTD', '01/10/2018', 'SIN15555P, SIN15556P, SIN15557P', 'TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND 80MG/40MG', 'Oxycodone hydrochloride / Naloxone hydrochloride dihydrate', 'NDA-3: New strength', 'MUNDIPHARMA PHARMACEUTICALS PTE. LTD.', '02/10/2018', 'SIN15560P, SIN15561P', 'SENSHIO FILM-COATED TABLET 60MG', 'Ospemifene', 'NDA-1: New chemical entity', 'SHIONOGI SINGAPORE PTE. LTD.', '26/10/2018', 'SIN15568P', 'IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ML']\n",
            "['VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TABLET 7MG/ 5MG & 14MG/ 10MG', 'Amlodipine and Perindopril Arginine', 'NDA-2: New dosage form, indication, dosing regimenNDA-3: New strength', 'SERVIER (S) PTE LTD', '01/10/2018', 'SIN15555P, SIN15556P, SIN15557P', 'TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND 80MG/40MG', 'Oxycodone hydrochloride / Naloxone hydrochloride dihydrate', 'NDA-3: New strength', 'MUNDIPHARMA PHARMACEUTICALS PTE. LTD.', '02/10/2018', 'SIN15560P, SIN15561P', 'SENSHIO FILM-COATED TABLET 60MG', 'Ospemifene', 'NDA-1: New chemical entity', 'SHIONOGI SINGAPORE PTE. LTD.', '26/10/2018', 'SIN15568P', 'IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ML', 'Durvalumab']\n",
            "['VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TABLET 7MG/ 5MG & 14MG/ 10MG', 'Amlodipine and Perindopril Arginine', 'NDA-2: New dosage form, indication, dosing regimenNDA-3: New strength', 'SERVIER (S) PTE LTD', '01/10/2018', 'SIN15555P, SIN15556P, SIN15557P', 'TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND 80MG/40MG', 'Oxycodone hydrochloride / Naloxone hydrochloride dihydrate', 'NDA-3: New strength', 'MUNDIPHARMA PHARMACEUTICALS PTE. LTD.', '02/10/2018', 'SIN15560P, SIN15561P', 'SENSHIO FILM-COATED TABLET 60MG', 'Ospemifene', 'NDA-1: New chemical entity', 'SHIONOGI SINGAPORE PTE. LTD.', '26/10/2018', 'SIN15568P', 'IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ML', 'Durvalumab', 'NDA-1: New biological entity']\n",
            "['VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TABLET 7MG/ 5MG & 14MG/ 10MG', 'Amlodipine and Perindopril Arginine', 'NDA-2: New dosage form, indication, dosing regimenNDA-3: New strength', 'SERVIER (S) PTE LTD', '01/10/2018', 'SIN15555P, SIN15556P, SIN15557P', 'TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND 80MG/40MG', 'Oxycodone hydrochloride / Naloxone hydrochloride dihydrate', 'NDA-3: New strength', 'MUNDIPHARMA PHARMACEUTICALS PTE. LTD.', '02/10/2018', 'SIN15560P, SIN15561P', 'SENSHIO FILM-COATED TABLET 60MG', 'Ospemifene', 'NDA-1: New chemical entity', 'SHIONOGI SINGAPORE PTE. LTD.', '26/10/2018', 'SIN15568P', 'IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ML', 'Durvalumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TABLET 7MG/ 5MG & 14MG/ 10MG', 'Amlodipine and Perindopril Arginine', 'NDA-2: New dosage form, indication, dosing regimenNDA-3: New strength', 'SERVIER (S) PTE LTD', '01/10/2018', 'SIN15555P, SIN15556P, SIN15557P', 'TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND 80MG/40MG', 'Oxycodone hydrochloride / Naloxone hydrochloride dihydrate', 'NDA-3: New strength', 'MUNDIPHARMA PHARMACEUTICALS PTE. LTD.', '02/10/2018', 'SIN15560P, SIN15561P', 'SENSHIO FILM-COATED TABLET 60MG', 'Ospemifene', 'NDA-1: New chemical entity', 'SHIONOGI SINGAPORE PTE. LTD.', '26/10/2018', 'SIN15568P', 'IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ML', 'Durvalumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2018']\n",
            "['VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TABLET 7MG/ 5MG & 14MG/ 10MG', 'Amlodipine and Perindopril Arginine', 'NDA-2: New dosage form, indication, dosing regimenNDA-3: New strength', 'SERVIER (S) PTE LTD', '01/10/2018', 'SIN15555P, SIN15556P, SIN15557P', 'TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND 80MG/40MG', 'Oxycodone hydrochloride / Naloxone hydrochloride dihydrate', 'NDA-3: New strength', 'MUNDIPHARMA PHARMACEUTICALS PTE. LTD.', '02/10/2018', 'SIN15560P, SIN15561P', 'SENSHIO FILM-COATED TABLET 60MG', 'Ospemifene', 'NDA-1: New chemical entity', 'SHIONOGI SINGAPORE PTE. LTD.', '26/10/2018', 'SIN15568P', 'IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ML', 'Durvalumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2018', 'SIN15569P']\n",
            "                                                   0  \\\n",
            "0  VIACORAM START TABLET 3.5MG/ 2.5MGVIACORAM TAB...   \n",
            "1  TARGIN PROLONGED RELEASE TABLETS 60MG/30MG AND...   \n",
            "2                    SENSHIO FILM-COATED TABLET 60MG   \n",
            "3  IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION ...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                Amlodipine and Perindopril Arginine   \n",
            "1  Oxycodone hydrochloride / Naloxone hydrochlori...   \n",
            "2                                         Ospemifene   \n",
            "3                                         Durvalumab   \n",
            "\n",
            "                                                   2  \\\n",
            "0  NDA-2: New dosage form, indication, dosing reg...   \n",
            "1                                NDA-3: New strength   \n",
            "2                         NDA-1: New chemical entity   \n",
            "3                       NDA-1: New biological entity   \n",
            "\n",
            "                                       3           4  \\\n",
            "0                    SERVIER (S) PTE LTD  01/10/2018   \n",
            "1  MUNDIPHARMA PHARMACEUTICALS PTE. LTD.  02/10/2018   \n",
            "2           SHIONOGI SINGAPORE PTE. LTD.  26/10/2018   \n",
            "3          ASTRAZENECA SINGAPORE PTE LTD  29/10/2018   \n",
            "\n",
            "                                 5  \n",
            "0  SIN15555P, SIN15556P, SIN15557P  \n",
            "1             SIN15560P, SIN15561P  \n",
            "2                        SIN15568P  \n",
            "3                        SIN15569P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-oct-2018\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P', 'HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 150MG/ML, 30MG/ML']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P', 'HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 150MG/ML, 30MG/ML', 'Emicizumab']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P', 'HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 150MG/ML, 30MG/ML', 'Emicizumab', 'NDA-1/3: New chemical entity, New strength']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P', 'HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 150MG/ML, 30MG/ML', 'Emicizumab', 'NDA-1/3: New chemical entity, New strength', 'ROCHE SINGAPORE PTE LTD']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P', 'HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 150MG/ML, 30MG/ML', 'Emicizumab', 'NDA-1/3: New chemical entity, New strength', 'ROCHE SINGAPORE PTE LTD', '09 Nov 2018']\n",
            "['ICLUSIG TABLET 15 MG AND 45 MG', 'Ponatinib HCl', 'NDA-1: New chemical entity', 'STEWARD CROSS PTE LTD', '19/11/2018', 'SIN15581P, SIN15582P', 'MIFEGYNE TABLETS 200MG', 'Mifepristone', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '23/11/2018', 'SIN15583P', 'KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL AND 500IU/VIAL', 'Antihemophilic factor (Recombinant)250 IU, Antihemophilic factor (Recombinant)500 IU,', 'NDA-2,3 : New manufacturing process, new strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '30 Nov 2018', 'SIN15587P, SIN15586P', 'PRIVIGEN SOLUTION FOR INFUSION 100g/L', 'Human Immunoglobulin', 'NDA-2 New formulation', 'CSL BEHRING PTE LTD', '7 Nov 2018', 'SIN15574P', 'DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) MENTHOL AND EUCALYPTUS FLAVOURDIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES (SUGAR FREE) HONEY LEMON FLAVOUR', 'Benzydamine Hydrochloride + Lignocaine Hydrochloride + 2,4 Dichlorobenzyl Alcohol', 'NDA-2: New formulation', 'Inova Pharmaceuticals (Singapore) Pte. Limited', '29 Nov 2018', 'SIN15584P, SIN15585P', 'HEPA-MERZ 5G/10ML Infusion CONCENTRATE', 'L-ornithine-L-aspartate', 'NDA-1: New chemical entity', 'MERZ ASIA PACIFIC PTE. LTD.', '09 Nov 2018', 'SIN15578P', 'HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 150MG/ML, 30MG/ML', 'Emicizumab', 'NDA-1/3: New chemical entity, New strength', 'ROCHE SINGAPORE PTE LTD', '09 Nov 2018', 'SIN15576P, SIN15577P']\n",
            "                                                   0  \\\n",
            "0                     ICLUSIG TABLET 15 MG AND 45 MG   \n",
            "1                             MIFEGYNE TABLETS 200MG   \n",
            "2  KOVALTRY POWDER AND SOLVENT FOR SOLUTION FOR I...   \n",
            "3              PRIVIGEN SOLUTION FOR INFUSION 100g/L   \n",
            "4  DIFFLAM PLUS ANAESTHETIC SORE THROAT LOZENGES ...   \n",
            "5             HEPA-MERZ 5G/10ML Infusion CONCENTRATE   \n",
            "6  HEMLIBRA (EMCIZUMAB) SOLUTION FOR INJECTION 15...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                      Ponatinib HCl   \n",
            "1                                       Mifepristone   \n",
            "2  Antihemophilic factor (Recombinant)250 IU, Ant...   \n",
            "3                               Human Immunoglobulin   \n",
            "4  Benzydamine Hydrochloride + Lignocaine Hydroch...   \n",
            "5                            L-ornithine-L-aspartate   \n",
            "6                                         Emicizumab   \n",
            "\n",
            "                                                   2  \\\n",
            "0                         NDA-1: New chemical entity   \n",
            "1                         NDA-1: New chemical entity   \n",
            "2  NDA-2,3 : New manufacturing process, new strength   \n",
            "3                              NDA-2 New formulation   \n",
            "4                             NDA-2: New formulation   \n",
            "5                         NDA-1: New chemical entity   \n",
            "6         NDA-1/3: New chemical entity, New strength   \n",
            "\n",
            "                                                   3            4  \\\n",
            "0                              STEWARD CROSS PTE LTD   19/11/2018   \n",
            "1  UNITED ITALIAN TRADING CORPORATION (PRIVATE) L...   23/11/2018   \n",
            "2                    BAYER (SOUTH EAST ASIA) PTE LTD  30 Nov 2018   \n",
            "3                                CSL BEHRING PTE LTD   7 Nov 2018   \n",
            "4     Inova Pharmaceuticals (Singapore) Pte. Limited  29 Nov 2018   \n",
            "5                        MERZ ASIA PACIFIC PTE. LTD.  09 Nov 2018   \n",
            "6                            ROCHE SINGAPORE PTE LTD  09 Nov 2018   \n",
            "\n",
            "                      5  \n",
            "0  SIN15581P, SIN15582P  \n",
            "1             SIN15583P  \n",
            "2  SIN15587P, SIN15586P  \n",
            "3             SIN15574P  \n",
            "4  SIN15584P, SIN15585P  \n",
            "5             SIN15578P  \n",
            "6  SIN15576P, SIN15577P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-nov-2018\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P', 'MAVIRET FILM-COATED TABLET 100MG/40MG']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P', 'MAVIRET FILM-COATED TABLET 100MG/40MG', 'Glecaprevir + Pibrentasvir']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P', 'MAVIRET FILM-COATED TABLET 100MG/40MG', 'Glecaprevir + Pibrentasvir', 'NDA-1: New chemical']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P', 'MAVIRET FILM-COATED TABLET 100MG/40MG', 'Glecaprevir + Pibrentasvir', 'NDA-1: New chemical', 'ABBVIE PTE. LTD.']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P', 'MAVIRET FILM-COATED TABLET 100MG/40MG', 'Glecaprevir + Pibrentasvir', 'NDA-1: New chemical', 'ABBVIE PTE. LTD.', '26/12/2018']\n",
            "['INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PREFILLED SYRINGE 0.5ML', 'Influenza Virus (NH) A/California/07/2009 X-181 (H1N1); Influenza Virus (NH) A/Texas/50/2012 (H3N2); Influenza Virus (NH) B/Brisbane/60/2008; Influenza Virus (NH) B/Massachusetts/2/2012', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.', '04/12/2018', 'SIN15591P', 'VOLTAREN 12 HOURS EMULGEL 2%', 'Diclofenac Diethylamine', 'NDA-2: New strength', 'GSK Consumer Healthcare Singapore Pte Ltd', '14/12/2018', 'SIN15598P', 'ESBRIET FILM COATED TABLET 267MG, 801MG', 'Pirfenidone', 'NDA-2, 3: New dosage form, new strength', 'ROCHE SINGAPORE PTE. LTD.', '18/12/2018', 'SIN15600P, SIN15601P', 'MAVIRET FILM-COATED TABLET 100MG/40MG', 'Glecaprevir + Pibrentasvir', 'NDA-1: New chemical', 'ABBVIE PTE. LTD.', '26/12/2018', 'SIN15603P']\n",
            "                                                   0  \\\n",
            "0  INFLUVAC TETRA, SUSPENSION FOR INJECTIONIN PRE...   \n",
            "1                       VOLTAREN 12 HOURS EMULGEL 2%   \n",
            "2            ESBRIET FILM COATED TABLET 267MG, 801MG   \n",
            "3              MAVIRET FILM-COATED TABLET 100MG/40MG   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Influenza Virus (NH) A/California/07/2009 X-18...   \n",
            "1                            Diclofenac Diethylamine   \n",
            "2                                        Pirfenidone   \n",
            "3                         Glecaprevir + Pibrentasvir   \n",
            "\n",
            "                                         2  \\\n",
            "0                   NDA-2: New combination   \n",
            "1                      NDA-2: New strength   \n",
            "2  NDA-2, 3: New dosage form, new strength   \n",
            "3                      NDA-1: New chemical   \n",
            "\n",
            "                                           3           4                     5  \n",
            "0  ABBOTT LABORATORIES (SINGAPORE) PTE. LTD.  04/12/2018             SIN15591P  \n",
            "1  GSK Consumer Healthcare Singapore Pte Ltd  14/12/2018             SIN15598P  \n",
            "2                  ROCHE SINGAPORE PTE. LTD.  18/12/2018  SIN15600P, SIN15601P  \n",
            "3                           ABBVIE PTE. LTD.  26/12/2018             SIN15603P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-dec-2018\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P', 'MINIRIN ORAL LYOPHILISATE 240 MCG']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P', 'MINIRIN ORAL LYOPHILISATE 240 MCG', 'Desmopressin acetate eqv. to Desmopressin']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P', 'MINIRIN ORAL LYOPHILISATE 240 MCG', 'Desmopressin acetate eqv. to Desmopressin', 'NDA-3: New strength']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P', 'MINIRIN ORAL LYOPHILISATE 240 MCG', 'Desmopressin acetate eqv. to Desmopressin', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PRIVATE LIMITED']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P', 'MINIRIN ORAL LYOPHILISATE 240 MCG', 'Desmopressin acetate eqv. to Desmopressin', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PRIVATE LIMITED', '22/01/2019']\n",
            "['BIKTARVY FILM-COATED TABLETS 50/200/25MG', 'Bictegravir sodium/ emtricitabine/ tenofovir alafenamide fumarate', 'NDA-1: New chemical entity', 'GILEAD SCIENCES SINGAPORE PTE LTD', '02/01/2019', 'SIN15604P', 'CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND 60 MG', 'Cabozantinib', 'NDA-1: New chemical entityNDA-3: New strength', 'IPSEN PHARMA PTE LTD', '03/01/2019', 'SIN15606P, SIN15607P, SIN15608P', 'PENTASA PROLONGED RELEASE GRANULES 4G/SACHET', 'Mesalazine', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PTE LTD', '18/01/2019', 'SIN15614P', 'MINIRIN ORAL LYOPHILISATE 240 MCG', 'Desmopressin acetate eqv. to Desmopressin', 'NDA-3: New strength', 'FERRING PHARMACEUTICALS PRIVATE LIMITED', '22/01/2019', 'SIN15615P']\n",
            "                                                   0  \\\n",
            "0           BIKTARVY FILM-COATED TABLETS 50/200/25MG   \n",
            "1  CABOMETYX FILM COATED TABLET 20 MG, 40 MG AND ...   \n",
            "2       PENTASA PROLONGED RELEASE GRANULES 4G/SACHET   \n",
            "3                  MINIRIN ORAL LYOPHILISATE 240 MCG   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Bictegravir sodium/ emtricitabine/ tenofovir a...   \n",
            "1                                       Cabozantinib   \n",
            "2                                         Mesalazine   \n",
            "3          Desmopressin acetate eqv. to Desmopressin   \n",
            "\n",
            "                                               2  \\\n",
            "0                     NDA-1: New chemical entity   \n",
            "1  NDA-1: New chemical entityNDA-3: New strength   \n",
            "2                            NDA-3: New strength   \n",
            "3                            NDA-3: New strength   \n",
            "\n",
            "                                         3           4  \\\n",
            "0        GILEAD SCIENCES SINGAPORE PTE LTD  02/01/2019   \n",
            "1                     IPSEN PHARMA PTE LTD  03/01/2019   \n",
            "2          FERRING PHARMACEUTICALS PTE LTD  18/01/2019   \n",
            "3  FERRING PHARMACEUTICALS PRIVATE LIMITED  22/01/2019   \n",
            "\n",
            "                                 5  \n",
            "0                        SIN15604P  \n",
            "1  SIN15606P, SIN15607P, SIN15608P  \n",
            "2                        SIN15614P  \n",
            "3                        SIN15615P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-jan-2019\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P', 'TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P', 'TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'MnB rLP2086 subfamily A, 120μg/ml, MnB rLP2086 subfamily B, 120μg/ml']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P', 'TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'MnB rLP2086 subfamily A, 120μg/ml, MnB rLP2086 subfamily B, 120μg/ml', 'NDA-1: New biological entity']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P', 'TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'MnB rLP2086 subfamily A, 120μg/ml, MnB rLP2086 subfamily B, 120μg/ml', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P', 'TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'MnB rLP2086 subfamily A, 120μg/ml, MnB rLP2086 subfamily B, 120μg/ml', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/02/2019']\n",
            "['CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.25 MG/7.5 MG, 12.5 MG/ 5 MG, 12.5 MG/7.5 MG, 25 MG/5 MG, 25 MG/ 7.5 MG', 'Carvedilol, Ivabradine', 'NDA-2: New combination, NDA-3: New strength', 'SERVIER (S) PTE LTD', '12/02/2019', 'SIN15624P, SIN15625P, SIN15626P, SIN15627P, SIN15628P, SIN15629P', 'TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'MnB rLP2086 subfamily A, 120μg/ml, MnB rLP2086 subfamily B, 120μg/ml', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/02/2019', 'SIN15634P']\n",
            "                                                   0  \\\n",
            "0  CARIVALAN FILM-COATED TABLET 6.25 MG/5 MG, 6.2...   \n",
            "1  TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DO...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                             Carvedilol, Ivabradine   \n",
            "1  MnB rLP2086 subfamily A, 120μg/ml, MnB rLP2086...   \n",
            "\n",
            "                                             2                       3  \\\n",
            "0  NDA-2: New combination, NDA-3: New strength     SERVIER (S) PTE LTD   \n",
            "1                 NDA-1: New biological entity  PFIZER PRIVATE LIMITED   \n",
            "\n",
            "            4                                                  5  \n",
            "0  12/02/2019  SIN15624P, SIN15625P, SIN15626P, SIN15627P, SI...  \n",
            "1  21/02/2019                                          SIN15634P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-feb-2019\n",
            "['KESTINE FILM-COATED TABLET 20MG']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P', 'REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, 36MCG/1.08ML, 72MCG/2.16ML']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P', 'REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, 36MCG/1.08ML, 72MCG/2.16ML', 'Follitropin Delta']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P', 'REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, 36MCG/1.08ML, 72MCG/2.16ML', 'Follitropin Delta', 'NDA-2: New dosage form, NDA-3: New strength']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P', 'REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, 36MCG/1.08ML, 72MCG/2.16ML', 'Follitropin Delta', 'NDA-2: New dosage form, NDA-3: New strength', 'FERRING PHARMACEUTICALS PRIVATE LIMITED']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P', 'REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, 36MCG/1.08ML, 72MCG/2.16ML', 'Follitropin Delta', 'NDA-2: New dosage form, NDA-3: New strength', 'FERRING PHARMACEUTICALS PRIVATE LIMITED', '25 MAR 2019']\n",
            "['KESTINE FILM-COATED TABLET 20MG', 'Micronized ebastine', 'NDA-3: New strength', 'ZUELLIG PHARMA PTE LTD', '12/03/2019', 'SIN15644P', 'TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/20MG/2.5MG, 100MG/20MG/5MG', 'Acetysalicylic acid, Atorvastatin, Ramipril', 'NDA-2: New combination, NDA-3: New strength', 'DCH AURIGA SINGAPORE', '19/03/2019', 'SIN15646P, SIN15647P, SIN15648P', 'JULUCA FILM-COATED TABLET 50MG/25MG', 'Dolutegravir / Rilpivirine', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE LTD', '22/03/2019', 'SIN15649P', 'REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 12MCG/0.36ML, 36MCG/1.08ML, 72MCG/2.16ML', 'Follitropin Delta', 'NDA-2: New dosage form, NDA-3: New strength', 'FERRING PHARMACEUTICALS PRIVATE LIMITED', '25 MAR 2019', 'SIN15650P, SIN15651P, SIN15652P']\n",
            "                                                   0  \\\n",
            "0                    KESTINE FILM-COATED TABLET 20MG   \n",
            "1  TRINOMIA HARD CAPSULES 100MG/20MG/10MG, 100MG/...   \n",
            "2                JULUCA FILM-COATED TABLET 50MG/25MG   \n",
            "3  REKOVELLE SOLUTION FOR INJECTION IN A PRE-FILL...   \n",
            "\n",
            "                                             1  \\\n",
            "0                          Micronized ebastine   \n",
            "1  Acetysalicylic acid, Atorvastatin, Ramipril   \n",
            "2                   Dolutegravir / Rilpivirine   \n",
            "3                            Follitropin Delta   \n",
            "\n",
            "                                             2  \\\n",
            "0                          NDA-3: New strength   \n",
            "1  NDA-2: New combination, NDA-3: New strength   \n",
            "2                       NDA-2: New combination   \n",
            "3  NDA-2: New dosage form, NDA-3: New strength   \n",
            "\n",
            "                                         3            4  \\\n",
            "0                   ZUELLIG PHARMA PTE LTD   12/03/2019   \n",
            "1                     DCH AURIGA SINGAPORE   19/03/2019   \n",
            "2                  GLAXOSMITHKLINE PTE LTD   22/03/2019   \n",
            "3  FERRING PHARMACEUTICALS PRIVATE LIMITED  25 MAR 2019   \n",
            "\n",
            "                                 5  \n",
            "0                        SIN15644P  \n",
            "1  SIN15646P, SIN15647P, SIN15648P  \n",
            "2                        SIN15649P  \n",
            "3  SIN15650P, SIN15651P, SIN15652P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-mar-2019\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P', 'DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG / 2ML']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P', 'DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG / 2ML', 'Dupilimumab']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P', 'DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG / 2ML', 'Dupilimumab', 'NDA-1: New chemical entity']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P', 'DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG / 2ML', 'Dupilimumab', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE LTD']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P', 'DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG / 2ML', 'Dupilimumab', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '29/04/2019']\n",
            "['ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FILM-COATED TABLET 90 MG, ALUNBRIG FILM-COATED TABLET 180 MG, ALUNBRIG INITIATION PACK FILM-COATED TABLET 90 MG & 180 MG', 'Brigatinib', 'NDA-1: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '04/04/2019', 'SIN15658P, SIN15659P, SIN15660P, SIN15661P', 'LYNPARZA FILM COATED TABLET 100MG, 150MG', 'Olaparib', 'NDA-2: New dosage form and NDA-3: New strength', 'ASTRAZENECA PTE LTD', '09/04/2019', 'SIN15662P, SIN15663P', 'CHOLIB FILM-COATED TABLET 145/20MG', 'Fenofibrate/Simvastatin', 'NDA-2: New combination', 'ABOTT LABORATORIES PTE LTD', '09/04/2019', 'SIN15664P', 'PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '15/04/2019', 'SIN15668P', 'DAFLON FILM-COATED TABLET 1000 mg', 'Diosmin/Hesperidin', 'NDA-3: New strength', 'SERVIER (S) PTE LTD', '16/04/2019', 'SIN15669P', 'TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '24/04/2019', 'SIN15671P', 'BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML', 'Avelumab', 'NDA-1: New chemical entity', 'MERCK PTE LTD', '25/04/2019', 'SIN15672P', 'DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG / 2ML', 'Dupilimumab', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '29/04/2019', 'SIN15675P']\n",
            "                                                   0  \\\n",
            "0  ALUNBRIG FILM-COATED TABLET 30 MG, ALUNBRIG FI...   \n",
            "1           LYNPARZA FILM COATED TABLET 100MG, 150MG   \n",
            "2                 CHOLIB FILM-COATED TABLET 145/20MG   \n",
            "3  PHENYLEPHRINE AGUETTANT SOLUTION FOR INJECTION...   \n",
            "4                  DAFLON FILM-COATED TABLET 1000 mg   \n",
            "5  TRUXIMA CONCENTRATE FOR SOLUTION FOR INFUSION ...   \n",
            "6  BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "7  DUPIXENT SOLUTION FOR INJECTION IN PRE-FILLED ...   \n",
            "\n",
            "                             1  \\\n",
            "0                   Brigatinib   \n",
            "1                     Olaparib   \n",
            "2      Fenofibrate/Simvastatin   \n",
            "3  Phenylephrine hydrochloride   \n",
            "4           Diosmin/Hesperidin   \n",
            "5                    Rituximab   \n",
            "6                     Avelumab   \n",
            "7                  Dupilimumab   \n",
            "\n",
            "                                                2  \\\n",
            "0                      NDA-1: New chemical entity   \n",
            "1  NDA-2: New dosage form and NDA-3: New strength   \n",
            "2                          NDA-2: New combination   \n",
            "3                          NDA-2: New dosage form   \n",
            "4                             NDA-3: New strength   \n",
            "5                               NDA-2: Biosimilar   \n",
            "6                      NDA-1: New chemical entity   \n",
            "7                      NDA-1: New chemical entity   \n",
            "\n",
            "                                                 3           4  \\\n",
            "0  TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.  04/04/2019   \n",
            "1                              ASTRAZENECA PTE LTD  09/04/2019   \n",
            "2                       ABOTT LABORATORIES PTE LTD  09/04/2019   \n",
            "3                                   INTEGA PTE LTD  15/04/2019   \n",
            "4                              SERVIER (S) PTE LTD  16/04/2019   \n",
            "5   CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED  24/04/2019   \n",
            "6                                    MERCK PTE LTD  25/04/2019   \n",
            "7                 SANOFI-AVENTIS SINGAPORE PTE LTD  29/04/2019   \n",
            "\n",
            "                                            5  \n",
            "0  SIN15658P, SIN15659P, SIN15660P, SIN15661P  \n",
            "1                        SIN15662P, SIN15663P  \n",
            "2                                   SIN15664P  \n",
            "3                                   SIN15668P  \n",
            "4                                   SIN15669P  \n",
            "5                                   SIN15671P  \n",
            "6                                   SIN15672P  \n",
            "7                                   SIN15675P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-apr-2019\n",
            "['XOFLUZA TABLETS 20MG AND 40MG']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P', 'VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P', 'VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG', 'Sofosbuvir + Velpatasvir + Voxilaprevir']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P', 'VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG', 'Sofosbuvir + Velpatasvir + Voxilaprevir', 'NDA-1']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P', 'VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG', 'Sofosbuvir + Velpatasvir + Voxilaprevir', 'NDA-1', 'GILEAD SCIENCES SINGAPORE PTE. LTD']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P', 'VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG', 'Sofosbuvir + Velpatasvir + Voxilaprevir', 'NDA-1', 'GILEAD SCIENCES SINGAPORE PTE. LTD', '31/05/2019']\n",
            "['XOFLUZA TABLETS 20MG AND 40MG', 'Baloxavir marboxil', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '03/05/2019', 'SIN15679P and SIN15680P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FILLED SYRINGE)', 'Benralizumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '09/05/2019', 'SIN15683P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150 AND 200MG', 'Sarilumab', 'NDA-1: New biological entityNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '09/05/2019', 'SIN15681P and SIN15682P', 'NEURONOX LYOPHILLISED POWDER FOR INJECTION 100 UNITS/VIAL', 'Clostridium botulinum toxin type A', 'NDA-2', 'FONDACO PTE LTD', '24/05/2019', 'SIN15692P', 'MAVENCLAD TABLET 10MG', 'Cladribine', 'NDA-1', 'MERCK PTE. LTD.', '24/05/2019', 'SIN15691P', 'ERLEADA FILM-COATED TABLET 60MG', 'Apalutamide', 'NDA-1', 'JOHNSON & JOHNSON PTE LTD', '27/05/2019', 'SIN15698P', 'BETADINE ANTISEPTIC LIQIUD 10% W/V', 'Povidone-Iodine 10%', 'NDA-2', 'MUNDIPHARMA PHARMACEUTICALS PTE LTD', '28/05/2019', 'SIN15699P', 'PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MCG/ML', 'Dexmedetomidine Hydrochloride', 'NDA-2', 'PFIZER PTE LTD', '22/05/2019', 'SIN15689P', 'AIRTAL FILM COATED TABLETS 100mg', 'Aceclofenac', 'NDA-1', 'ZUELLIG PHARMA PTE. LTD.', '29/05/2019', 'SIN15700P', 'TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/MLTRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PRE-FILLED PEN 200 U/ML', 'Insulin Degludec', 'NDA-1/NDA-3', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15703PSIN15704P', 'RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100U/ml', 'Insulin Degludec + Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '31/05/2019', 'SIN15706P', 'VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG', 'Sofosbuvir + Velpatasvir + Voxilaprevir', 'NDA-1', 'GILEAD SCIENCES SINGAPORE PTE. LTD', '31/05/2019', 'SIN15705P']\n",
            "                                                    0  \\\n",
            "0                       XOFLUZA TABLETS 20MG AND 40MG   \n",
            "1   FASENRA SOLUTION FOR INJECTION 30MG/ML (PRE FI...   \n",
            "2   KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED S...   \n",
            "3   NEURONOX LYOPHILLISED POWDER FOR INJECTION 100...   \n",
            "4                               MAVENCLAD TABLET 10MG   \n",
            "5                     ERLEADA FILM-COATED TABLET 60MG   \n",
            "6                  BETADINE ANTISEPTIC LIQIUD 10% W/V   \n",
            "7   PRECEDEX IN 0.9% SODIUM CHLORIDE INJECTION 4MC...   \n",
            "8                    AIRTAL FILM COATED TABLETS 100mg   \n",
            "9   TRESIBA FLEXTOUCH SOLUTION FOR INJECTION IN PR...   \n",
            "10  RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN ...   \n",
            "11       VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG   \n",
            "\n",
            "                                          1  \\\n",
            "0                        Baloxavir marboxil   \n",
            "1                              Benralizumab   \n",
            "2                                 Sarilumab   \n",
            "3        Clostridium botulinum toxin type A   \n",
            "4                                Cladribine   \n",
            "5                               Apalutamide   \n",
            "6                       Povidone-Iodine 10%   \n",
            "7             Dexmedetomidine Hydrochloride   \n",
            "8                               Aceclofenac   \n",
            "9                          Insulin Degludec   \n",
            "10        Insulin Degludec + Insulin Aspart   \n",
            "11  Sofosbuvir + Velpatasvir + Voxilaprevir   \n",
            "\n",
            "                                                  2  \\\n",
            "0                        NDA-1: New chemical entity   \n",
            "1                      NDA-1: New biological entity   \n",
            "2   NDA-1: New biological entityNDA-3: New strength   \n",
            "3                                             NDA-2   \n",
            "4                                             NDA-1   \n",
            "5                                             NDA-1   \n",
            "6                                             NDA-2   \n",
            "7                                             NDA-2   \n",
            "8                                             NDA-1   \n",
            "9                                       NDA-1/NDA-3   \n",
            "10                                            NDA-2   \n",
            "11                                            NDA-1   \n",
            "\n",
            "                                          3           4  \\\n",
            "0                   ROCHE SINGAPORE PTE LTD  03/05/2019   \n",
            "1             ASTRAZENECA SINGAPORE PTE LTD  09/05/2019   \n",
            "2          SANOFI-AVENTIS SINGAPORE PTE LTD  09/05/2019   \n",
            "3                           FONDACO PTE LTD  24/05/2019   \n",
            "4                           MERCK PTE. LTD.  24/05/2019   \n",
            "5                 JOHNSON & JOHNSON PTE LTD  27/05/2019   \n",
            "6       MUNDIPHARMA PHARMACEUTICALS PTE LTD  28/05/2019   \n",
            "7                            PFIZER PTE LTD  22/05/2019   \n",
            "8                  ZUELLIG PHARMA PTE. LTD.  29/05/2019   \n",
            "9   NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  31/05/2019   \n",
            "10  NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  31/05/2019   \n",
            "11       GILEAD SCIENCES SINGAPORE PTE. LTD  31/05/2019   \n",
            "\n",
            "                          5  \n",
            "0   SIN15679P and SIN15680P  \n",
            "1                 SIN15683P  \n",
            "2   SIN15681P and SIN15682P  \n",
            "3                 SIN15692P  \n",
            "4                 SIN15691P  \n",
            "5                 SIN15698P  \n",
            "6                 SIN15699P  \n",
            "7                 SIN15689P  \n",
            "8                 SIN15700P  \n",
            "9        SIN15703PSIN15704P  \n",
            "10                SIN15706P  \n",
            "11                SIN15705P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---may-2019\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P', 'PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300IU+150IU)/0.48ML, (450IU+ 225 IU)/0.72ML, (900IU + 450IU)/1.44ML']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P', 'PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300IU+150IU)/0.48ML, (450IU+ 225 IU)/0.72ML, (900IU + 450IU)/1.44ML', 'Follitropin alfa (r-hFSH), Lutropin alfa (r-LH)']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P', 'PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300IU+150IU)/0.48ML, (450IU+ 225 IU)/0.72ML, (900IU + 450IU)/1.44ML', 'Follitropin alfa (r-hFSH), Lutropin alfa (r-LH)', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P', 'PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300IU+150IU)/0.48ML, (450IU+ 225 IU)/0.72ML, (900IU + 450IU)/1.44ML', 'Follitropin alfa (r-hFSH), Lutropin alfa (r-LH)', 'NDA-2: New dosage formNDA-3: New strength', 'MERCK PTE LTD']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P', 'PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300IU+150IU)/0.48ML, (450IU+ 225 IU)/0.72ML, (900IU + 450IU)/1.44ML', 'Follitropin alfa (r-hFSH), Lutropin alfa (r-LH)', 'NDA-2: New dosage formNDA-3: New strength', 'MERCK PTE LTD', '11/06/2019']\n",
            "['CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/ CRESEMBA CAPSULES 100MG', 'Isavuconazonium sulfate', 'NDA-1/ NDA-2', 'PFIZER PRIVATE LIMITED', '13/06/2019', 'SIN15717P/ SIN15716P', 'HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-FILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength / dosing regimen', 'ABBVIE PTE LTD', '17/06/2019', 'SIN15718P', 'FUCICORT LIPID CREAM', 'Betamethasone valerate, Fusidic acid', 'NDA-2: New dosage form', 'LEO PHARMA ASIA PTE LTD', '18/06/2019', 'SIN15720P', 'PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFILTRATION', 'Disodium Phosphate Dihydrate + Potassium Chloride + Sodium Chloride + Sodium Hydrogen Carbonate + Magnesium Chloride Hexahydrate + Calcium Chloride Dihydrate', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '27/06/2019', 'SIN15730P', 'PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLED PEN (300IU+150IU)/0.48ML, (450IU+ 225 IU)/0.72ML, (900IU + 450IU)/1.44ML', 'Follitropin alfa (r-hFSH), Lutropin alfa (r-LH)', 'NDA-2: New dosage formNDA-3: New strength', 'MERCK PTE LTD', '11/06/2019', 'SIN15711P, SIN15712P, SIN15713P']\n",
            "                                                   0  \\\n",
            "0  CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION F...   \n",
            "1  HUMIRA SOLUTION FOR INJECTION 20MG/0.2ML (PRE-...   \n",
            "2                               FUCICORT LIPID CREAM   \n",
            "3  PHOXILIUM SOLUTION FOR HAEMODIALYSIS/ HAEMOFIL...   \n",
            "4  PERGOVERIS SOLUTION FOR INJECTION IN PRE-FILLE...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                            Isavuconazonium sulfate   \n",
            "1                                         Adalimumab   \n",
            "2               Betamethasone valerate, Fusidic acid   \n",
            "3  Disodium Phosphate Dihydrate + Potassium Chlor...   \n",
            "4    Follitropin alfa (r-hFSH), Lutropin alfa (r-LH)   \n",
            "\n",
            "                                           2  \\\n",
            "0                               NDA-1/ NDA-2   \n",
            "1       NDA-2: New strength / dosing regimen   \n",
            "2                     NDA-2: New dosage form   \n",
            "3                     NDA-2: New combination   \n",
            "4  NDA-2: New dosage formNDA-3: New strength   \n",
            "\n",
            "                                  3           4  \\\n",
            "0            PFIZER PRIVATE LIMITED  13/06/2019   \n",
            "1                    ABBVIE PTE LTD  17/06/2019   \n",
            "2           LEO PHARMA ASIA PTE LTD  18/06/2019   \n",
            "3  BAXTER HEALTHCARE (ASIA) PTE LTD  27/06/2019   \n",
            "4                     MERCK PTE LTD  11/06/2019   \n",
            "\n",
            "                                 5  \n",
            "0             SIN15717P/ SIN15716P  \n",
            "1                        SIN15718P  \n",
            "2                        SIN15720P  \n",
            "3                        SIN15730P  \n",
            "4  SIN15711P, SIN15712P, SIN15713P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---jun-2019\n",
            "['GILENYA CAPSULE 0.25MG']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P', 'VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P', 'VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG', 'Abemaciclib']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P', 'VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG', 'Abemaciclib', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P', 'VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG', 'Abemaciclib', 'NDA-1: New chemical entityNDA-3: New strength', 'ELI LILLY (SINGAPORE) PTE LTD']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P', 'VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG', 'Abemaciclib', 'NDA-1: New chemical entityNDA-3: New strength', 'ELI LILLY (SINGAPORE) PTE LTD', '26/08/2019']\n",
            "['GILENYA CAPSULE 0.25MG', 'Fingolimod', 'NDA-2: New strength / indication / dosing regimen', 'NOVARTIS (SINGAPORE) PTE LTD', '05/08/2019', 'SIN15761P', 'REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG, 0.5MG AND 0.25MG', 'Brexpiprazole', 'NDA-1: New chemical entityNDA-3: New strengths', 'LUNDBECK SINGAPORE PTE. LTD.', '05/08/2019', 'SIN15763P, SIN15764P, SIN15765P, SIN15766P, SIN15767, SIN15768P', 'BERIATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION 250IU/VIAL, 500IU/VIAL', 'Human coagulation factor VIII', 'NDA-2: Others (Factor VIII product)', 'CSL Behring Pte Ltd', '07/08/2019', 'SIN15771P, SIN15772P', 'SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE', 'Purified inactivated influenza virus surface antigen [A/Christchurch/16/2010, NIB-74xp (H1N1)]Purified inactivated influenza virus surface antigen [A/HongKong/4801/2014, NYMC X263 (H3N2)]Purified inactivated influenza virus surface antigen [B/Brisbane/60/2008, NYMC BX-35]Purified inactivated influenza virus surface antigen [B/Phuket/3073/2013]', 'NDA-2: New combination', 'AJ BIOLOGICS PTE. LTD.', '16/08/2019', 'SIN15781P', 'VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG', 'Abemaciclib', 'NDA-1: New chemical entityNDA-3: New strength', 'ELI LILLY (SINGAPORE) PTE LTD', '26/08/2019', 'SIN15788P, SIN15789P, SIN15790P']\n",
            "                                                   0  \\\n",
            "0                             GILENYA CAPSULE 0.25MG   \n",
            "1  REXULTI FILM-COATED TABLETS 4MG, 3MG, 2MG, 1MG...   \n",
            "2  BERIATE POWDER AND SOLVENT FOR SOLUTION FOR IN...   \n",
            "3          SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE   \n",
            "4  VERZENIO FILM-COATED TABLET 50MG, 100MG AND 150MG   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Fingolimod   \n",
            "1                                      Brexpiprazole   \n",
            "2                      Human coagulation factor VIII   \n",
            "3  Purified inactivated influenza virus surface a...   \n",
            "4                                        Abemaciclib   \n",
            "\n",
            "                                                   2  \\\n",
            "0  NDA-2: New strength / indication / dosing regimen   \n",
            "1     NDA-1: New chemical entityNDA-3: New strengths   \n",
            "2                NDA-2: Others (Factor VIII product)   \n",
            "3                             NDA-2: New combination   \n",
            "4      NDA-1: New chemical entityNDA-3: New strength   \n",
            "\n",
            "                               3           4  \\\n",
            "0   NOVARTIS (SINGAPORE) PTE LTD  05/08/2019   \n",
            "1   LUNDBECK SINGAPORE PTE. LTD.  05/08/2019   \n",
            "2            CSL Behring Pte Ltd  07/08/2019   \n",
            "3         AJ BIOLOGICS PTE. LTD.  16/08/2019   \n",
            "4  ELI LILLY (SINGAPORE) PTE LTD  26/08/2019   \n",
            "\n",
            "                                                   5  \n",
            "0                                          SIN15761P  \n",
            "1  SIN15763P, SIN15764P, SIN15765P, SIN15766P, SI...  \n",
            "2                               SIN15771P, SIN15772P  \n",
            "3                                          SIN15781P  \n",
            "4                    SIN15788P, SIN15789P, SIN15790P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---aug-2019\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P', 'ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 10MCG/0.5MLENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 20MCG/1ML']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P', 'ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 10MCG/0.5MLENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 20MCG/1ML', 'Hepatitis B Surface antigen']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P', 'ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 10MCG/0.5MLENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 20MCG/1ML', 'Hepatitis B Surface antigen', 'NDA-2: New presentation']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P', 'ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 10MCG/0.5MLENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 20MCG/1ML', 'Hepatitis B Surface antigen', 'NDA-2: New presentation', 'GlaxoSmithKline Pte Ltd']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P', 'ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 10MCG/0.5MLENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 20MCG/1ML', 'Hepatitis B Surface antigen', 'NDA-2: New presentation', 'GlaxoSmithKline Pte Ltd', '13/09/2019']\n",
            "['PRIFTIN FILM-COATED TABLET 150 MG', 'Rifapentine', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '02/09/2019', 'SIN15793P', 'VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKANAMET FILM-COATED TABLETS 50 MG/1000 MGVOKANAMET FILM-COATED TABLETS 150 MG/500 MGVOKANAMET FILM-COATED TABLETS 150 MG/1000 MG', 'Canagliflozin and Metformin', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE. LTD', '05/09/2019', 'SIN15797PSIN15798PSIN15799PSIN15800P', 'PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)10ML SUSPENSION FOR INJECTION VIAL', 'Pandemic Influenza Virus Type A, inactivated and disrupted', 'NDA-1: New chemical entity', 'SEQIRUS PTE LTD\\xa0.', '06/09/2019', 'SIN15801P', 'TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5MCG/25MCG', 'Fluticasone furoate (micronized)Umeclidinium bromide (micronized)Vilanterol trifenatate (micronized)', 'NDA-2: New combination', 'GLAXOSMITHKLINE PTE. LTD.', '12/09/2019', 'SIN15806P', 'IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALIDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIAL', 'Albutrepenonacog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD', '19/09/2019', 'SIN15811PSIN15812PSIN15813PSIN15814P', 'KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGKANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG', 'Fimasartan, Hydrochlorothiazide', 'NDA-2: New combinationNDA-3: New strength', 'Zuellig Pharma Pte Ltd', '26/09/2019', 'SIN15818P, SIN15819P', 'AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 1000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 2000IU/VIALAFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 3000IU/VIAL', 'Lonoctocog alfa', 'NDA-1: New biological entityNDA-3: New strength', 'CSL BEHRING PTE. LTD.', '27/09/2019', 'SIN15821P, SIN15822P, SIN15823P, SIN15824P, SIN15820P', 'ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 10MCG/0.5MLENGERIX-B SUSPENSION FOR INJECTION IN PREFILLED SYRING 20MCG/1ML', 'Hepatitis B Surface antigen', 'NDA-2: New presentation', 'GlaxoSmithKline Pte Ltd', '13/09/2019', 'SIN15808P, SIN15807P']\n",
            "                                                   0  \\\n",
            "0                  PRIFTIN FILM-COATED TABLET 150 MG   \n",
            "1  VOKANAMET FILM-COATED TABLETS 50 MG/500 MGVOKA...   \n",
            "2  PANVAX PANDEMIC INFLUENZA VACCINE (ADJUVANTED)...   \n",
            "3  TRELEGY ELLIPTA INHALATION POWDER 100MCG/62.5M...   \n",
            "4  IDELVION POWDER AND SOLVENT FOR SOLUTION FOR I...   \n",
            "5  KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MGK...   \n",
            "6  AFSTYLA POWDER AND SOLVENT FOR SOLUTION FOR IN...   \n",
            "7  ENGERIX-B SUSPENSION FOR INJECTION IN PREFILLE...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                        Rifapentine   \n",
            "1                        Canagliflozin and Metformin   \n",
            "2  Pandemic Influenza Virus Type A, inactivated a...   \n",
            "3  Fluticasone furoate (micronized)Umeclidinium b...   \n",
            "4                              Albutrepenonacog alfa   \n",
            "5                    Fimasartan, Hydrochlorothiazide   \n",
            "6                                    Lonoctocog alfa   \n",
            "7                        Hepatitis B Surface antigen   \n",
            "\n",
            "                                                 2  \\\n",
            "0                       NDA-1: New chemical entity   \n",
            "1                           NDA-2: New combination   \n",
            "2                       NDA-1: New chemical entity   \n",
            "3                           NDA-2: New combination   \n",
            "4  NDA-1: New biological entityNDA-3: New strength   \n",
            "5        NDA-2: New combinationNDA-3: New strength   \n",
            "6  NDA-1: New biological entityNDA-3: New strength   \n",
            "7                          NDA-2: New presentation   \n",
            "\n",
            "                                    3           4  \\\n",
            "0  SANOFI-AVENTIS SINGAPORE PTE. LTD.  02/09/2019   \n",
            "1          JOHNSON & JOHNSON PTE. LTD  05/09/2019   \n",
            "2                   SEQIRUS PTE LTD .  06/09/2019   \n",
            "3           GLAXOSMITHKLINE PTE. LTD.  12/09/2019   \n",
            "4                CSL BEHRING PTE. LTD  19/09/2019   \n",
            "5              Zuellig Pharma Pte Ltd  26/09/2019   \n",
            "6               CSL BEHRING PTE. LTD.  27/09/2019   \n",
            "7             GlaxoSmithKline Pte Ltd  13/09/2019   \n",
            "\n",
            "                                                   5  \n",
            "0                                          SIN15793P  \n",
            "1               SIN15797PSIN15798PSIN15799PSIN15800P  \n",
            "2                                          SIN15801P  \n",
            "3                                          SIN15806P  \n",
            "4               SIN15811PSIN15812PSIN15813PSIN15814P  \n",
            "5                               SIN15818P, SIN15819P  \n",
            "6  SIN15821P, SIN15822P, SIN15823P, SIN15824P, SI...  \n",
            "7                               SIN15808P, SIN15807P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---sep-2019\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P', 'HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION; HERZUMA™ 150MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P', 'HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION; HERZUMA™ 150MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION', 'Trastuzumab']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P', 'HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION; HERZUMA™ 150MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P', 'HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION; HERZUMA™ 150MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P', 'HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION; HERZUMA™ 150MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '29/10/2019']\n",
            "['ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIBLE TABLETS 300MG', 'Erdosteine', 'NDA-1: New chemical entityNDA-2: New dosage form', 'HYPHENS PHARMA PTE. LTD.', '02/10/2019', 'SIN15825P, SIN15826P', 'FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-2', 'WELLCHEM PHARMACEUTICALS PTE LTD', '16/10/2019', 'SIN15829P', 'LORVIQUA FILM-COATED TABLET 25 AND 100MG', 'Lorlatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '16/10/2019', 'SIN15830PSIN15831P', 'TASIGNA\\xa0 CAPSULE 50MG', 'Nilotinib', 'NDA-2', 'NOVARTIS (SINGAPORE) PTE LTD', '23/10/2019', 'SIN15837P', 'HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION; HERZUMA™ 150MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '29/10/2019', 'SIN15838P, SIN15839P']\n",
            "                                                   0                 1  \\\n",
            "0  ERDOMED HARD CAPSULES 300MG, ERDOMED DISPERSIB...        Erdosteine   \n",
            "1  FIBRYGA POWDER FOR SOLUTION FOR INJECTION OR I...  Human Fibrinogen   \n",
            "2           LORVIQUA FILM-COATED TABLET 25 AND 100MG        Lorlatinib   \n",
            "3                              TASIGNA  CAPSULE 50MG         Nilotinib   \n",
            "4  HERZUMA™ 440MG POWDER FOR CONCENTRATE FOR SOLU...       Trastuzumab   \n",
            "\n",
            "                                                  2  \\\n",
            "0  NDA-1: New chemical entityNDA-2: New dosage form   \n",
            "1                                             NDA-2   \n",
            "2     NDA-1: New chemical entityNDA-3: New strength   \n",
            "3                                             NDA-2   \n",
            "4              NDA-2: BiosimilarNDA-3: New strength   \n",
            "\n",
            "                                                3           4  \\\n",
            "0                        HYPHENS PHARMA PTE. LTD.  02/10/2019   \n",
            "1                WELLCHEM PHARMACEUTICALS PTE LTD  16/10/2019   \n",
            "2                          PFIZER PRIVATE LIMITED  16/10/2019   \n",
            "3                    NOVARTIS (SINGAPORE) PTE LTD  23/10/2019   \n",
            "4  CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED  29/10/2019   \n",
            "\n",
            "                      5  \n",
            "0  SIN15825P, SIN15826P  \n",
            "1             SIN15829P  \n",
            "2    SIN15830PSIN15831P  \n",
            "3             SIN15837P  \n",
            "4  SIN15838P, SIN15839P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---oct-2019\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P', 'NERLYNX FILM-COATED TABLETS 40 MG']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P', 'NERLYNX FILM-COATED TABLETS 40 MG', 'Neratinib maleate']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P', 'NERLYNX FILM-COATED TABLETS 40 MG', 'Neratinib maleate', 'NDA-1: New chemical entity']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P', 'NERLYNX FILM-COATED TABLETS 40 MG', 'Neratinib maleate', 'NDA-1: New chemical entity', 'SPECIALISED THERAPEUTICS ASIA PTE LTD']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P', 'NERLYNX FILM-COATED TABLETS 40 MG', 'Neratinib maleate', 'NDA-1: New chemical entity', 'SPECIALISED THERAPEUTICS ASIA PTE LTD', '25/11/2019']\n",
            "['VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG and 70MG', 'Lisdexamfetamine dimesylate', 'NDA-1: New chemical entity, NDA-3: New strength', 'SHIRE SINGAPORE PTE LTD', '01/11/2019', 'SIN15840P, SIN15841P, SIN15842P, SIN15843P, SIN15844P and SIN15845P', 'LIVALO FILM COATED TABLETS 2MG, 4MG', 'Pitavastatin', 'NDA-1: New chemical entity, NDA-3: New strength', 'DKSH SINGAPORE PTE LTD', '22/11/2019', 'SIN15859P, SIN15860P', 'OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG PER VIAL', 'Trastuzumab', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE.LTD\\xa0.', '04/11/2019', 'SIN15850P', 'MONOFER SOLUTION FOR INJECTION OR INFUSION 100 MG/ML', 'Ferric Derisomaltose 417 mg/ml (Elementary Iron 100 mg/ml)', 'NDA-1: New chemical entity', 'COMPAI PHARMA PTE LTD', '14/11/2019', 'SIN15855P', 'NERLYNX FILM-COATED TABLETS 40 MG', 'Neratinib maleate', 'NDA-1: New chemical entity', 'SPECIALISED THERAPEUTICS ASIA PTE LTD', '25/11/2019', 'SIN15861P']\n",
            "                                                   0  \\\n",
            "0  VYVANSE CAPSULES 20MG, 30MG, 40MG, 50MG, 60MG ...   \n",
            "1                LIVALO FILM COATED TABLETS 2MG, 4MG   \n",
            "2  OGIVRI LYOPHILIZED POWDER FOR INJECTION440MG P...   \n",
            "3  MONOFER SOLUTION FOR INJECTION OR INFUSION 100...   \n",
            "4                  NERLYNX FILM-COATED TABLETS 40 MG   \n",
            "\n",
            "                                                   1  \\\n",
            "0                        Lisdexamfetamine dimesylate   \n",
            "1                                       Pitavastatin   \n",
            "2                                        Trastuzumab   \n",
            "3  Ferric Derisomaltose 417 mg/ml (Elementary Iro...   \n",
            "4                                  Neratinib maleate   \n",
            "\n",
            "                                                 2  \\\n",
            "0  NDA-1: New chemical entity, NDA-3: New strength   \n",
            "1  NDA-1: New chemical entity, NDA-3: New strength   \n",
            "2                                NDA-2: Biosimilar   \n",
            "3                       NDA-1: New chemical entity   \n",
            "4                       NDA-1: New chemical entity   \n",
            "\n",
            "                                       3           4  \\\n",
            "0                SHIRE SINGAPORE PTE LTD  01/11/2019   \n",
            "1                 DKSH SINGAPORE PTE LTD  22/11/2019   \n",
            "2        MYLAN PHARMACEUTICALS PTE.LTD .  04/11/2019   \n",
            "3                  COMPAI PHARMA PTE LTD  14/11/2019   \n",
            "4  SPECIALISED THERAPEUTICS ASIA PTE LTD  25/11/2019   \n",
            "\n",
            "                                                   5  \n",
            "0  SIN15840P, SIN15841P, SIN15842P, SIN15843P, SI...  \n",
            "1                               SIN15859P, SIN15860P  \n",
            "2                                          SIN15850P  \n",
            "3                                          SIN15855P  \n",
            "4                                          SIN15861P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---nov-2019\n",
            "['PIFELTRO FILM COATED TABLETS 100MG']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P', 'ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION FOR INFUSION 2G/0.5G']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P', 'ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION FOR INFUSION 2G/0.5G', 'Avibactam sodium, Ceftazidime pentahydrate']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P', 'ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION FOR INFUSION 2G/0.5G', 'Avibactam sodium, Ceftazidime pentahydrate', 'NDA-1: New chemical entity']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P', 'ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION FOR INFUSION 2G/0.5G', 'Avibactam sodium, Ceftazidime pentahydrate', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P', 'ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION FOR INFUSION 2G/0.5G', 'Avibactam sodium, Ceftazidime pentahydrate', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '12/12/2019']\n",
            "['PIFELTRO FILM COATED TABLETS 100MG', 'Doravirine', 'NDA-1: New chemical entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '012/12/2019', 'SIN15869P', 'ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION FOR INFUSION 2G/0.5G', 'Avibactam sodium, Ceftazidime pentahydrate', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '12/12/2019', 'SIN 15870P']\n",
            "                                                   0  \\\n",
            "0                 PIFELTRO FILM COATED TABLETS 100MG   \n",
            "1  ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUION F...   \n",
            "\n",
            "                                            1                           2  \\\n",
            "0                                  Doravirine  NDA-1: New chemical entity   \n",
            "1  Avibactam sodium, Ceftazidime pentahydrate  NDA-1: New chemical entity   \n",
            "\n",
            "                                  3            4           5  \n",
            "0  MSD PHARMA (SINGAPORE) PTE. LTD.  012/12/2019   SIN15869P  \n",
            "1            PFIZER PRIVATE LIMITED   12/12/2019  SIN 15870P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---dec-2019\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P', 'PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P', 'PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Letermovir']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P', 'PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Letermovir', 'NDA 1/2/3']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P', 'PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Letermovir', 'NDA 1/2/3', 'MSD PHARMA (SINGAPORE) PTE LTD']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P', 'PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Letermovir', 'NDA 1/2/3', 'MSD PHARMA (SINGAPORE) PTE LTD', '30/07/2019']\n",
            "['AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML', 'Adalimumab', 'NDA-2/3: Biosimilar', 'AMGEN SINGAPORE MANUFACTURING PTE. LTD.', 'PFS: 02/07/2019PF autoinjector: 31/07/2019', 'SIN15731P, SIN15732P; SIN15760P', 'KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG AND 200MG', 'Sarilumab', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE LTD', '08/07/2019', 'SIN15737P and SIN15738P', 'TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ', 'Sodium molybdate', 'NDA-2', 'QT INSTRUMENT (S) PTE LTD', '10/07/2019', 'SIN15741P', 'SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG', 'Cariprazine', 'NDA-1: New chemical entityNDA-3: New strength', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '11/07/2019', 'SIN15743P, SIN15744P, SIN15745P, SIN15746P', 'BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL', 'Inotuzumab Ozogamicin', 'NDA-1', 'PFIZER PRIVATE LIMITED', '17/07/2019', 'SIN15747P', 'BAT STERILE SOLUTION FOR INJECTION', 'Botulism antitoxin (equine) serotypes A, B, C, D, E, F, G', 'NDA-1', 'EMERGENT SALES AND MARKETING SINGAPORE PTE LTD', '18/07/2019', 'SIN15749P', 'CALQUENCE HARD CAPSULES 100MG', 'Acalabrutinib', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/07/2019', 'SIN15753P', 'PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Letermovir', 'NDA 1/2/3', 'MSD PHARMA (SINGAPORE) PTE LTD', '30/07/2019', 'SIN15757P, SIN15758P, SIN15759P']\n",
            "                                                   0  \\\n",
            "0  AMGEVITA SOLUTION FOR INJECTION IN PREFILLED S...   \n",
            "1  KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "2              TEKCIS RADIONUCLIDE GENERATOR 2-50GBQ   \n",
            "3      SYMVENU® HARD CAPSULES 1.5MG, 3MG, 4.5MG, 6MG   \n",
            "4  BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION F...   \n",
            "5                 BAT STERILE SOLUTION FOR INJECTION   \n",
            "6                      CALQUENCE HARD CAPSULES 100MG   \n",
            "7  PREVYMIS FILM COATED TABLET 240MG, 480MGPREVYM...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Adalimumab   \n",
            "1                                          Sarilumab   \n",
            "2                                   Sodium molybdate   \n",
            "3                                        Cariprazine   \n",
            "4                              Inotuzumab Ozogamicin   \n",
            "5  Botulism antitoxin (equine) serotypes A, B, C,...   \n",
            "6                                      Acalabrutinib   \n",
            "7                                         Letermovir   \n",
            "\n",
            "                                               2  \\\n",
            "0                            NDA-2/3: Biosimilar   \n",
            "1      NDA-2: New dosage formNDA-3: New strength   \n",
            "2                                          NDA-2   \n",
            "3  NDA-1: New chemical entityNDA-3: New strength   \n",
            "4                                          NDA-1   \n",
            "5                                          NDA-1   \n",
            "6                     NDA-1: New chemical entity   \n",
            "7                                      NDA 1/2/3   \n",
            "\n",
            "                                                3  \\\n",
            "0         AMGEN SINGAPORE MANUFACTURING PTE. LTD.   \n",
            "1                SANOFI-AVENTIS SINGAPORE PTE LTD   \n",
            "2                       QT INSTRUMENT (S) PTE LTD   \n",
            "3      MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD   \n",
            "4                          PFIZER PRIVATE LIMITED   \n",
            "5  EMERGENT SALES AND MARKETING SINGAPORE PTE LTD   \n",
            "6                   ASTRAZENECA SINGAPORE PTE LTD   \n",
            "7                  MSD PHARMA (SINGAPORE) PTE LTD   \n",
            "\n",
            "                                            4  \\\n",
            "0  PFS: 02/07/2019PF autoinjector: 31/07/2019   \n",
            "1                                  08/07/2019   \n",
            "2                                  10/07/2019   \n",
            "3                                  11/07/2019   \n",
            "4                                  17/07/2019   \n",
            "5                                  18/07/2019   \n",
            "6                                  25/07/2019   \n",
            "7                                  30/07/2019   \n",
            "\n",
            "                                            5  \n",
            "0             SIN15731P, SIN15732P; SIN15760P  \n",
            "1                     SIN15737P and SIN15738P  \n",
            "2                                   SIN15741P  \n",
            "3  SIN15743P, SIN15744P, SIN15745P, SIN15746P  \n",
            "4                                   SIN15747P  \n",
            "5                                   SIN15749P  \n",
            "6                                   SIN15753P  \n",
            "7             SIN15757P, SIN15758P, SIN15759P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2019\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P', 'RAPAMUNE TABLET 0.5 MG']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P', 'RAPAMUNE TABLET 0.5 MG', 'Sirolimus']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P', 'RAPAMUNE TABLET 0.5 MG', 'Sirolimus', 'NDA-3: New strength']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P', 'RAPAMUNE TABLET 0.5 MG', 'Sirolimus', 'NDA-3: New strength', 'PFIZER PRIVATE LIMITED']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P', 'RAPAMUNE TABLET 0.5 MG', 'Sirolimus', 'NDA-3: New strength', 'PFIZER PRIVATE LIMITED', '20/01/2020']\n",
            "['BILAXTEN ORODISPERSIBLE TABLET 10MG', 'Bilastine', 'NDA-2: New dosage form', 'A. MENARINI SINGAPORE PTE. LTD.', '13/01/2020', 'SIN15874P', 'VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG', 'Trimetazidine', 'NDA-2: New dosage form', 'SERVIER (S) PTE LTD', '20/01/2020', 'SIN15877P', 'SPEDRA TABLET 50MG, 100MG, 200MG', 'Avafanil', 'NDA-1/3: New chemical entity/New strength', 'A.Menarini Singapore Pte Ltd', '24/01/2020', 'SIN15879P, SIN15880P, SIN15881P', 'RAPAMUNE TABLET 0.5 MG', 'Sirolimus', 'NDA-3: New strength', 'PFIZER PRIVATE LIMITED', '20/01/2020', 'SIN15878P']\n",
            "                                                 0              1  \\\n",
            "0              BILAXTEN ORODISPERSIBLE TABLET 10MG      Bilastine   \n",
            "1  VASTAREL XR EXTENDED-RELEASE HARD CAPSULE 80 MG  Trimetazidine   \n",
            "2                 SPEDRA TABLET 50MG, 100MG, 200MG       Avafanil   \n",
            "3                           RAPAMUNE TABLET 0.5 MG      Sirolimus   \n",
            "\n",
            "                                           2                                3  \\\n",
            "0                     NDA-2: New dosage form  A. MENARINI SINGAPORE PTE. LTD.   \n",
            "1                     NDA-2: New dosage form              SERVIER (S) PTE LTD   \n",
            "2  NDA-1/3: New chemical entity/New strength     A.Menarini Singapore Pte Ltd   \n",
            "3                        NDA-3: New strength           PFIZER PRIVATE LIMITED   \n",
            "\n",
            "            4                                5  \n",
            "0  13/01/2020                        SIN15874P  \n",
            "1  20/01/2020                        SIN15877P  \n",
            "2  24/01/2020  SIN15879P, SIN15880P, SIN15881P  \n",
            "3  20/01/2020                        SIN15878P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---jan-2020\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P', 'HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P', 'HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P', 'HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-1: New chemical entity, NDA-2: New dosage form']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P', 'HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'CSL Behring Pte Ltd']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P', 'HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'CSL Behring Pte Ltd', '28/02/2020']\n",
            "['SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM', 'Tiotropium', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '18/02/2020', 'SIN15885P', 'GLANATEC OPHTHALMIC SOLUTION 0.4% W/V', 'Ripasudil Hydrochloride Hydrate', 'NDA-1: New chemical entity', 'DKSH Singapore Ptd Ltd', '18/02/2020', 'SIN15886P', 'BOOSTRIX POLIO SUSPENSION FOR INJECTION', 'TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID(2 iu/0.5 ml),PERTACTIN(2.5 mcg/0.5 ml), FILAMENTOUS HAEMAGGLUTININ(8 mcg/0.5 ml),PERTUSSIS TOXOID(8mcg/0.5ml)', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '20/02/2020', 'SIN15888P', 'SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM / 2.5 MICROGRAM', 'Tiotropium / Olodaterol', 'NDA-2: New presentation', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '25/01/2020', 'SIN15890P', 'ENSTILAR CUTANEOUS FORM', 'Betamethasone dipropionate 0.5mg/g and Calcipotriol 50mcg/g', 'NDA-2: New presentation', 'Leo Pharma AsiaPtd Ltd', '27/02/2020', 'SIN15892P', 'VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX SOFT GELATIN CAPSULE 61 MG', 'Tafamidis meglumine (for Vyndaqel),Tafamidis (for Vyndamax)', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'Pfizer Private Limited', '27/02/2020', 'SIN15893P. SIN15894P', 'HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL', 'Human Fibrinogen', 'NDA-1: New chemical entity, NDA-2: New dosage form', 'CSL Behring Pte Ltd', '28/02/2020', 'SIN15895P']\n",
            "                                                   0  \\\n",
            "0  SPIRIVA RESPIMAT RE-USABLE SOLUTION FOR INHALA...   \n",
            "1              GLANATEC OPHTHALMIC SOLUTION 0.4% W/V   \n",
            "2            BOOSTRIX POLIO SUSPENSION FOR INJECTION   \n",
            "3  SPIOLTO RESPIMAT RE-USABLE SOLUTION FOR INHALA...   \n",
            "4                            ENSTILAR CUTANEOUS FORM   \n",
            "5  VYNDAQEL SOFT GELATIN CAPSULE 20 MG,VYNDAMAX S...   \n",
            "6  HAEMOCOMPLETTAN P POWDER FOR SOLUTION FOR INJE...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Tiotropium   \n",
            "1                    Ripasudil Hydrochloride Hydrate   \n",
            "2  TETANUS TOXOID(20 iu/0.5 ml),DIPHTHERIA TOXOID...   \n",
            "3                            Tiotropium / Olodaterol   \n",
            "4  Betamethasone dipropionate 0.5mg/g and Calcipo...   \n",
            "5  Tafamidis meglumine (for Vyndaqel),Tafamidis (...   \n",
            "6                                   Human Fibrinogen   \n",
            "\n",
            "                                                   2  \\\n",
            "0                            NDA-2: New presentation   \n",
            "1                         NDA-1: New chemical entity   \n",
            "2                                              NDA-2   \n",
            "3                            NDA-2: New presentation   \n",
            "4                            NDA-2: New presentation   \n",
            "5  NDA-1: New chemical entity, NDA-2: New dosage ...   \n",
            "6  NDA-1: New chemical entity, NDA-2: New dosage ...   \n",
            "\n",
            "                                          3           4                     5  \n",
            "0  BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.  18/02/2020             SIN15885P  \n",
            "1                    DKSH Singapore Ptd Ltd  18/02/2020             SIN15886P  \n",
            "2                   GLAXOSMITHKLINE PTE LTD  20/02/2020             SIN15888P  \n",
            "3  BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.  25/01/2020             SIN15890P  \n",
            "4                    Leo Pharma AsiaPtd Ltd  27/02/2020             SIN15892P  \n",
            "5                    Pfizer Private Limited  27/02/2020  SIN15893P. SIN15894P  \n",
            "6                       CSL Behring Pte Ltd  28/02/2020             SIN15895P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---feb-2020\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P', 'ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P', 'ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%', 'Human albumin']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P', 'ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%', 'Human albumin', 'NDA-2: New dosage formNDA-3: Subsequent strengths']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P', 'ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%', 'Human albumin', 'NDA-2: New dosage formNDA-3: Subsequent strengths', 'CSL Behring Pte Ltd']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P', 'ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%', 'Human albumin', 'NDA-2: New dosage formNDA-3: Subsequent strengths', 'CSL Behring Pte Ltd', '11/03/2020']\n",
            "['PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML', 'Phenylephrine hydrochloride', 'NDA-2: New dosage form', 'INTEGA PTE LTD', '03/03/2020', 'SIN15896P', 'CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI ORODISPERSIBLE FILM 5MG', 'Tadalafil', 'NDA-2: New dosage formNDA-3: New strength', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '09/03/2020', 'SIN15898P,SIN15899P', 'STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FILM-COATED TABLETS 15MG', 'Ertugliflozin L-PGA', 'NDA-1: New chemical entityNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15901P, SIN15902P', 'STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJAN FILM-COATED TABLETS 15MG/100 MG', 'Sitagliptin phosphate monohydrate / ertugliflozin L-PGA', 'NDA-2: New combinationNDA-3: New strength', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '11/03/2020', 'SIN15904P, SIN15905P', 'DELSTRIGO FILM COATED TABLET', 'Lamivudine 100mg, Tenofovir disoproxil fumarate 300mg, Doravirine 100mg', 'NDA-2: New combination', 'MSD PHARMA (SINGAPORE) PRIVATE LIMITED', '13 Mar 2020', 'SIN15909P', 'HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED PEN)HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PREFILLED SYRINGE)', 'Adalimumab', 'NDA-2: New strength', 'ABBVIE PTE. LTD.', '19/03/2020', 'SIN15914P, SIN15915P', 'PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS', 'Alpelisib', 'NDA-1 (250MG): New chemical entityNDA-3: Subsequent strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '25/03/2020', 'SIN15916P, SIN15917P and SIN15918P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120MG/ML', 'Galcanezumab', 'NDA-1: New chemical entity', 'Eli Lilly (Singapore) Pte Ltd', '25/03/2020', 'SIN15919P', 'ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%', 'Human albumin', 'NDA-2: New dosage formNDA-3: Subsequent strengths', 'CSL Behring Pte Ltd', '11/03/2020', 'SIN15903P, SIN15906P and SIN15907P']\n",
            "                                                   0  \\\n",
            "0        PHENYLALPHA SOLUTION FOR INJECTION 50MCG/ML   \n",
            "1  CALIBERI ORODISPERSIBLE FILM 20MGCALIBERI OROD...   \n",
            "2  STEGLATRO FILM-COATED TABLETS 5MGSTEGLATRO FIL...   \n",
            "3  STEGLUJAN FILM-COATED TABLETS 5MG/100MGSTEGLUJ...   \n",
            "4                       DELSTRIGO FILM COATED TABLET   \n",
            "5  HUMIRA SOLUTION FOR INJECTION 80 MG/0.8ML (PRE...   \n",
            "6         PIQRAY 250, 300 AND 200MG DAILY DOSE PACKS   \n",
            "7  EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED ...   \n",
            "8          ALBURX SOLUTION FOR INFUSION 5%, 20%, 25%   \n",
            "\n",
            "                                                   1  \\\n",
            "0                        Phenylephrine hydrochloride   \n",
            "1                                          Tadalafil   \n",
            "2                                Ertugliflozin L-PGA   \n",
            "3  Sitagliptin phosphate monohydrate / ertugliflo...   \n",
            "4  Lamivudine 100mg, Tenofovir disoproxil fumarat...   \n",
            "5                                         Adalimumab   \n",
            "6                                          Alpelisib   \n",
            "7                                       Galcanezumab   \n",
            "8                                      Human albumin   \n",
            "\n",
            "                                                   2  \\\n",
            "0                             NDA-2: New dosage form   \n",
            "1          NDA-2: New dosage formNDA-3: New strength   \n",
            "2      NDA-1: New chemical entityNDA-3: New strength   \n",
            "3          NDA-2: New combinationNDA-3: New strength   \n",
            "4                             NDA-2: New combination   \n",
            "5                                NDA-2: New strength   \n",
            "6  NDA-1 (250MG): New chemical entityNDA-3: Subse...   \n",
            "7                         NDA-1: New chemical entity   \n",
            "8  NDA-2: New dosage formNDA-3: Subsequent strengths   \n",
            "\n",
            "                                                 3            4  \\\n",
            "0                                   INTEGA PTE LTD   03/03/2020   \n",
            "1  ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED   09/03/2020   \n",
            "2                 MSD PHARMA (SINGAPORE) PTE. LTD.   11/03/2020   \n",
            "3                 MSD PHARMA (SINGAPORE) PTE. LTD.   11/03/2020   \n",
            "4           MSD PHARMA (SINGAPORE) PRIVATE LIMITED  13 Mar 2020   \n",
            "5                                 ABBVIE PTE. LTD.   19/03/2020   \n",
            "6                     NOVARTIS (SINGAPORE) PTE LTD   25/03/2020   \n",
            "7                    Eli Lilly (Singapore) Pte Ltd   25/03/2020   \n",
            "8                              CSL Behring Pte Ltd   11/03/2020   \n",
            "\n",
            "                                    5  \n",
            "0                           SIN15896P  \n",
            "1                 SIN15898P,SIN15899P  \n",
            "2                SIN15901P, SIN15902P  \n",
            "3                SIN15904P, SIN15905P  \n",
            "4                           SIN15909P  \n",
            "5                SIN15914P, SIN15915P  \n",
            "6  SIN15916P, SIN15917P and SIN15918P  \n",
            "7                           SIN15919P  \n",
            "8  SIN15903P, SIN15906P and SIN15907P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---mar-2020\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P', 'ISENTRESS HD FILM COATED TABLET 600MG']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P', 'ISENTRESS HD FILM COATED TABLET 600MG', 'Raltegravir']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P', 'ISENTRESS HD FILM COATED TABLET 600MG', 'Raltegravir', 'NDA-2: New strength']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P', 'ISENTRESS HD FILM COATED TABLET 600MG', 'Raltegravir', 'NDA-2: New strength', 'MSD Pharma (Singapore) Pte. Ltd.']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P', 'ISENTRESS HD FILM COATED TABLET 600MG', 'Raltegravir', 'NDA-2: New strength', 'MSD Pharma (Singapore) Pte. Ltd.', '27/04/2020']\n",
            "['NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, 500IU, 1000IU, 2000IU', 'SIMOCTOCOG ALFA', 'NDA-2: New dosage formNDA-3: New strength', 'WELLCHEM PHARMACEUTICALS PTE LTD', '01/04/2020', 'SIN15920P, SIN15921P, SIN15922P, SIN15923P', 'TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μg PER ACTUATION', 'Beclometasone dipropionate anhydrous 0.1mg/actuation, Formoterol fumarate dehydrate 0.006mg/actuation, Glycopyrronium bromide 0.0125mg/actuation', 'NDA-2: New combination', 'ORIENT EUROPHARMA PTE LTD', '02/04/2020', 'SIN15924P', 'AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED PEN 140MG/MLAIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED SYRINGE 140MG/ML', 'Erenumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '03/04/2020', 'SIN15925P, SIN15926P', 'XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL', 'Eravacycline', 'NDA-1: New drug', 'Everest Medicines (Singapore) Pte Ltd', '15/04/2020', 'SIN15930P', 'Complicated Intra-abdominal InfectionsXERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms:Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosusgroup,Clostridium perfringens, Bacteroidesspecies, andParabacteroides distasonisin patients 18 years or older [see Microbiology (10.4) and Clinical Studies (12.112)].Limitations of UseXERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies (12.2)].', 'SAMSCA TABLET 15MG', 'Tolvaptan', 'NDA-1:New Drug', 'Otsuka Pharmaceuticals (Singapore) Pte Ltd', '24/04/2020', 'SIN15934P', 'ISENTRESS HD FILM COATED TABLET 600MG', 'Raltegravir', 'NDA-2: New strength', 'MSD Pharma (Singapore) Pte. Ltd.', '27/04/2020', 'SIN15935P']\n",
            "                                                   0  \\\n",
            "0  NUWIQ POWDER AND SOLVENT FOR INJECTION 250IU, ...   \n",
            "1  TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/...   \n",
            "2  AIMOVIG SOLUTION FOR INJECTION FOR PRE-FILLED ...   \n",
            "3  XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR...   \n",
            "4  Complicated Intra-abdominal InfectionsXERAVA i...   \n",
            "5                                          SIN15934P   \n",
            "6                                          SIN15935P   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                    SIMOCTOCOG ALFA   \n",
            "1  Beclometasone dipropionate anhydrous 0.1mg/act...   \n",
            "2                                           Erenumab   \n",
            "3                                       Eravacycline   \n",
            "4                                 SAMSCA TABLET 15MG   \n",
            "5              ISENTRESS HD FILM COATED TABLET 600MG   \n",
            "6                                               None   \n",
            "\n",
            "                                           2  \\\n",
            "0  NDA-2: New dosage formNDA-3: New strength   \n",
            "1                     NDA-2: New combination   \n",
            "2                        NDA-3: New strength   \n",
            "3                            NDA-1: New drug   \n",
            "4                                  Tolvaptan   \n",
            "5                                Raltegravir   \n",
            "6                                       None   \n",
            "\n",
            "                                       3  \\\n",
            "0       WELLCHEM PHARMACEUTICALS PTE LTD   \n",
            "1              ORIENT EUROPHARMA PTE LTD   \n",
            "2           Novartis (Singapore) Pte Ltd   \n",
            "3  Everest Medicines (Singapore) Pte Ltd   \n",
            "4                         NDA-1:New Drug   \n",
            "5                    NDA-2: New strength   \n",
            "6                                   None   \n",
            "\n",
            "                                            4  \\\n",
            "0                                  01/04/2020   \n",
            "1                                  02/04/2020   \n",
            "2                                  03/04/2020   \n",
            "3                                  15/04/2020   \n",
            "4  Otsuka Pharmaceuticals (Singapore) Pte Ltd   \n",
            "5            MSD Pharma (Singapore) Pte. Ltd.   \n",
            "6                                        None   \n",
            "\n",
            "                                            5  \n",
            "0  SIN15920P, SIN15921P, SIN15922P, SIN15923P  \n",
            "1                                   SIN15924P  \n",
            "2                        SIN15925P, SIN15926P  \n",
            "3                                   SIN15930P  \n",
            "4                                  24/04/2020  \n",
            "5                                  27/04/2020  \n",
            "6                                        None  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---apr-2020\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P', 'TALZENNA CAPSULE 0.25MG AND 1MG']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P', 'TALZENNA CAPSULE 0.25MG AND 1MG', 'Talazoparib tosylate']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P', 'TALZENNA CAPSULE 0.25MG AND 1MG', 'Talazoparib tosylate', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P', 'TALZENNA CAPSULE 0.25MG AND 1MG', 'Talazoparib tosylate', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P', 'TALZENNA CAPSULE 0.25MG AND 1MG', 'Talazoparib tosylate', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '22/05/2020']\n",
            "['AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225MG/1.5ML', 'FREMANEZUMAB', 'NDA-1: New biological entity', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '08 MAY 2020', 'SIN15937P', 'TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG', 'Tucatinib', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '19/05/2020', 'SIN15942P, SIN15943P', 'TALZENNA CAPSULE 0.25MG AND 1MG', 'Talazoparib tosylate', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '22/05/2020', 'SIN15944P, SIN15945P']\n",
            "                                                   0                     1  \\\n",
            "0  AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYR...          FREMANEZUMAB   \n",
            "1        TUKYSA FILM-COATED TABLETS 50 MG AND 150 MG             Tucatinib   \n",
            "2                    TALZENNA CAPSULE 0.25MG AND 1MG  Talazoparib tosylate   \n",
            "\n",
            "                                               2  \\\n",
            "0                   NDA-1: New biological entity   \n",
            "1                     NDA-1: New chemical entity   \n",
            "2  NDA-1: New chemical entityNDA-3: New strength   \n",
            "\n",
            "                                  3            4                     5  \n",
            "0  DRUG HOUSES OF AUSTRALIA PTE LTD  08 MAY 2020             SIN15937P  \n",
            "1           NYPRAX PHARMA PTE. LTD.   19/05/2020  SIN15942P, SIN15943P  \n",
            "2            PFIZER PRIVATE LIMITED   22/05/2020  SIN15944P, SIN15945P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---may-2020\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P', 'LYSAKARE SOLUTION FOR INFUSION 25G / 25G']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P', 'LYSAKARE SOLUTION FOR INFUSION 25G / 25G', 'L-Arginine Hydrochloride, L-Lysine Hydrochloride']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P', 'LYSAKARE SOLUTION FOR INFUSION 25G / 25G', 'L-Arginine Hydrochloride, L-Lysine Hydrochloride', 'NDA-2: New combination']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P', 'LYSAKARE SOLUTION FOR INFUSION 25G / 25G', 'L-Arginine Hydrochloride, L-Lysine Hydrochloride', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P', 'LYSAKARE SOLUTION FOR INFUSION 25G / 25G', 'L-Arginine Hydrochloride, L-Lysine Hydrochloride', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '31/08/2020']\n",
            "['BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG', 'Erdafitinib', 'NDA-1/3', 'JOHNSON & JOHNSON PTE. LTD.', '07/08/2020', 'SIN15986P, SIN15987P, SIN15988P', 'DOVATO FILM-COATED TABLET 50MG/ 300MG', 'Dolutegravir, Lamivudine', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '13/08/2020', 'SIN15989P', 'VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib', 'NDA-1/2/3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '17/08/2020', 'SIN15991P, SIN15992P, SIN15993P', 'FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJECTION IN VIAL 100U/ML', 'Insulin Aspart', 'NDA-2', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '17/08/2020', 'SIN15994P, SIN15995P', 'LYSAKARE SOLUTION FOR INFUSION 25G / 25G', 'L-Arginine Hydrochloride, L-Lysine Hydrochloride', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '31/08/2020', 'SIN16003P']\n",
            "                                                   0  \\\n",
            "0         BALVERSA FILM-COATED TABLETS 3MG, 4MG, 5MG   \n",
            "1              DOVATO FILM-COATED TABLET 50MG/ 300MG   \n",
            "2  VITRAKVI HARD CAPSULE 100MG AND 25MGVITRAKVI O...   \n",
            "3  FIASP FLEXTOUCH 100U/MLFIASP SOLUTION FOR INJE...   \n",
            "4           LYSAKARE SOLUTION FOR INFUSION 25G / 25G   \n",
            "\n",
            "                                                  1                       2  \\\n",
            "0                                       Erdafitinib                 NDA-1/3   \n",
            "1                          Dolutegravir, Lamivudine                   NDA-2   \n",
            "2                                     Larotrectinib               NDA-1/2/3   \n",
            "3                                    Insulin Aspart                   NDA-2   \n",
            "4  L-Arginine Hydrochloride, L-Lysine Hydrochloride  NDA-2: New combination   \n",
            "\n",
            "                                         3           4  \\\n",
            "0              JOHNSON & JOHNSON PTE. LTD.  07/08/2020   \n",
            "1                  GLAXOSMITHKLINE PTE LTD  13/08/2020   \n",
            "2          BAYER (SOUTH EAST ASIA) PTE LTD  17/08/2020   \n",
            "3  NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  17/08/2020   \n",
            "4             NOVARTIS (SINGAPORE) PTE LTD  31/08/2020   \n",
            "\n",
            "                                 5  \n",
            "0  SIN15986P, SIN15987P, SIN15988P  \n",
            "1                        SIN15989P  \n",
            "2  SIN15991P, SIN15992P, SIN15993P  \n",
            "3             SIN15994P, SIN15995P  \n",
            "4                        SIN16003P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---aug-2020\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P', 'LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P', 'LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML', 'Lipegfilgrastim']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P', 'LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML', 'Lipegfilgrastim', 'NDA-1']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P', 'LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML', 'Lipegfilgrastim', 'NDA-1', 'Drug Houses of Australia Pte Ltd']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P', 'LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML', 'Lipegfilgrastim', 'NDA-1', 'Drug Houses of Australia Pte Ltd', '25/09/2020']\n",
            "['POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG', 'Polatuzumab vedotin', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE LTD', '08/09/2020', 'SIN16007P', 'SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED PEN 100U/ML', 'Insulin glargine', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '14/09/2020', 'SIN16009P', 'FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '21/09/2020', 'SIN16012P', 'ODEFSEY FILM COATED TABLET 200MG/25MG/25MG', 'Emtricitabine / Rilpivirine hydrochloride / Tenofovir alafenamide fumarate', 'NDA-2: New combination', 'JOHNSON & JOHNSON PTE LTD', '24/09/2020', 'SIN16015P', 'LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML', 'Lipegfilgrastim', 'NDA-1', 'Drug Houses of Australia Pte Ltd', '25/09/2020', 'SIN16019P']\n",
            "                                                   0  \\\n",
            "0  POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR...   \n",
            "1  SEMGLEE SOLUTION FOR INJECTION IN A PREFILLED ...   \n",
            "2          FULPHILA SOLUTION FOR INJECTION 6MG/0.6ML   \n",
            "3         ODEFSEY FILM COATED TABLET 200MG/25MG/25MG   \n",
            "4               LONQUEX PRE-FILLED SYRINGE 6MG/0.6ML   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                Polatuzumab vedotin   \n",
            "1                                   Insulin glargine   \n",
            "2                                      Pegfilgrastim   \n",
            "3  Emtricitabine / Rilpivirine hydrochloride / Te...   \n",
            "4                                    Lipegfilgrastim   \n",
            "\n",
            "                              2                                 3           4  \\\n",
            "0  NDA-1: New biological entity           ROCHE SINGAPORE PTE LTD  08/09/2020   \n",
            "1             NDA-2: Biosimilar   MYLAN PHARMACEUTICALS PTE. LTD.  14/09/2020   \n",
            "2             NDA-2: Biosimilar   MYLAN PHARMACEUTICALS PTE. LTD.  21/09/2020   \n",
            "3        NDA-2: New combination         JOHNSON & JOHNSON PTE LTD  24/09/2020   \n",
            "4                         NDA-1  Drug Houses of Australia Pte Ltd  25/09/2020   \n",
            "\n",
            "           5  \n",
            "0  SIN16007P  \n",
            "1  SIN16009P  \n",
            "2  SIN16012P  \n",
            "3  SIN16015P  \n",
            "4  SIN16019P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---sep-2020\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\"]\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P', 'SPRAVATO NASAL SPRAY 28 MG/VIAL']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P', 'SPRAVATO NASAL SPRAY 28 MG/VIAL', 'Esketamine']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P', 'SPRAVATO NASAL SPRAY 28 MG/VIAL', 'Esketamine', 'NDA-1']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P', 'SPRAVATO NASAL SPRAY 28 MG/VIAL', 'Esketamine', 'NDA-1', 'Johnson & Johnson Pte Ltd']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P', 'SPRAVATO NASAL SPRAY 28 MG/VIAL', 'Esketamine', 'NDA-1', 'Johnson & Johnson Pte Ltd', '27 Oct 2020']\n",
            "['PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFENT NASAL SPRAY SOLUTION 400MCG/SPRAY', 'Fentanyl', 'NDA-2: New dosage form', 'A.MENARINI SINGAPORE PTE. LTD.', '12/10/2020', 'SIN16026P, SIN16027P', 'XYZAL FILM-COATED TABLET 5 MG', 'Levocetirizine dihydrochloride (5 mg)', \"NDA-2*: New forensic classification of the 50's pack size (Split license from SIN12084P)\", 'GlaxoSmithKline Pte. Ltd.', '14/10/2020', 'SIN16028P', 'DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML', 'Daratumumab', 'NDA-2: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '27/10/2020', 'SIN16032P', 'SPRAVATO NASAL SPRAY 28 MG/VIAL', 'Esketamine', 'NDA-1', 'Johnson & Johnson Pte Ltd', '27 Oct 2020', 'SIN16033P']\n",
            "                                                   0  \\\n",
            "0  PECFENT NASAL SPRAY SOLUTION 100MCG/SPRAYPECFE...   \n",
            "1                      XYZAL FILM-COATED TABLET 5 MG   \n",
            "2     DARZALEX SC SOLUTION FOR INJECTION 1800MG/15ML   \n",
            "3                    SPRAVATO NASAL SPRAY 28 MG/VIAL   \n",
            "\n",
            "                                       1  \\\n",
            "0                               Fentanyl   \n",
            "1  Levocetirizine dihydrochloride (5 mg)   \n",
            "2                            Daratumumab   \n",
            "3                             Esketamine   \n",
            "\n",
            "                                                   2  \\\n",
            "0                             NDA-2: New dosage form   \n",
            "1  NDA-2*: New forensic classification of the 50'...   \n",
            "2                             NDA-2: New dosage form   \n",
            "3                                              NDA-1   \n",
            "\n",
            "                                3            4                     5  \n",
            "0  A.MENARINI SINGAPORE PTE. LTD.   12/10/2020  SIN16026P, SIN16027P  \n",
            "1       GlaxoSmithKline Pte. Ltd.   14/10/2020             SIN16028P  \n",
            "2       JOHNSON & JOHNSON PTE LTD   27/10/2020             SIN16032P  \n",
            "3       Johnson & Johnson Pte Ltd  27 Oct 2020             SIN16033P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---oct-2020\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P', 'TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440MG']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P', 'TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440MG', 'Trastuzumab']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P', 'TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440MG', 'Trastuzumab', 'NDA-2']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P', 'TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440MG', 'Trastuzumab', 'NDA-2', 'Pfizer Private Limited']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P', 'TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440MG', 'Trastuzumab', 'NDA-2', 'Pfizer Private Limited', '11 Nov 2020']\n",
            "['MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG', 'Siponimod', 'NDA-1: New chemical entity', 'Novartis (Singapore) Pte Ltd', '16 Nov 2020', 'SIN16039P, SIN16040P', 'FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)', 'Benralizumab', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '18/11/2020', 'SIN16043P', 'ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/ 500IU/ 1000IU/ 1500IU/ 2000IU/ 3000IU', 'Rurioctocog alfa pegol [Antihemophilic Factor (Recombinant), PEGylated]', 'NDA-1 and NDA-3: New biological entity and new strength', 'Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.', '24 Nov 2020', 'SIN16048P, SIN16049P, SIN16050P, SIN16051P, SIN16052P, SIN16053P', 'TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440MG', 'Trastuzumab', 'NDA-2', 'Pfizer Private Limited', '11 Nov 2020', 'SIN16038P']\n",
            "                                                   0  \\\n",
            "0         MAYZENT FILM-COATED TABLETS 0.25MG AND 2MG   \n",
            "1  FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOIN...   \n",
            "2  ADYNOVATE POWDER AND SOLVENT FOR SOLUTION FOR ...   \n",
            "3  TRAZIMERA POWDER FOR CONCENTRATE FOR SOLUTION ...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                          Siponimod   \n",
            "1                                       Benralizumab   \n",
            "2  Rurioctocog alfa pegol [Antihemophilic Factor ...   \n",
            "3                                        Trastuzumab   \n",
            "\n",
            "                                                   2  \\\n",
            "0                         NDA-1: New chemical entity   \n",
            "1                             NDA-2: New dosage form   \n",
            "2  NDA-1 and NDA-3: New biological entity and new...   \n",
            "3                                              NDA-2   \n",
            "\n",
            "                                                 3            4  \\\n",
            "0                     Novartis (Singapore) Pte Ltd  16 Nov 2020   \n",
            "1                    ASTRAZENECA SINGAPORE PTE LTD   18/11/2020   \n",
            "2  Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd.  24 Nov 2020   \n",
            "3                           Pfizer Private Limited  11 Nov 2020   \n",
            "\n",
            "                                                   5  \n",
            "0                               SIN16039P, SIN16040P  \n",
            "1                                          SIN16043P  \n",
            "2  SIN16048P, SIN16049P, SIN16050P, SIN16051P, SI...  \n",
            "3                                          SIN16038P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---nov-2020\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P', 'REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE-FILLED SYRINGEREMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE=FILLED PEN']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P', 'REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE-FILLED SYRINGEREMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE=FILLED PEN', 'Infliximab']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P', 'REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE-FILLED SYRINGEREMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE=FILLED PEN', 'Infliximab', 'NDA-2: New presentation and new route of administration']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P', 'REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE-FILLED SYRINGEREMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE=FILLED PEN', 'Infliximab', 'NDA-2: New presentation and new route of administration', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P', 'REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE-FILLED SYRINGEREMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE=FILLED PEN', 'Infliximab', 'NDA-2: New presentation and new route of administration', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '29/12/2020']\n",
            "['LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG', 'Edoxaban Tosilate', 'NDA-1: New chemical/biological entityNDA-3: New strength', 'A.MENARINI SINGAPORE PTE LTD', '18/12/2020', 'SIN16059P, SIN16060P, SIN16061P', 'NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML', 'Dinalbuphine sebacate', 'NDA-1: New chemical entity', 'INTEGA PTE LTD', '15/12/2020', 'SIN16058P', 'EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Galcanezumab', 'NDA-2: New presentation/indication/strength', 'Eli Lilly (Singapore) Pte Ltd', '18 Dec 20', 'SIN16063P', 'REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE-FILLED SYRINGEREMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120MG/ML IN PRE=FILLED PEN', 'Infliximab', 'NDA-2: New presentation and new route of administration', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '29/12/2020', 'SIN16069P, SIN16070P']\n",
            "                                                   0                      1  \\\n",
            "0     LIXIANA FILM-COATED TABLET 15MG, 30MG AND 60MG      Edoxaban Tosilate   \n",
            "1      NALDEBAIN EXTENDED RELEASE INJECTION 75 MG/ML  Dinalbuphine sebacate   \n",
            "2  EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED ...           Galcanezumab   \n",
            "3  REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 12...             Infliximab   \n",
            "\n",
            "                                                   2  \\\n",
            "0  NDA-1: New chemical/biological entityNDA-3: Ne...   \n",
            "1                         NDA-1: New chemical entity   \n",
            "2        NDA-2: New presentation/indication/strength   \n",
            "3  NDA-2: New presentation and new route of admin...   \n",
            "\n",
            "                                                3           4  \\\n",
            "0                    A.MENARINI SINGAPORE PTE LTD  18/12/2020   \n",
            "1                                  INTEGA PTE LTD  15/12/2020   \n",
            "2                   Eli Lilly (Singapore) Pte Ltd   18 Dec 20   \n",
            "3  CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED  29/12/2020   \n",
            "\n",
            "                                 5  \n",
            "0  SIN16059P, SIN16060P, SIN16061P  \n",
            "1                        SIN16058P  \n",
            "2                        SIN16063P  \n",
            "3             SIN16069P, SIN16070P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---dec-2020\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Rituxiamb']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Rituxiamb', 'NDA-2/3: New biosimilar']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Rituxiamb', 'NDA-2/3: New biosimilar', 'Novartis (Singapore) Pte Ltd']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Rituxiamb', 'NDA-2/3: New biosimilar', 'Novartis (Singapore) Pte Ltd', '30/06/2020']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Rituxiamb', 'NDA-2/3: New biosimilar', 'Novartis (Singapore) Pte Ltd', '30/06/2020', 'SIN15969P, SIN15970P']\n",
            "['LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML', 'Lutetium (177Lu) oxodotreotide', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '01/06/2020', 'SIN15947P', 'IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Infliximab', 'NDA-2', 'PFIZER PRIVATE LIMITED', '03/06/2020', 'SIN15948P', 'VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALVEKLURY SOLUTION FOR IV INFUSION 5MG/ML', 'Remdesivir', 'NDA-1/2', 'GILEAD SCIENCES SINGAPORE PTE LTD', '10/06/2020 (Conditional approval)', 'SIN15950P, SIN15951P', 'BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML', 'Insulin glargine', 'NDA-2', 'DUOPHARMA (SINGAPORE) PTE LTD', '12/06/2020', 'SIN15954P', 'RINVOQ EXTENDED RELEASE TABLETS 15MG', 'Upadacitinib', 'NDA-1', 'Abbvie Pte. Ltd.', '16/06/2020', 'SIN15959P', 'LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G', 'Sodium zirconium cyclosilicate', 'NDA-1/3', 'ASTRAZENECA SINGAPORE PTE LTD', '22/06/2020', 'SIN15961P, SIN15962P', 'BILAXTEN ORAL SOLUTION 2.5MG/ML', 'Bilastine', 'NDA-2', 'A Menarini Singapore Pte Ltd', '24/06/2020', 'SIN15963P', 'Symptomatic treatment of allergic rhino-conjunctivitis and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.', 'TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION 840MG/14ML', 'Atezolizumab', 'NDA-2', 'ROCHE SINGAPORE PTE. LTD.', '25 June 2020', 'SIN15964P', 'Triple-negative breast cancerTecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.', 'VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-COATED TABLET 30MGVIZIMPRO FILM-COATED TABLET 45MG', 'Dacomitinib monohydrate', 'NDA-1/3: New chemical entity', 'Pfizer Private Limited', '25/06/2020', 'SIN15965P, SIN15966P, SIN15967P', 'VIZIMPRO is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deltion or exon 21 L858R substitution mutations).', 'RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLRIXATHONG CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Rituxiamb', 'NDA-2/3: New biosimilar', 'Novartis (Singapore) Pte Ltd', '30/06/2020', 'SIN15969P, SIN15970P', 'RIXATHON is indicated for the treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin’s lymphomas. RIXATHON is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma (DLCL) in combination with CHOP (cyclophosphamide, doxorubicin vincristine and prednisone) chemotherapy. RIXATHON is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with CVP chemotherapy. RIXATHON maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.Chronic Lymphocytic LeukaemiaRIXATHON is indicated in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.']\n",
            "                                                    0  \\\n",
            "0          LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML   \n",
            "1   IXIFI POWDER FOR CONCENTRATE FOR SOLUTION FOR ...   \n",
            "2   VEKLURY LYOPHILIZED POWDER FOR IV INFUSION 100...   \n",
            "3   BASALOG ONE SOLUTION FOR INJECTION IN A PRE-FI...   \n",
            "4                RINVOQ EXTENDED RELEASE TABLETS 15MG   \n",
            "5          LOKELMA POWDER FOR ORAL SUSPENSION 5G, 10G   \n",
            "6                     BILAXTEN ORAL SOLUTION 2.5MG/ML   \n",
            "7   Symptomatic treatment of allergic rhino-conjun...   \n",
            "8                                           SIN15964P   \n",
            "9                                          25/06/2020   \n",
            "10                       Novartis (Singapore) Pte Ltd   \n",
            "\n",
            "                                                    1  \\\n",
            "0                      Lutetium (177Lu) oxodotreotide   \n",
            "1                                          Infliximab   \n",
            "2                                          Remdesivir   \n",
            "3                                    Insulin glargine   \n",
            "4                                        Upadacitinib   \n",
            "5                      Sodium zirconium cyclosilicate   \n",
            "6                                           Bilastine   \n",
            "7   TECENTRIQ CONCENTRATE FOR SOLUTION FORINFUSION...   \n",
            "8   Triple-negative breast cancerTecentriq, in com...   \n",
            "9                     SIN15965P, SIN15966P, SIN15967P   \n",
            "10                                         30/06/2020   \n",
            "\n",
            "                                                    2  \\\n",
            "0                          NDA-1: New chemical entity   \n",
            "1                                               NDA-2   \n",
            "2                                             NDA-1/2   \n",
            "3                                               NDA-2   \n",
            "4                                               NDA-1   \n",
            "5                                             NDA-1/3   \n",
            "6                                               NDA-2   \n",
            "7                                        Atezolizumab   \n",
            "8   VIZIMPRO FILM-COATED TABLET 15MGVIZIMPRO FILM-...   \n",
            "9   VIZIMPRO is indicated for the first-line treat...   \n",
            "10                               SIN15969P, SIN15970P   \n",
            "\n",
            "                                                    3  \\\n",
            "0                        NOVARTIS (SINGAPORE) PTE LTD   \n",
            "1                              PFIZER PRIVATE LIMITED   \n",
            "2                   GILEAD SCIENCES SINGAPORE PTE LTD   \n",
            "3                       DUOPHARMA (SINGAPORE) PTE LTD   \n",
            "4                                    Abbvie Pte. Ltd.   \n",
            "5                       ASTRAZENECA SINGAPORE PTE LTD   \n",
            "6                        A Menarini Singapore Pte Ltd   \n",
            "7                                               NDA-2   \n",
            "8                             Dacomitinib monohydrate   \n",
            "9   RIXATHON CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "10  RIXATHON is indicated for the treatment of pat...   \n",
            "\n",
            "                                    4                        5  \n",
            "0                          01/06/2020                SIN15947P  \n",
            "1                          03/06/2020                SIN15948P  \n",
            "2   10/06/2020 (Conditional approval)     SIN15950P, SIN15951P  \n",
            "3                          12/06/2020                SIN15954P  \n",
            "4                          16/06/2020                SIN15959P  \n",
            "5                          22/06/2020     SIN15961P, SIN15962P  \n",
            "6                          24/06/2020                SIN15963P  \n",
            "7           ROCHE SINGAPORE PTE. LTD.             25 June 2020  \n",
            "8        NDA-1/3: New chemical entity   Pfizer Private Limited  \n",
            "9                           Rituxiamb  NDA-2/3: New biosimilar  \n",
            "10                               None                     None  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---june-2020\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P', 'FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG, 600MCG AND 800MCG']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P', 'FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG, 600MCG AND 800MCG', 'Fentanyl Citrate']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P', 'FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG, 600MCG AND 800MCG', 'Fentanyl Citrate', 'NDA-2: New dosage formNDA-3: Subsequent new strengths']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P', 'FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG, 600MCG AND 800MCG', 'Fentanyl Citrate', 'NDA-2: New dosage formNDA-3: Subsequent new strengths', 'DRUG HOUSES OF AUSTRALIA PTE LTD']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P', 'FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG, 600MCG AND 800MCG', 'Fentanyl Citrate', 'NDA-2: New dosage formNDA-3: Subsequent new strengths', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '28 July 2020']\n",
            "['ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML', 'Lutetium (177Lu) chloride', 'NDA-1: New chemical entity', 'QT INSTRUMENTS (S) PTE LTD', '03/07/2020', 'SIN15971P', 'SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG', 'Risankizumab', 'NDA-1: New chemical entity', 'ABBVIE PTE LTD', '06/07/2020', 'SIN15972P', 'FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG, 600MCG AND 800MCG', 'Fentanyl Citrate', 'NDA-2: New dosage formNDA-3: Subsequent new strengths', 'DRUG HOUSES OF AUSTRALIA PTE LTD', '28 July 2020', 'SIN15977P, SIN15978P, SIN15979P, SIN15980P, SIN15981P']\n",
            "                                                   0  \\\n",
            "0  ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SO...   \n",
            "1  SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED S...   \n",
            "2  FENTORA® BUCCAL TABLETS 100MCG, 200MCG, 400MCG...   \n",
            "\n",
            "                           1  \\\n",
            "0  Lutetium (177Lu) chloride   \n",
            "1               Risankizumab   \n",
            "2           Fentanyl Citrate   \n",
            "\n",
            "                                                   2  \\\n",
            "0                         NDA-1: New chemical entity   \n",
            "1                         NDA-1: New chemical entity   \n",
            "2  NDA-2: New dosage formNDA-3: Subsequent new st...   \n",
            "\n",
            "                                  3             4  \\\n",
            "0        QT INSTRUMENTS (S) PTE LTD    03/07/2020   \n",
            "1                    ABBVIE PTE LTD    06/07/2020   \n",
            "2  DRUG HOUSES OF AUSTRALIA PTE LTD  28 July 2020   \n",
            "\n",
            "                                                   5  \n",
            "0                                          SIN15971P  \n",
            "1                                          SIN15972P  \n",
            "2  SIN15977P, SIN15978P, SIN15979P, SIN15980P, SI...  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2020\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P', 'CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P', 'CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)', 'Loratadine']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P', 'CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)', 'Loratadine', 'NDA-2']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P', 'CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)', 'Loratadine', 'NDA-2', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P', 'CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)', 'Loratadine', 'NDA-2', 'BAYER (SOUTH EAST ASIA) PTE LTD', '29/1/2021']\n",
            "['SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR INJECTION 16 MICROLITRE PER VIAL', 'Perfluorobutane (microbubbles)', 'NDA-1', 'GE HEALTHCARE PTE. LTD.', '06/01/2021', 'SIN16077P', 'SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML', '[Antigen] Recombinant Varicella Zoster Virus glycoprotein E (gE)', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '12/01/2021', 'SIN16079P', 'IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL', 'Adalimumab', 'NDA-2', 'FRESENIUS KABI (SINGAPORE) PTE LTD', '25/01/2021', 'SIN16083PSIN16084PSIN16085P', 'ROZLYTREK HARD CAPSULES 100MG AND 200MG', 'Entrectinib', 'NDA-1,3', 'ROCHE SINGAPORE PTE LTD', '27/01/2021', 'SIN16086P, SIN16087P', 'XOSPATA® FILM-COATED TABLETS 40 MG', 'Gilteritinib', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '28/01/2021', 'SIN16088P', 'CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)', 'Loratadine', 'NDA-2', 'BAYER (SOUTH EAST ASIA) PTE LTD', '29/1/2021', 'SIN16091P']\n",
            "                                                   0  \\\n",
            "0  SONAZOID POWDER AND SOLVENT FOR DISPERSION FOR...   \n",
            "1  SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION ...   \n",
            "2  IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PE...   \n",
            "3            ROZLYTREK HARD CAPSULES 100MG AND 200MG   \n",
            "4                 XOSPATA® FILM-COATED TABLETS 40 MG   \n",
            "5            CLARITYN SYRUP 5 MG/5 ML (GRAPE FLAVOR)   \n",
            "\n",
            "                                                   1        2  \\\n",
            "0                     Perfluorobutane (microbubbles)    NDA-1   \n",
            "1  [Antigen] Recombinant Varicella Zoster Virus g...    NDA-1   \n",
            "2                                         Adalimumab    NDA-2   \n",
            "3                                        Entrectinib  NDA-1,3   \n",
            "4                                       Gilteritinib    NDA-1   \n",
            "5                                         Loratadine    NDA-2   \n",
            "\n",
            "                                     3           4  \\\n",
            "0              GE HEALTHCARE PTE. LTD.  06/01/2021   \n",
            "1              GLAXOSMITHKLINE PTE LTD  12/01/2021   \n",
            "2   FRESENIUS KABI (SINGAPORE) PTE LTD  25/01/2021   \n",
            "3              ROCHE SINGAPORE PTE LTD  27/01/2021   \n",
            "4  ASTELLAS PHARMA SINGAPORE PTE. LTD.  28/01/2021   \n",
            "5      BAYER (SOUTH EAST ASIA) PTE LTD   29/1/2021   \n",
            "\n",
            "                             5  \n",
            "0                    SIN16077P  \n",
            "1                    SIN16079P  \n",
            "2  SIN16083PSIN16084PSIN16085P  \n",
            "3         SIN16086P, SIN16087P  \n",
            "4                    SIN16088P  \n",
            "5                    SIN16091P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---jan-2021\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P', 'VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNITS/VIAL']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P', 'VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNITS/VIAL', 'Velaglucerase alfa']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P', 'VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNITS/VIAL', 'Velaglucerase alfa', 'NDA-1: New Chemical Entity']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P', 'VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNITS/VIAL', 'Velaglucerase alfa', 'NDA-1: New Chemical Entity', 'Takeda Pharmaceuticals (Asia Pacific) Pte Ltd']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P', 'VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNITS/VIAL', 'Velaglucerase alfa', 'NDA-1: New Chemical Entity', 'Takeda Pharmaceuticals (Asia Pacific) Pte Ltd', '24/02/2021']\n",
            "['KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4MLKESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML', 'Ofatumumab', 'NDA-1: New biological entityNDA-2: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/02/2021', 'SIN16100P, SIN16101P', 'NUBEQA FILM-COATED TABLET 300MG', 'Darolutamide milled', 'NDA-1: New chemical entity', 'BAYER (SOUTH EAST ASIA) PTE LTD', '11/02/2021', 'SIN16103P', 'GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc) STERILE GENERATOR', 'Sodium pertechnetate (99mTc)', 'NDA-2: New dosage form/indication', 'TRANSMEDIC PTE LTD', '24/02/2021', 'SIN16108P', 'VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNITS/VIAL', 'Velaglucerase alfa', 'NDA-1: New Chemical Entity', 'Takeda Pharmaceuticals (Asia Pacific) Pte Ltd', '24/02/2021', 'SIN16107P']\n",
            "                                                   0  \\\n",
            "0  KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED ...   \n",
            "1                    NUBEQA FILM-COATED TABLET 300MG   \n",
            "2  GENTECH MOLYBDENUM (99Mo) / TECHNETIUM (99mTc)...   \n",
            "3  VPRIV POWDER FOR SOLUTION FOR INFUSION 400UNIT...   \n",
            "\n",
            "                              1  \\\n",
            "0                    Ofatumumab   \n",
            "1           Darolutamide milled   \n",
            "2  Sodium pertechnetate (99mTc)   \n",
            "3            Velaglucerase alfa   \n",
            "\n",
            "                                                 2  \\\n",
            "0  NDA-1: New biological entityNDA-2: New strength   \n",
            "1                       NDA-1: New chemical entity   \n",
            "2                NDA-2: New dosage form/indication   \n",
            "3                       NDA-1: New Chemical Entity   \n",
            "\n",
            "                                               3           4  \\\n",
            "0                   NOVARTIS (SINGAPORE) PTE LTD  05/02/2021   \n",
            "1                BAYER (SOUTH EAST ASIA) PTE LTD  11/02/2021   \n",
            "2                             TRANSMEDIC PTE LTD  24/02/2021   \n",
            "3  Takeda Pharmaceuticals (Asia Pacific) Pte Ltd  24/02/2021   \n",
            "\n",
            "                      5  \n",
            "0  SIN16100P, SIN16101P  \n",
            "1             SIN16103P  \n",
            "2             SIN16108P  \n",
            "3             SIN16107P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---feb-2021\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P', 'SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSIONSMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P', 'SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSIONSMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION', 'SMOFLipid 20% (SIN13246P)Amino acids ± electrolytesGlucose']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P', 'SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSIONSMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION', 'SMOFLipid 20% (SIN13246P)Amino acids ± electrolytesGlucose', 'NDA-2: New strength']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P', 'SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSIONSMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION', 'SMOFLipid 20% (SIN13246P)Amino acids ± electrolytesGlucose', 'NDA-2: New strength', 'Fresenius Kabi (Singapore) Pte Ltd']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P', 'SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSIONSMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION', 'SMOFLipid 20% (SIN13246P)Amino acids ± electrolytesGlucose', 'NDA-2: New strength', 'Fresenius Kabi (Singapore) Pte Ltd', '24 Mar 2021']\n",
            "['NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL, 500IU/VIAL AND 1000IU/VIAL', 'Turoctocog Alfa', 'NDA-1: New biological entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/03/2021', 'SIN16109P, SIN16110P, SIN16111P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML AND 150MG/1.0ML', 'Omalizumab', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '04/03/2021', 'SIN16115P and SIN16116P', 'ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIAL (50 MBQ TO 6000 MBQ)', 'Sodium Iodide [I-131] 50 to 6000 MBq', 'NDA-2: New strength', 'Transmedic Pte Ltd', '08/03/2021', 'SIN16117P', 'SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML', 'Golimumab', 'NDA-2: New strength', 'Johnson & Johnson Pte. Ltd.', '09/03/2021', 'SIN16118P', 'ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML', 'Aripiprazole', 'NDA-2: New strengthNDA-2: New dosage form', 'OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.', '10/03/2021', 'SIN16119PSIN16120P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml', 'Dupilumab', 'NDA-2: New strength, new indication and dosing regimen', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '15 Mar 2021', 'SIN16121P', 'PANADOL CHILDREN SUSPENSION 250MG/5ML', 'Paracetamol', 'NDA-2: New dosage form', 'GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.', '30/03/2021', 'SIN16142P', 'SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSIONSMOFKABIVEN EXTRA NITROGEN ELECTROLYTE-FREE EMULSION FOR INFUSION', 'SMOFLipid 20% (SIN13246P)Amino acids ± electrolytesGlucose', 'NDA-2: New strength', 'Fresenius Kabi (Singapore) Pte Ltd', '24 Mar 2021', 'SIN16135PSIN16136P']\n",
            "                                                   0  \\\n",
            "0  NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR ...   \n",
            "1  XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SY...   \n",
            "2  ANSTO-SODIUM IODIDE [131I] THERAPY CAPSULE VIA...   \n",
            "3  SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "4     ABILIFY TABLET 2MGABILIFY ORAL SOLUTION 1MG/ML   \n",
            "5  DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLE...   \n",
            "6              PANADOL CHILDREN SUSPENSION 250MG/5ML   \n",
            "7  SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSI...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                    Turoctocog Alfa   \n",
            "1                                         Omalizumab   \n",
            "2               Sodium Iodide [I-131] 50 to 6000 MBq   \n",
            "3                                          Golimumab   \n",
            "4                                       Aripiprazole   \n",
            "5                                          Dupilumab   \n",
            "6                                        Paracetamol   \n",
            "7  SMOFLipid 20% (SIN13246P)Amino acids ± electro...   \n",
            "\n",
            "                                                   2  \\\n",
            "0    NDA-1: New biological entityNDA-3: New strength   \n",
            "1          NDA-2: New dosage formNDA-3: New strength   \n",
            "2                                NDA-2: New strength   \n",
            "3                                NDA-2: New strength   \n",
            "4          NDA-2: New strengthNDA-2: New dosage form   \n",
            "5  NDA-2: New strength, new indication and dosing...   \n",
            "6                             NDA-2: New dosage form   \n",
            "7                                NDA-2: New strength   \n",
            "\n",
            "                                              3            4  \\\n",
            "0       NOVO NORDISK PHARMA (SINGAPORE) PTE LTD   01/03/2021   \n",
            "1                  NOVARTIS (SINGAPORE) PTE LTD   04/03/2021   \n",
            "2                            Transmedic Pte Ltd   08/03/2021   \n",
            "3                   Johnson & Johnson Pte. Ltd.   09/03/2021   \n",
            "4  OTSUKA PHARMACEUTICALS (SINGAPORE) PTE. LTD.   10/03/2021   \n",
            "5            SANOFI-AVENTIS SINGAPORE PTE. LTD.  15 Mar 2021   \n",
            "6   GSK CONSUMER HEALTHCARE SINGAPORE PTE. LTD.   30/03/2021   \n",
            "7            Fresenius Kabi (Singapore) Pte Ltd  24 Mar 2021   \n",
            "\n",
            "                                 5  \n",
            "0  SIN16109P, SIN16110P, SIN16111P  \n",
            "1          SIN16115P and SIN16116P  \n",
            "2                        SIN16117P  \n",
            "3                        SIN16118P  \n",
            "4               SIN16119PSIN16120P  \n",
            "5                        SIN16121P  \n",
            "6                        SIN16142P  \n",
            "7               SIN16135PSIN16136P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---mar-2021\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P', 'Nucala Solution for Injection in Pre-filled Syringe 100mg/mLNucala Solution for Injection in Pre-filled Pen 100mg/mL']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P', 'Nucala Solution for Injection in Pre-filled Syringe 100mg/mLNucala Solution for Injection in Pre-filled Pen 100mg/mL', 'Mepolizumab']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P', 'Nucala Solution for Injection in Pre-filled Syringe 100mg/mLNucala Solution for Injection in Pre-filled Pen 100mg/mL', 'Mepolizumab', 'NDA-2: New presentation']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P', 'Nucala Solution for Injection in Pre-filled Syringe 100mg/mLNucala Solution for Injection in Pre-filled Pen 100mg/mL', 'Mepolizumab', 'NDA-2: New presentation', 'GlaxoSmithKline Pte Ltd']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P', 'Nucala Solution for Injection in Pre-filled Syringe 100mg/mLNucala Solution for Injection in Pre-filled Pen 100mg/mL', 'Mepolizumab', 'NDA-2: New presentation', 'GlaxoSmithKline Pte Ltd', '27/04/2021']\n",
            "['VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML', 'Human Fibrinogen and Human Thrombin', 'NDA-2: New dosage form', 'GRIFOLS ASIA PACIFIC PTE LTD', '01/04/2021', 'SIN16143P', 'EYBELIS OPHTHALMIC SOLUTION 0.002%', 'Omidenepag Isopropyl', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '07/04/2021', 'SIN16150P', 'ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCGATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG', 'Indacaterol/Mometasone furoate', 'NDA-2/3: New combination/New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '07/04/2021', 'SIN16147PSIN16148PSIN16149P', 'ENERZAIR BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /50 MCG /160 MCG', 'Indacaterol/ Glycopyrronium/ Mometasone furoate', 'NDA-2: New combination', 'NOVARTIS (SINGAPORE) PTE LTD', '14/04/2021', 'SIN16153P', 'OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED PEN 1 MG/DOSE, 0.25 MG, 0.5 G/DOSE', 'Semaglutide', 'NDA-1: New Biological Entity', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '21/04/2021', 'SIN16164P, SIN16165P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1/3: New Biological Entity, New Strengths', 'KYOWA KIRIN ASIA PACIFIC PTE LTD', '30/04/2021', 'SIN16176P, SIN16177P, SIN16178P', 'MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '10/04/2021', 'SIN16151P', 'Nucala Solution for Injection in Pre-filled Syringe 100mg/mLNucala Solution for Injection in Pre-filled Pen 100mg/mL', 'Mepolizumab', 'NDA-2: New presentation', 'GlaxoSmithKline Pte Ltd', '27/04/2021', 'SIN16171P, SIN16172P']\n",
            "                                                   0  \\\n",
            "0  VERASEAL SOLUTION FOR SEALANT 80 MG/ML, 500 IU/ML   \n",
            "1                 EYBELIS OPHTHALMIC SOLUTION 0.002%   \n",
            "2  ATECTURA BREEZHALER INHALATION POWDER, HARD CA...   \n",
            "3  ENERZAIR BREEZHALER INHALATION POWDER, HARD CA...   \n",
            "4  OZEMPIC SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "5  CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG...   \n",
            "6  MVASI CONCENTRATE FOR SOLUTION FOR INFUSION 25...   \n",
            "7  Nucala Solution for Injection in Pre-filled Sy...   \n",
            "\n",
            "                                                 1  \\\n",
            "0              Human Fibrinogen and Human Thrombin   \n",
            "1                             Omidenepag Isopropyl   \n",
            "2                   Indacaterol/Mometasone furoate   \n",
            "3  Indacaterol/ Glycopyrronium/ Mometasone furoate   \n",
            "4                                      Semaglutide   \n",
            "5                                        Burosumab   \n",
            "6                                      Bevacizumab   \n",
            "7                                      Mepolizumab   \n",
            "\n",
            "                                               2  \\\n",
            "0                         NDA-2: New dosage form   \n",
            "1                     NDA-1: New chemical entity   \n",
            "2          NDA-2/3: New combination/New strength   \n",
            "3                         NDA-2: New combination   \n",
            "4                   NDA-1: New Biological Entity   \n",
            "5  NDA-1/3: New Biological Entity, New Strengths   \n",
            "6                              NDA-2: Biosimilar   \n",
            "7                        NDA-2: New presentation   \n",
            "\n",
            "                                         3           4  \\\n",
            "0             GRIFOLS ASIA PACIFIC PTE LTD  01/04/2021   \n",
            "1     SANTEN PHARMACEUTICAL ASIA PTE. LTD.  07/04/2021   \n",
            "2             NOVARTIS (SINGAPORE) PTE LTD  07/04/2021   \n",
            "3             NOVARTIS (SINGAPORE) PTE LTD  14/04/2021   \n",
            "4  NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  21/04/2021   \n",
            "5         KYOWA KIRIN ASIA PACIFIC PTE LTD  30/04/2021   \n",
            "6    AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD  10/04/2021   \n",
            "7                  GlaxoSmithKline Pte Ltd  27/04/2021   \n",
            "\n",
            "                                 5  \n",
            "0                        SIN16143P  \n",
            "1                        SIN16150P  \n",
            "2      SIN16147PSIN16148PSIN16149P  \n",
            "3                        SIN16153P  \n",
            "4             SIN16164P, SIN16165P  \n",
            "5  SIN16176P, SIN16177P, SIN16178P  \n",
            "6                        SIN16151P  \n",
            "7             SIN16171P, SIN16172P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---apr-2021\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1: New chemical entity, NDA-3: New strengths']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1: New chemical entity, NDA-3: New strengths', 'Kyowa Kirin Asia Pacific Pte Ltd']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1: New chemical entity, NDA-3: New strengths', 'Kyowa Kirin Asia Pacific Pte Ltd', '3/5/2021']\n",
            "['REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML', 'Agalsidase alfa', 'NDA-1: New biological entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/05/2021', 'SIN16197P', 'APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5MG, 300MG/10MG', 'Irbesartan, amlodipine besilate', 'NDA-2: New combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '14/05/2021', 'SIN16194P, SIN16195P, SIN16196P', 'REMLEAS HARD CAPSULES 40MG', 'Valbenazine ditosylate 73mg eqv valbenazine 40mg', 'NDA-1: New chemical entity', 'MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD', '19/5/2021', 'SIN16198P', 'KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 440MG/VIAL', 'Trastuzumab', 'NDA-2: BiosimilarNDA-3: New strength', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '25/5/2021', 'SIN16206P, SIN16207P', 'EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML', 'Romosozumab', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '27/5/2021', 'SIN16208P', 'CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG/ML, 30MG/ML', 'Burosumab', 'NDA-1: New chemical entity, NDA-3: New strengths', 'Kyowa Kirin Asia Pacific Pte Ltd', '3/5/2021', 'SIN16176P, SIN16177P, SIN16178P']\n",
            "                                                   0  \\\n",
            "0  REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "1  APROVASC FILM COATED TABLET 150MG/5MG, 300MG/5...   \n",
            "2                         REMLEAS HARD CAPSULES 40MG   \n",
            "3  KANJINTI POWDER FOR INJECTION 150MG/VIAL AND 4...   \n",
            "4  EVENITY SOLUTION FOR INJECTION IN PRE-FILLED S...   \n",
            "5  CRYSVITA® SOLUTION FOR INJECTION 10MG/ML, 20MG...   \n",
            "\n",
            "                                                  1  \\\n",
            "0                                   Agalsidase alfa   \n",
            "1                   Irbesartan, amlodipine besilate   \n",
            "2  Valbenazine ditosylate 73mg eqv valbenazine 40mg   \n",
            "3                                       Trastuzumab   \n",
            "4                                       Romosozumab   \n",
            "5                                         Burosumab   \n",
            "\n",
            "                                                  2  \\\n",
            "0                      NDA-1: New biological entity   \n",
            "1                            NDA-2: New combination   \n",
            "2                        NDA-1: New chemical entity   \n",
            "3              NDA-2: BiosimilarNDA-3: New strength   \n",
            "4                        NDA-1: New chemical entity   \n",
            "5  NDA-1: New chemical entity, NDA-3: New strengths   \n",
            "\n",
            "                                                 3           4  \\\n",
            "0  TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.  17/05/2021   \n",
            "1               SANOFI-AVENTIS SINGAPORE PTE. LTD.  14/05/2021   \n",
            "2       MITSUBISHI TANABE PHARMA SINGAPORE PTE LTD   19/5/2021   \n",
            "3            AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD   25/5/2021   \n",
            "4            AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD   27/5/2021   \n",
            "5                 Kyowa Kirin Asia Pacific Pte Ltd    3/5/2021   \n",
            "\n",
            "                                 5  \n",
            "0                        SIN16197P  \n",
            "1  SIN16194P, SIN16195P, SIN16196P  \n",
            "2                        SIN16198P  \n",
            "3             SIN16206P, SIN16207P  \n",
            "4                        SIN16208P  \n",
            "5  SIN16176P, SIN16177P, SIN16178P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---may-2021\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P', 'PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/15 ML, 600 MG/600 MG/10 ML']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P', 'PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/15 ML, 600 MG/600 MG/10 ML', 'Pertuzumab, Trastuzumab']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P', 'PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/15 ML, 600 MG/600 MG/10 ML', 'Pertuzumab, Trastuzumab', 'NDA-2: New combination/dosing regimenNDA-3: New strength']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P', 'PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/15 ML, 600 MG/600 MG/10 ML', 'Pertuzumab, Trastuzumab', 'NDA-2: New combination/dosing regimenNDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P', 'PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/15 ML, 600 MG/600 MG/10 ML', 'Pertuzumab, Trastuzumab', 'NDA-2: New combination/dosing regimenNDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '22/06/2021']\n",
            "['VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLUTION 0.024%', 'Latanoprostene Bunod', 'NDA-1: New chemical entity', 'Bausch & Lomb (Singapore) Private Limited', '01/06/2021', 'SIN16214P', 'RYBELSUS TABLET 3MG, 7MG AND 14MG', 'Semaglutide', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '01/06/2021', 'SIN16251P, SIN16216P, SIN16217P', 'IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 420MG, 560MG', 'Ibrutinib', 'NDA-2: New dosage formNDA-3: New strength', 'JOHNSON & JOHNSON PTE. LTD.', '03/06/2021', 'SIN16218P, SIN16219P, SIN16220P, SIN16221P', 'MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ VIAL', 'Gemtuzumab ozogamicin', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '21/06/2021', 'SIN16243P', 'PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '24/06/2021', 'SIN16249P', 'PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/15 ML, 600 MG/600 MG/10 ML', 'Pertuzumab, Trastuzumab', 'NDA-2: New combination/dosing regimenNDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '22/06/2021', 'SIN16247P, SIN16248P']\n",
            "                                                   0                        1  \\\n",
            "0  VYZULTA (LATANOPROSTENE BUNOD) OPHTHALMIC SOLU...     Latanoprostene Bunod   \n",
            "1                  RYBELSUS TABLET 3MG, 7MG AND 14MG              Semaglutide   \n",
            "2  IMBRUVICA FILM-COATED TABLETS 140MG, 280MG, 42...                Ibrutinib   \n",
            "3  MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION F...    Gemtuzumab ozogamicin   \n",
            "4  PELGRAZ SOLUTION FOR INJECTION IN A PRE-FILLED...            Pegfilgrastim   \n",
            "5  PHESGO SOLUTION FOR INJECTION 1200 MG/600 MG/1...  Pertuzumab, Trastuzumab   \n",
            "\n",
            "                                                   2  \\\n",
            "0                         NDA-1: New chemical entity   \n",
            "1      NDA-1: New chemical entityNDA-3: New strength   \n",
            "2          NDA-2: New dosage formNDA-3: New strength   \n",
            "3                       NDA-1: New biological entity   \n",
            "4                                  NDA-2: Biosimilar   \n",
            "5  NDA-2: New combination/dosing regimenNDA-3: Ne...   \n",
            "\n",
            "                                           3           4  \\\n",
            "0  Bausch & Lomb (Singapore) Private Limited  01/06/2021   \n",
            "1    NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  01/06/2021   \n",
            "2                JOHNSON & JOHNSON PTE. LTD.  03/06/2021   \n",
            "3                     PFIZER PRIVATE LIMITED  21/06/2021   \n",
            "4          ACCORD HEALTHCARE PRIVATE LIMITED  24/06/2021   \n",
            "5                  ROCHE SINGAPORE PTE. LTD.  22/06/2021   \n",
            "\n",
            "                                            5  \n",
            "0                                   SIN16214P  \n",
            "1             SIN16251P, SIN16216P, SIN16217P  \n",
            "2  SIN16218P, SIN16219P, SIN16220P, SIN16221P  \n",
            "3                                   SIN16243P  \n",
            "4                                   SIN16249P  \n",
            "5                        SIN16247P, SIN16248P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---june-2021\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P', 'ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE 48 MU/0.5ML AND 30 MU/0.5ML']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P', 'ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE 48 MU/0.5ML AND 30 MU/0.5ML', 'Filgrastim']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P', 'ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE 48 MU/0.5ML AND 30 MU/0.5ML', 'Filgrastim', 'NDA-2/3']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P', 'ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE 48 MU/0.5ML AND 30 MU/0.5ML', 'Filgrastim', 'NDA-2/3', 'ACCORD HEALTHCARE PRIVATE LIMITED']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P', 'ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE 48 MU/0.5ML AND 30 MU/0.5ML', 'Filgrastim', 'NDA-2/3', 'ACCORD HEALTHCARE PRIVATE LIMITED', '08/07/2021']\n",
            "['HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8ML', 'Adalimumab', 'NDA-2: New dosage form', 'NOVARTIS (SINGAPORE) PTE LTD', '08/07/2021', 'SIN16273P', 'TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PREPARATION, 20MG/VIAL', 'Sodium pyrophosphate decahydrate', 'NDA-1: New chemical entity', 'LICENCE HOLDER IN CAPS', '09/07/2021', 'SIN16274P', 'KOSELUGO HARD CAPSULES 10MG/ 25MG', 'Selumetinib', 'NDA-1/ 3', 'ASTRAZENECA SINGAPORE PTE LTD', '09/07/2021', 'SIN16275P, SIN16276P', 'PERTAGEN SUSPENSION FOR INJECTION', 'Filamentous Haemagglutinin, Recombinant Pertussis Toxin', 'NDA-2', 'NOVEM HEALTHCARE PTE LTD', '23/07/2021', 'SIN16283P', 'ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIRABEV SOLUTION FOR INJECTION 400 mg/16 mL', 'Bevacizumab (PF-06439535)', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '26/07/2021', 'SIN16286P, SIN16287P', 'ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN PRE-FILLED SYRINGE 48 MU/0.5ML AND 30 MU/0.5ML', 'Filgrastim', 'NDA-2/3', 'ACCORD HEALTHCARE PRIVATE LIMITED', '08/07/2021', 'SIN16267P and SIN16268P']\n",
            "                                                   0  \\\n",
            "0  HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "1  TECHNESCAN PYP, KIT FOR RADIOPHARMACEUTICAL PR...   \n",
            "2                  KOSELUGO HARD CAPSULES 10MG/ 25MG   \n",
            "3                  PERTAGEN SUSPENSION FOR INJECTION   \n",
            "4  ZIRABEV SOLUTION FOR INJECTION 100 mg/4 mL,ZIR...   \n",
            "5  ACCOFIL SOLUTION FOR INJECTION OR INFUSION IN ...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Adalimumab   \n",
            "1                   Sodium pyrophosphate decahydrate   \n",
            "2                                        Selumetinib   \n",
            "3  Filamentous Haemagglutinin, Recombinant Pertus...   \n",
            "4                          Bevacizumab (PF-06439535)   \n",
            "5                                         Filgrastim   \n",
            "\n",
            "                            2                                  3           4  \\\n",
            "0      NDA-2: New dosage form       NOVARTIS (SINGAPORE) PTE LTD  08/07/2021   \n",
            "1  NDA-1: New chemical entity             LICENCE HOLDER IN CAPS  09/07/2021   \n",
            "2                    NDA-1/ 3      ASTRAZENECA SINGAPORE PTE LTD  09/07/2021   \n",
            "3                       NDA-2           NOVEM HEALTHCARE PTE LTD  23/07/2021   \n",
            "4                     NDA-2/3             PFIZER PRIVATE LIMITED  26/07/2021   \n",
            "5                     NDA-2/3  ACCORD HEALTHCARE PRIVATE LIMITED  08/07/2021   \n",
            "\n",
            "                         5  \n",
            "0                SIN16273P  \n",
            "1                SIN16274P  \n",
            "2     SIN16275P, SIN16276P  \n",
            "3                SIN16283P  \n",
            "4     SIN16286P, SIN16287P  \n",
            "5  SIN16267P and SIN16268P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2021\n",
            "['LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML']\n",
            "['LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML', 'Inclisiran sodium eqv inclisiran']\n",
            "['LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML', 'Inclisiran sodium eqv inclisiran', 'NDA-1: New chemical entity']\n",
            "['LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML', 'Inclisiran sodium eqv inclisiran', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML', 'Inclisiran sodium eqv inclisiran', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '03/08/2021']\n",
            "['LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML', 'Inclisiran sodium eqv inclisiran', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '03/08/2021', 'SIN16295P']\n",
            "                                                   0  \\\n",
            "0  LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYR...   \n",
            "\n",
            "                                  1                           2  \\\n",
            "0  Inclisiran sodium eqv inclisiran  NDA-1: New chemical entity   \n",
            "\n",
            "                              3           4          5  \n",
            "0  NOVARTIS (SINGAPORE) PTE LTD  03/08/2021  SIN16295P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---august-2021\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P', 'COSENTYX POWDER FOR SOLUTION FOR INJECTION IN PREFILLED SYRINGE 75MG/0.5ML']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P', 'COSENTYX POWDER FOR SOLUTION FOR INJECTION IN PREFILLED SYRINGE 75MG/0.5ML', 'Secukinumab']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P', 'COSENTYX POWDER FOR SOLUTION FOR INJECTION IN PREFILLED SYRINGE 75MG/0.5ML', 'Secukinumab', 'NDA-3: New strength']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P', 'COSENTYX POWDER FOR SOLUTION FOR INJECTION IN PREFILLED SYRINGE 75MG/0.5ML', 'Secukinumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P', 'COSENTYX POWDER FOR SOLUTION FOR INJECTION IN PREFILLED SYRINGE 75MG/0.5ML', 'Secukinumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '1 Sep 21']\n",
            "['PROVEBLUE SOLUTION FOR INJECTION 5MG/ML', 'Methylthioninium chloride trihydrate (methylene blue)', 'NDA-1: New chemical/biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '03/09/2021', 'SIN16319P', 'DAYVIGO FILM-COATED TABLET 5MG AND 10MG', 'Lemborexant', 'NDA-1: New chemical entityNDA-3: New strength', 'Eisai (Singapore) Pte Ltd', '15/09/2021', 'SIN16320P, SIN16321P', 'Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg', 'Palbociclib', 'NDA-2: New dosage form', 'Pfizer Private Limited', '15/09/2021', 'SIN16322P, SIN16323P, SIN16324P', 'VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML', 'Eptinezumab', 'NDA-1: New biological entity', 'LUNDBECK SINGAPORE PTE LTD', '16 /09/2021', 'SIN16325P', 'TAKIPRIL SOLUTION FOR INJECTION 20MG/ML', 'Prilocaine hydrochloride', 'NDA-2: New strength / combination', 'B. BRAUN SINGAPORE PTE LTD', '17/09/2021', 'SIN16326P', 'ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL', 'Lurbinectedin', 'NDA-1: New chemical entity', 'Specialised Therapeutics Asia Pte Ltd', '21/09/2021', 'SIN16327P', 'INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU (80MG)/0.8ML', 'Enoxaparin Sodium', 'NDA-2: New dosage form', 'HC HEALTHCARE PTE. LTD.', '22/09/2021', 'SIN16331P', 'YUPELRI INHALATION SOLUTION 175MCG/3ML', 'Revefenacin', 'NDA-1: New chemical entity', 'MYLAN PHARMACEUTICALS PTE. LTD.', '28/09/2021', 'SIN16336P', 'COSENTYX POWDER FOR SOLUTION FOR INJECTION IN PREFILLED SYRINGE 75MG/0.5ML', 'Secukinumab', 'NDA-3: New strength', 'Novartis (Singapore) Pte Ltd', '1 Sep 21', 'SIN16315P']\n",
            "                                                   0  \\\n",
            "0            PROVEBLUE SOLUTION FOR INJECTION 5MG/ML   \n",
            "1            DAYVIGO FILM-COATED TABLET 5MG AND 10MG   \n",
            "2   Ibrance Film Coated Tablet 75 mg, 100 mg, 125 mg   \n",
            "3  VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 1...   \n",
            "4            TAKIPRIL SOLUTION FOR INJECTION 20MG/ML   \n",
            "5  ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/...   \n",
            "6  INHIXA SOLUTION FOR INJECTION 8000 ANTI-Xa IU ...   \n",
            "7             YUPELRI INHALATION SOLUTION 175MCG/3ML   \n",
            "8  COSENTYX POWDER FOR SOLUTION FOR INJECTION IN ...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Methylthioninium chloride trihydrate (methylen...   \n",
            "1                                        Lemborexant   \n",
            "2                                        Palbociclib   \n",
            "3                                        Eptinezumab   \n",
            "4                           Prilocaine hydrochloride   \n",
            "5                                      Lurbinectedin   \n",
            "6                                  Enoxaparin Sodium   \n",
            "7                                        Revefenacin   \n",
            "8                                        Secukinumab   \n",
            "\n",
            "                                               2  \\\n",
            "0          NDA-1: New chemical/biological entity   \n",
            "1  NDA-1: New chemical entityNDA-3: New strength   \n",
            "2                         NDA-2: New dosage form   \n",
            "3                   NDA-1: New biological entity   \n",
            "4              NDA-2: New strength / combination   \n",
            "5                     NDA-1: New chemical entity   \n",
            "6                         NDA-2: New dosage form   \n",
            "7                     NDA-1: New chemical entity   \n",
            "8                            NDA-3: New strength   \n",
            "\n",
            "                                       3            4  \\\n",
            "0      PHARM-D SINGAPORE PRIVATE LIMITED   03/09/2021   \n",
            "1              Eisai (Singapore) Pte Ltd   15/09/2021   \n",
            "2                 Pfizer Private Limited   15/09/2021   \n",
            "3             LUNDBECK SINGAPORE PTE LTD  16 /09/2021   \n",
            "4             B. BRAUN SINGAPORE PTE LTD   17/09/2021   \n",
            "5  Specialised Therapeutics Asia Pte Ltd   21/09/2021   \n",
            "6                HC HEALTHCARE PTE. LTD.   22/09/2021   \n",
            "7        MYLAN PHARMACEUTICALS PTE. LTD.   28/09/2021   \n",
            "8           Novartis (Singapore) Pte Ltd     1 Sep 21   \n",
            "\n",
            "                                 5  \n",
            "0                        SIN16319P  \n",
            "1             SIN16320P, SIN16321P  \n",
            "2  SIN16322P, SIN16323P, SIN16324P  \n",
            "3                        SIN16325P  \n",
            "4                        SIN16326P  \n",
            "5                        SIN16327P  \n",
            "6                        SIN16331P  \n",
            "7                        SIN16336P  \n",
            "8                        SIN16315P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---september-2021\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis', 'ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis', 'ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Trastuzumab deruxtecan']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis', 'ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Trastuzumab deruxtecan', 'NDA-1: New biological entity']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis', 'ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Trastuzumab deruxtecan', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis', 'ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Trastuzumab deruxtecan', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '22/10/2021']\n",
            "['SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML,SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML', 'Risankizumab', 'NDA-2: New dosage form / strength', 'ABBVIE PTE. LTD.', '01/10/2021', 'SIN16338P, SIN16339P', 'BRUKINSA CAPSULE 80MG', 'Zanubrutinib', 'NDA-1: New chemical entity', 'BEIGENE SINGAPORE PTE. LTD.', '01/10/2021', 'SIN16341P', 'VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG', 'Vericiguat', 'NDA-1: New chemical entityNDA-3: New strength', 'BAYER (SOUTH EAST ASIA) PTE LTD', '01/10/2021', 'SIN16340P, SIN16342P, SIN16343P', 'AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5 ML', 'Fremanezumab', 'NDA-2*: New presentation', 'TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.', '04/10/2021', 'SIN16344P', 'POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30 MG', 'Polatuzumab vedotin', 'NDA-3: New strength', 'ROCHE SINGAPORE PTE. LTD.', '05/10/2021', 'SIN16345P', 'LATUDA TABLET 20MG', 'Active ingredient', 'NDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '12/10/2021', 'SIN16346P', 'ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML', 'Satralizumab', 'NDA-1', 'ROCHE SINGAPORE PTE. LTD.', '19/10/2021', 'SIN16348P', 'EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML', 'Risdiplam', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE. LTD.', '20/10/2021', 'SIN16349P', 'Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.', 'TABRECTA FILM-COATED TABLET 150mg,TABRECTA FILM-COATED TABLET 200mg', 'Capmatinib', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '22/10/2021', 'SIN16350P, SIN16351P', 'Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.*Evaluated as part of Project Orbis', 'ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'Trastuzumab deruxtecan', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '22/10/2021', 'SIN16352P']\n",
            "                                                    0  \\\n",
            "0   SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED S...   \n",
            "1                               BRUKINSA CAPSULE 80MG   \n",
            "2         VERQUVO FILM-COATED TABLET 10MG, 5MG, 2.5MG   \n",
            "3   AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN...   \n",
            "4   POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR...   \n",
            "5                                  LATUDA TABLET 20MG   \n",
            "6   ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED S...   \n",
            "7          EVRYSDI POWDER FOR ORAL SOLUTION 0.75MG/ML   \n",
            "8   Evrysdi is indicated for the treatment of spin...   \n",
            "9                                SIN16350P, SIN16351P   \n",
            "10                                         22/10/2021   \n",
            "\n",
            "                                                    1  \\\n",
            "0                                        Risankizumab   \n",
            "1                                        Zanubrutinib   \n",
            "2                                          Vericiguat   \n",
            "3                                        Fremanezumab   \n",
            "4                                 Polatuzumab vedotin   \n",
            "5                                   Active ingredient   \n",
            "6                                        Satralizumab   \n",
            "7                                           Risdiplam   \n",
            "8   TABRECTA FILM-COATED TABLET 150mg,TABRECTA FIL...   \n",
            "9   Tabrecta is indicated for the treatment of adu...   \n",
            "10                                          SIN16352P   \n",
            "\n",
            "                                                    2  \\\n",
            "0                   NDA-2: New dosage form / strength   \n",
            "1                          NDA-1: New chemical entity   \n",
            "2       NDA-1: New chemical entityNDA-3: New strength   \n",
            "3                            NDA-2*: New presentation   \n",
            "4                                 NDA-3: New strength   \n",
            "5                                 NDA-3: New strength   \n",
            "6                                               NDA-1   \n",
            "7                          NDA-1: New chemical entity   \n",
            "8                                          Capmatinib   \n",
            "9   ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FO...   \n",
            "10                                               None   \n",
            "\n",
            "                                                    3  \\\n",
            "0                                    ABBVIE PTE. LTD.   \n",
            "1                         BEIGENE SINGAPORE PTE. LTD.   \n",
            "2                     BAYER (SOUTH EAST ASIA) PTE LTD   \n",
            "3   TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE....   \n",
            "4                           ROCHE SINGAPORE PTE. LTD.   \n",
            "5                            DKSH SINGAPORE PTE. LTD.   \n",
            "6                           ROCHE SINGAPORE PTE. LTD.   \n",
            "7                           ROCHE SINGAPORE PTE. LTD.   \n",
            "8       NDA-1: New chemical entityNDA-3: New strength   \n",
            "9                              Trastuzumab deruxtecan   \n",
            "10                                               None   \n",
            "\n",
            "                               4                                5  \n",
            "0                     01/10/2021             SIN16338P, SIN16339P  \n",
            "1                     01/10/2021                        SIN16341P  \n",
            "2                     01/10/2021  SIN16340P, SIN16342P, SIN16343P  \n",
            "3                     04/10/2021                        SIN16344P  \n",
            "4                     05/10/2021                        SIN16345P  \n",
            "5                     12/10/2021                        SIN16346P  \n",
            "6                     19/10/2021                        SIN16348P  \n",
            "7                     20/10/2021                        SIN16349P  \n",
            "8   NOVARTIS (SINGAPORE) PTE LTD                       22/10/2021  \n",
            "9   NDA-1: New biological entity    ASTRAZENECA SINGAPORE PTE LTD  \n",
            "10                          None                             None  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---october-2021\n",
            "['SLINDA FILM-COATED TABLETS 4MG']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P', 'TEPMETKO FILM-COATED TABLET 225 MG']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P', 'TEPMETKO FILM-COATED TABLET 225 MG', 'Tepotinib']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P', 'TEPMETKO FILM-COATED TABLET 225 MG', 'Tepotinib', 'NDA-1']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P', 'TEPMETKO FILM-COATED TABLET 225 MG', 'Tepotinib', 'NDA-1', 'Merck Pte Ltd']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P', 'TEPMETKO FILM-COATED TABLET 225 MG', 'Tepotinib', 'NDA-1', 'Merck Pte Ltd', '25/11/2021']\n",
            "['SLINDA FILM-COATED TABLETS 4MG', 'Drospirenone', 'NDA-2', 'Intega Pte Ltd', '01/11/2021', 'SIN16354P', 'COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED UNOREADY PEN 300MG/2MLCOSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 300MG/2ML', 'Secukinumab', 'NDA-2 and NDA-3', 'Novartis (Singapore) Pte Ltd', '02/11/2021', 'SIN16358P, SIN16359P', 'HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED SYRINGEHULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE-FILLED PEN', 'Adalimumab', 'NDA-2', 'Mylan Pharmaceuticals Pte. Ltd.', '02/11/2021', 'SIN16360P, SIN16361P', 'DOMIDE CAPSULES 50mg', 'Thalidomide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '02/11/2021', 'SIN16362P', 'CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG', 'Trastuzumab', 'NDA-2', 'Pharma To Market Pte Ltd', '25 Nov 2021', 'SIN16384P', 'KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM-COATED TABLET 20 MG', 'Finerenone', 'NDA-1 and NDA-3', 'BAYER (SOUTH EAST ASIA) PTE LTD', '25/11/2021', 'SIN16387P, SIN16388P', 'TEPMETKO FILM-COATED TABLET 225 MG', 'Tepotinib', 'NDA-1', 'Merck Pte Ltd', '25/11/2021', 'SIN16386P']\n",
            "                                                   0             1  \\\n",
            "0                     SLINDA FILM-COATED TABLETS 4MG  Drospirenone   \n",
            "1  COSENTYX SOLUTION FOR INJECTION IN PRE-FILLED ...   Secukinumab   \n",
            "2  HULIO SOLUTION FOR INJECTION 40MG/0.8ML IN PRE...    Adalimumab   \n",
            "3                               DOMIDE CAPSULES 50mg   Thalidomide   \n",
            "4     CANHERA LYOPHILIZED POWDER FOR INJECTION 440MG   Trastuzumab   \n",
            "5  KERENDIA FILM-COATED TABLET 10 MGKERENDIA FILM...    Finerenone   \n",
            "6                 TEPMETKO FILM-COATED TABLET 225 MG     Tepotinib   \n",
            "\n",
            "                            2                                  3            4  \\\n",
            "0                       NDA-2                     Intega Pte Ltd   01/11/2021   \n",
            "1             NDA-2 and NDA-3       Novartis (Singapore) Pte Ltd   02/11/2021   \n",
            "2                       NDA-2    Mylan Pharmaceuticals Pte. Ltd.   02/11/2021   \n",
            "3  NDA-1: New chemical entity  PHARM-D SINGAPORE PRIVATE LIMITED   02/11/2021   \n",
            "4                       NDA-2           Pharma To Market Pte Ltd  25 Nov 2021   \n",
            "5             NDA-1 and NDA-3    BAYER (SOUTH EAST ASIA) PTE LTD   25/11/2021   \n",
            "6                       NDA-1                      Merck Pte Ltd   25/11/2021   \n",
            "\n",
            "                      5  \n",
            "0             SIN16354P  \n",
            "1  SIN16358P, SIN16359P  \n",
            "2  SIN16360P, SIN16361P  \n",
            "3             SIN16362P  \n",
            "4             SIN16384P  \n",
            "5  SIN16387P, SIN16388P  \n",
            "6             SIN16386P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---november-2021\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P', 'ONCASPAR POWDER FOR SOLUTION FOR INJECTION / INFUSION 750 U/ML']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P', 'ONCASPAR POWDER FOR SOLUTION FOR INJECTION / INFUSION 750 U/ML', 'Pegaspargase']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P', 'ONCASPAR POWDER FOR SOLUTION FOR INJECTION / INFUSION 750 U/ML', 'Pegaspargase', 'NDA-1: New biological entity']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P', 'ONCASPAR POWDER FOR SOLUTION FOR INJECTION / INFUSION 750 U/ML', 'Pegaspargase', 'NDA-1: New biological entity', 'SERVIER (S) PTE LTD']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P', 'ONCASPAR POWDER FOR SOLUTION FOR INJECTION / INFUSION 750 U/ML', 'Pegaspargase', 'NDA-1: New biological entity', 'SERVIER (S) PTE LTD', '27/12/2021']\n",
            "['NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML', 'Pegfilgrastim', 'NDA-2: Biosimilar', 'PHARMA TO MARKET PTE. LTD', '07/12/2021', 'SIN16393P', 'COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSECOMIRNATY CONCENTRATE FOR DISPERSION FOR INJECTION 10MCG/DOSE', 'Tozinameran', 'NDA-1/2: New biological entity', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD', '10/12/2021', 'SIN16396P, SIN16397P', 'ONCASPAR POWDER FOR SOLUTION FOR INJECTION / INFUSION 750 U/ML', 'Pegaspargase', 'NDA-1: New biological entity', 'SERVIER (S) PTE LTD', '27/12/2021', 'SIN16408P']\n",
            "                                                   0              1  \\\n",
            "0  NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLE...  Pegfilgrastim   \n",
            "1  COMIRNATY DISPERSION FOR INJECTION 30MCG/DOSEC...    Tozinameran   \n",
            "2  ONCASPAR POWDER FOR SOLUTION FOR INJECTION / I...   Pegaspargase   \n",
            "\n",
            "                                2  \\\n",
            "0               NDA-2: Biosimilar   \n",
            "1  NDA-1/2: New biological entity   \n",
            "2    NDA-1: New biological entity   \n",
            "\n",
            "                                               3           4  \\\n",
            "0                      PHARMA TO MARKET PTE. LTD  07/12/2021   \n",
            "1  BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE LTD  10/12/2021   \n",
            "2                            SERVIER (S) PTE LTD  27/12/2021   \n",
            "\n",
            "                      5  \n",
            "0             SIN16393P  \n",
            "1  SIN16396P, SIN16397P  \n",
            "2             SIN16408P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---december-2021\n",
            "['LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W']\n",
            "['LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W', 'Luliconazole']\n",
            "['LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W', 'Luliconazole', 'NDA-1: New chemical']\n",
            "['LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W', 'Luliconazole', 'NDA-1: New chemical', 'ZUELLIG PHARMA PTE LTD']\n",
            "['LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W', 'Luliconazole', 'NDA-1: New chemical', 'ZUELLIG PHARMA PTE LTD', '14/02/2022']\n",
            "['LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W', 'Luliconazole', 'NDA-1: New chemical', 'ZUELLIG PHARMA PTE LTD', '14/02/2022', 'SIN16428P']\n",
            "                                            0             1  \\\n",
            "0  LUCONAC EXTERNAL SOLUTION FOR NAILS 5% W/W  Luliconazole   \n",
            "\n",
            "                     2                       3           4          5  \n",
            "0  NDA-1: New chemical  ZUELLIG PHARMA PTE LTD  14/02/2022  SIN16428P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---feb-2022\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P', 'TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P', 'TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL', 'Sacituzumab govitecan']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P', 'TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL', 'Sacituzumab govitecan', 'NDA-1: New biological entity']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P', 'TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL', 'Sacituzumab govitecan', 'NDA-1: New biological entity', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P', 'TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL', 'Sacituzumab govitecan', 'NDA-1: New biological entity', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '31/01/2022']\n",
            "['CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG', 'Naltrexone hydrochloride / bupropion hydrochloride', 'NDA-2: New combination', 'INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED', '03/01/2022', 'SIN16411P', 'CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG', 'Abrocitinib', 'NDA-1: New chemical entityNDA-3: New strength', 'PFIZER PRIVATE LIMITED', '05/01/2022', 'SIN16412P, SIN16413P, SIN16414P', 'SALONPAS DICLOFENAC GEL 1%', 'Diclofenac', 'NDA-2: New dosage form', 'HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BRANCH', '17/01/2022', 'SIN16418P', 'TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL', 'Sacituzumab govitecan', 'NDA-1: New biological entity', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '31/01/2022', 'SIN16425P']\n",
            "                                                   0  \\\n",
            "0         CONTRAVE PROLONGED RELEASE TABLET 8MG/90MG   \n",
            "1     CIBINQO FILM COATED TABLETS 50MG, 100MG, 200MG   \n",
            "2                         SALONPAS DICLOFENAC GEL 1%   \n",
            "3  TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 ...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Naltrexone hydrochloride / bupropion hydrochlo...   \n",
            "1                                        Abrocitinib   \n",
            "2                                         Diclofenac   \n",
            "3                              Sacituzumab govitecan   \n",
            "\n",
            "                                               2  \\\n",
            "0                         NDA-2: New combination   \n",
            "1  NDA-1: New chemical entityNDA-3: New strength   \n",
            "2                         NDA-2: New dosage form   \n",
            "3                   NDA-1: New biological entity   \n",
            "\n",
            "                                                   3           4  \\\n",
            "0     INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED  03/01/2022   \n",
            "1                             PFIZER PRIVATE LIMITED  05/01/2022   \n",
            "2  HISAMITSU PHARMACEUTICAL CO., INC SINGAPORE BR...  17/01/2022   \n",
            "3            EVEREST MEDICINES (SINGAPORE) PTE. LTD.  31/01/2022   \n",
            "\n",
            "                                 5  \n",
            "0                        SIN16411P  \n",
            "1  SIN16412P, SIN16413P, SIN16414P  \n",
            "2                        SIN16418P  \n",
            "3                        SIN16425P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---january-2022\n",
            "Empty DataFrame\n",
            "Columns: []\n",
            "Index: []\n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---february-2022\n",
            "['XPOVIO FILM-COATED TABLETS 20MG']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 100MG/0.67ML']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 100MG/0.67ML', 'Dupilumab']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 100MG/0.67ML', 'Dupilumab', 'NDA-2: New formulation']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 100MG/0.67ML', 'Dupilumab', 'NDA-2: New formulation', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 100MG/0.67ML', 'Dupilumab', 'NDA-2: New formulation', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/03/2022']\n",
            "['XPOVIO FILM-COATED TABLETS 20MG', 'Selinexor', 'NDA-1: New chemical/biological entity', 'ANTENGENE SINGAPORE PTE LTD', '01/03/2022', 'SIN16434P', 'VANCOVER CAPSULE 125MG AND 250MG', 'Vancomycin', 'NDA-2/3: New formulation and new strength', 'ORIENT EUROPHARMA PTE LTD', '11/03/2022', 'SIN16444P and SIN16445P', 'PRONAXEN ORAL SUSPENSION 25MG/ML', 'Naproxen', 'NDA-2: New formulation', 'ORION PHARMA (SG) PTE LTD', '23/03/2022', 'SIN16449P', 'RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML AND 500MG/50ML', 'Rituximab', 'NDA-2: Biosimilar', 'PFIZER PRIVATE LIMITED', '25/03/2022', 'SIN16451P and SIN16452P', 'MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FOR INJECTION IN 0.5 ML VIAL', 'Neisseria meningitidis group A polysaccharide 10 µgNeisseria meningitidis group C polysaccharide 10 µgNeisseria meningitidis group Y polysaccharide 10 µgNeisseria meningitidis group W polysaccharide 10 µgConjugated to tetanus toxoid carrier protein 55 µg', 'NDA-2: New Dosage', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '29/03/2022', 'SIN16454P', 'DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 100MG/0.67ML', 'Dupilumab', 'NDA-2: New formulation', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/03/2022', 'SIN16458P']\n",
            "                                                   0  \\\n",
            "0                    XPOVIO FILM-COATED TABLETS 20MG   \n",
            "1                   VANCOVER CAPSULE 125MG AND 250MG   \n",
            "2                   PRONAXEN ORAL SUSPENSION 25MG/ML   \n",
            "3  RUXIENCE CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "4  MENQUADFI - MENINGOCOCCOL VACCINE, SOLUTION FO...   \n",
            "5  DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLE...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                          Selinexor   \n",
            "1                                         Vancomycin   \n",
            "2                                           Naproxen   \n",
            "3                                          Rituximab   \n",
            "4  Neisseria meningitidis group A polysaccharide ...   \n",
            "5                                          Dupilumab   \n",
            "\n",
            "                                           2  \\\n",
            "0      NDA-1: New chemical/biological entity   \n",
            "1  NDA-2/3: New formulation and new strength   \n",
            "2                     NDA-2: New formulation   \n",
            "3                          NDA-2: Biosimilar   \n",
            "4                          NDA-2: New Dosage   \n",
            "5                     NDA-2: New formulation   \n",
            "\n",
            "                                    3           4                        5  \n",
            "0         ANTENGENE SINGAPORE PTE LTD  01/03/2022                SIN16434P  \n",
            "1           ORIENT EUROPHARMA PTE LTD  11/03/2022  SIN16444P and SIN16445P  \n",
            "2           ORION PHARMA (SG) PTE LTD  23/03/2022                SIN16449P  \n",
            "3              PFIZER PRIVATE LIMITED  25/03/2022  SIN16451P and SIN16452P  \n",
            "4  SANOFI-AVENTIS SINGAPORE PTE. LTD.  29/03/2022                SIN16454P  \n",
            "5  SANOFI-AVENTIS SINGAPORE PTE. LTD.  30/03/2022                SIN16458P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---march-2022\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P', 'ALIGRIN TABLET 20MG']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P', 'ALIGRIN TABLET 20MG', 'Bilastine']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P', 'ALIGRIN TABLET 20MG', 'Bilastine', 'NDA-2']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P', 'ALIGRIN TABLET 20MG', 'Bilastine', 'NDA-2', 'A. MENARINI SINGAPORE PTE LTD']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P', 'ALIGRIN TABLET 20MG', 'Bilastine', 'NDA-2', 'A. MENARINI SINGAPORE PTE LTD', '12/04/2022']\n",
            "['ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG', 'Niraparib', 'NDA-1: New chemical entityNDA-3: New strength', 'GLAXOSMITHKLINE PTE LTD', '01/04/2022', 'SIN16459P, SIN16460P, SIN16461P', 'HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3500 IU ANTI-XA/0.2 MLHIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2500IU ANTI-XA/0.2ML', 'Bemiparin Sodium', 'NDA-1: New chemical entityNDA-3: New strength', 'DCH AURIGA SINGAPORE', '01/04/2022', 'SIN16462P, SIN16463P', 'B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML', 'Ibuprofen', 'NDA-2: New dosage form', 'B.BRAUN SINGAPORE PTE LTD', '04/04/2022', 'SIN16467P', 'REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25MG/VIAL AND 75MG/VIAL', 'Luspatercept', 'NDA-1: New biological entityNDA-3: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '06/04/2022', 'SIN16470P, SIN16471P', 'GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML) SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Follitropin alfa', 'NDA-3: New strength', 'MERCK PTE. LTD', '11/04/2022', 'SIN16473P', 'ALIGRIN TABLET 20MG', 'Bilastine', 'NDA-2', 'A. MENARINI SINGAPORE PTE LTD', '12/04/2022', 'SIN16474P']\n",
            "                                                   0                 1  \\\n",
            "0      ZEJULA FILM-COATED TABLET 100MG, 200MG, 300MG         Niraparib   \n",
            "1  HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYR...  Bemiparin Sodium   \n",
            "2     B.BRAUN IBUPROFEN SOLUTION FOR INFUSION 4MG/ML         Ibuprofen   \n",
            "3  REBLOZYL POWDER FOR SOLUTION FOR INJECTION 25M...      Luspatercept   \n",
            "4  GONAL-F 150 IU/0.25 ML (11 MICROGRAMS/0.25 ML)...  Follitropin alfa   \n",
            "5                                ALIGRIN TABLET 20MG         Bilastine   \n",
            "\n",
            "                                                 2  \\\n",
            "0    NDA-1: New chemical entityNDA-3: New strength   \n",
            "1    NDA-1: New chemical entityNDA-3: New strength   \n",
            "2                           NDA-2: New dosage form   \n",
            "3  NDA-1: New biological entityNDA-3: New strength   \n",
            "4                              NDA-3: New strength   \n",
            "5                                            NDA-2   \n",
            "\n",
            "                                            3           4  \\\n",
            "0                     GLAXOSMITHKLINE PTE LTD  01/04/2022   \n",
            "1                        DCH AURIGA SINGAPORE  01/04/2022   \n",
            "2                   B.BRAUN SINGAPORE PTE LTD  04/04/2022   \n",
            "3  BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.  06/04/2022   \n",
            "4                              MERCK PTE. LTD  11/04/2022   \n",
            "5               A. MENARINI SINGAPORE PTE LTD  12/04/2022   \n",
            "\n",
            "                                 5  \n",
            "0  SIN16459P, SIN16460P, SIN16461P  \n",
            "1             SIN16462P, SIN16463P  \n",
            "2                        SIN16467P  \n",
            "3             SIN16470P, SIN16471P  \n",
            "4                        SIN16473P  \n",
            "5                        SIN16474P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---april-2022\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P', 'BOOSTAGEN SUSPENSION FOR INJECTION']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P', 'BOOSTAGEN SUSPENSION FOR INJECTION', 'Diphtheria Toxoid (DT)(2.0 Lf / 0.5ml), Filamentous Haemagglutinin (FHA)(5ug/0.5ml), Recombinant Pertussis Toxin (rPT)(5ug/0.5ml), Tetanus Toxoid (TT)(7.5 Lf/0.5ml)']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P', 'BOOSTAGEN SUSPENSION FOR INJECTION', 'Diphtheria Toxoid (DT)(2.0 Lf / 0.5ml), Filamentous Haemagglutinin (FHA)(5ug/0.5ml), Recombinant Pertussis Toxin (rPT)(5ug/0.5ml), Tetanus Toxoid (TT)(7.5 Lf/0.5ml)', 'NDA-1']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P', 'BOOSTAGEN SUSPENSION FOR INJECTION', 'Diphtheria Toxoid (DT)(2.0 Lf / 0.5ml), Filamentous Haemagglutinin (FHA)(5ug/0.5ml), Recombinant Pertussis Toxin (rPT)(5ug/0.5ml), Tetanus Toxoid (TT)(7.5 Lf/0.5ml)', 'NDA-1', 'NOVEM HEALTHCARE PTE LTD']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P', 'BOOSTAGEN SUSPENSION FOR INJECTION', 'Diphtheria Toxoid (DT)(2.0 Lf / 0.5ml), Filamentous Haemagglutinin (FHA)(5ug/0.5ml), Recombinant Pertussis Toxin (rPT)(5ug/0.5ml), Tetanus Toxoid (TT)(7.5 Lf/0.5ml)', 'NDA-1', 'NOVEM HEALTHCARE PTE LTD', '18/05/2022']\n",
            "['XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML', 'Rivaroxaban', 'NDA-2: New dosage form', 'BAYER (SOUTH EAST ASIA) PTE LTD', '06 May 2022', 'SIN16487P', 'NOXBETA TABLET 5 MG', 'Nebivolol (as nebivolol hydrochloride)', 'NDA-2: New brand', 'A. MENARINI SINGAPORE PTE. LTD.', '06 May 2022', 'SIN16486P', 'PARMODIA FILM-COATED TABLETS 0.1 MG', 'Pemafibrate', 'NDA-1', 'DKSH SINGAPORE PTE. LTD.', '18 May 2022', 'SIN16492P', 'PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 20MG AND 30MG', 'Enfortumab vedotin', 'NDA-1', 'ASTELLAS PHARMA SINGAPORE PTE. LTD.', '30 May 2022', 'SIN16502P, SIN16503P', 'TIVICAY DISPERISBLE TABLET 5MG', 'Dolutegravir', 'NDA-2', 'GLAXOSMITHKLINE PTE LTD', '30 May 2022', 'SIN16504P', 'BOOSTAGEN SUSPENSION FOR INJECTION', 'Diphtheria Toxoid (DT)(2.0 Lf / 0.5ml), Filamentous Haemagglutinin (FHA)(5ug/0.5ml), Recombinant Pertussis Toxin (rPT)(5ug/0.5ml), Tetanus Toxoid (TT)(7.5 Lf/0.5ml)', 'NDA-1', 'NOVEM HEALTHCARE PTE LTD', '18/05/2022', 'SIN16493P']\n",
            "                                                   0  \\\n",
            "0        XARELTO GRANULES FOR ORAL SUSPENSION 1MG/ML   \n",
            "1                                NOXBETA TABLET 5 MG   \n",
            "2                PARMODIA FILM-COATED TABLETS 0.1 MG   \n",
            "3  PADCEV POWDER FOR CONCENTRATE FOR SOLUTION FOR...   \n",
            "4                     TIVICAY DISPERISBLE TABLET 5MG   \n",
            "5                 BOOSTAGEN SUSPENSION FOR INJECTION   \n",
            "\n",
            "                                                   1                       2  \\\n",
            "0                                        Rivaroxaban  NDA-2: New dosage form   \n",
            "1             Nebivolol (as nebivolol hydrochloride)        NDA-2: New brand   \n",
            "2                                        Pemafibrate                   NDA-1   \n",
            "3                                 Enfortumab vedotin                   NDA-1   \n",
            "4                                       Dolutegravir                   NDA-2   \n",
            "5  Diphtheria Toxoid (DT)(2.0 Lf / 0.5ml), Filame...                   NDA-1   \n",
            "\n",
            "                                     3            4                     5  \n",
            "0      BAYER (SOUTH EAST ASIA) PTE LTD  06 May 2022             SIN16487P  \n",
            "1      A. MENARINI SINGAPORE PTE. LTD.  06 May 2022             SIN16486P  \n",
            "2             DKSH SINGAPORE PTE. LTD.  18 May 2022             SIN16492P  \n",
            "3  ASTELLAS PHARMA SINGAPORE PTE. LTD.  30 May 2022  SIN16502P, SIN16503P  \n",
            "4              GLAXOSMITHKLINE PTE LTD  30 May 2022             SIN16504P  \n",
            "5             NOVEM HEALTHCARE PTE LTD   18/05/2022             SIN16493P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---may-2022\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P', 'RINVOQ EXTENDED-RELEASE TABLETS 30MG']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P', 'RINVOQ EXTENDED-RELEASE TABLETS 30MG', 'Upadacitinib hemihydrate equivalent to Upadacitinib']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P', 'RINVOQ EXTENDED-RELEASE TABLETS 30MG', 'Upadacitinib hemihydrate equivalent to Upadacitinib', 'NDA-3: New strength']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P', 'RINVOQ EXTENDED-RELEASE TABLETS 30MG', 'Upadacitinib hemihydrate equivalent to Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P', 'RINVOQ EXTENDED-RELEASE TABLETS 30MG', 'Upadacitinib hemihydrate equivalent to Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '21/06/2022']\n",
            "['MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300MG PER 100ML VIAL', 'Ibuprofen sodium dihydrate/ Paracetamol', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '03/06/2022', 'SIN16507P', 'YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.4ML', 'Adalimumab', 'NDA-2', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '09/06/2022', 'SIN16508P', 'FYCOMPA ORAL SUSPENSION 0.5MG/ML', 'Perampanel', 'NDA-2', 'EISAI (SINGAPORE) PTE LTD', '10/06/2022', 'SIN16512P', 'VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML', 'Faricimab', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '16/06/2022', 'SIN16514P', 'LUMAKRAS FILM-COATED TABLET 120MG', 'Sotorasib', 'NDA-1: New chemical entity', 'AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD', '28/06/2022', 'SIN16522P', 'RYALTRIS NASAL SPRAY 600/25MCG', 'Mometasone furoate monohydrate, Olopatadine HCl', 'NDA-2: New combination', 'GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.', '28/06/2022', 'SIN16523P', 'RINVOQ EXTENDED-RELEASE TABLETS 30MG', 'Upadacitinib hemihydrate equivalent to Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '21/06/2022', 'SIN16518P']\n",
            "                                                   0  \\\n",
            "0  MAXIGESIC IV SOLUTION FOR INFUSION 1000MG/300M...   \n",
            "1  YUFLYMA SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "2                   FYCOMPA ORAL SUSPENSION 0.5MG/ML   \n",
            "3        VABYSMO SOLUTION FOR INJECTION 6 MG/0.05 ML   \n",
            "4                  LUMAKRAS FILM-COATED TABLET 120MG   \n",
            "5                     RYALTRIS NASAL SPRAY 600/25MCG   \n",
            "6               RINVOQ EXTENDED-RELEASE TABLETS 30MG   \n",
            "\n",
            "                                                   1  \\\n",
            "0            Ibuprofen sodium dihydrate/ Paracetamol   \n",
            "1                                         Adalimumab   \n",
            "2                                         Perampanel   \n",
            "3                                          Faricimab   \n",
            "4                                          Sotorasib   \n",
            "5    Mometasone furoate monohydrate, Olopatadine HCl   \n",
            "6  Upadacitinib hemihydrate equivalent to Upadaci...   \n",
            "\n",
            "                              2  \\\n",
            "0        NDA-2: New combination   \n",
            "1                         NDA-2   \n",
            "2                         NDA-2   \n",
            "3  NDA-1: New biological entity   \n",
            "4    NDA-1: New chemical entity   \n",
            "5        NDA-2: New combination   \n",
            "6           NDA-3: New strength   \n",
            "\n",
            "                                                3           4          5  \n",
            "0                 APEX PHARMA MARKETING PTE. LTD.  03/06/2022  SIN16507P  \n",
            "1  CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED  09/06/2022  SIN16508P  \n",
            "2                       EISAI (SINGAPORE) PTE LTD  10/06/2022  SIN16512P  \n",
            "3                       ROCHE SINGAPORE PTE. LTD.  16/06/2022  SIN16514P  \n",
            "4           AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD  28/06/2022  SIN16522P  \n",
            "5    GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.  28/06/2022  SIN16523P  \n",
            "6                                  ABBVIE PTE LTD  21/06/2022  SIN16518P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---june-2022\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P', 'PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 mmol/ml']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P', 'PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 mmol/ml', 'Gadoxetate, disodium']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P', 'PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 mmol/ml', 'Gadoxetate, disodium', 'NDA-2: New presentation']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P', 'PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 mmol/ml', 'Gadoxetate, disodium', 'NDA-2: New presentation', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P', 'PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 mmol/ml', 'Gadoxetate, disodium', 'NDA-2: New presentation', 'BAYER (SOUTH EAST ASIA) PTE LTD', '21/07/2022']\n",
            "['NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG/0.5MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50MG/MLNEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED PEN 50MG/ML', 'Etanercept', 'NDA-2: BiosimilarNDA-3: Subsequent strength', 'MYLAN PHARMACEUTICALS PTE. LTD.', '04/07/2022', 'SIN16531PSIN16532PSIN16533P', 'FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE + 2.5MG/DOSE', 'Lidocaine/Prilocaine', 'NDA-2: New dosage form/indication', 'Orient Europharma', '5/7/2022', 'SIN16538P', 'VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 600 MG/3 MLVOCABRIA PROLONGED-RELEASE SUSPENSION FOR INJECTION 400 MG/ 2 ML', 'Cabotegravir', 'NDA-1: New chemical entity', 'GLAXOSMITHKLINE PTE LTD', '5/7/2022', 'SIN16541P, SIN16542P, SIN16543P', 'SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FILM-COATED TABLET 40 MG', 'Asciminib hydrochloride', 'NDA-1: New chemical entityNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '05/07/2022', 'SIN16539P, SIN16540P', 'SALONPAS DICLOFENAC PATCH 15MG', 'Diclofenac Sodium', 'NDA-2: New dosage form', 'Hisamitsu Pharmaceutical Co., Inc. Singapore Branch', '07/070/2022', 'SIN16546P', 'RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML', 'Amivantamab 50mg/ml', 'NDA-1: New biological entity', 'JOHNSON & JOHNSON PTE. LTD.', '13/07/2022', 'SIN16548P', 'TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIALTEPADINA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15 MG/VIAL', 'Thiotepa', 'NDA-1: New chemical entityNDA-3: New strength', 'AXXESSBIO PTE LID', '18/7/2022', 'SIN16552PSIN16553P', 'ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FILM-COATED TABLET 20MG/10MGROZEVON FILM-COATED TABLET 10MG/10MGROZEVON FILM-COATED TABLET 5MG/10MG', 'Active ingredient', 'NDA-2: New combination', 'NOVEM PHARMA PRIVATE LIMITED', '04/07/2022', 'SIN16534PSIN16535PSIN16536PSIN16537P', 'PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 mmol/ml', 'Gadoxetate, disodium', 'NDA-2: New presentation', 'BAYER (SOUTH EAST ASIA) PTE LTD', '21/07/2022', 'SIN16559P']\n",
            "                                                   0                        1  \\\n",
            "0  NEPEXTO SOLUTION FOR INJECTION IN PRE-FILLED S...               Etanercept   \n",
            "1  FORTACIN CUTANEOUS SPRAY SOLUTION 7.5MG/DOSE +...     Lidocaine/Prilocaine   \n",
            "2  VOCABRIA FILM-COATED TABLETS 30MGVOCABRIA PROL...             Cabotegravir   \n",
            "3  SCEMBLIX FILM-COATED TABLET 20 MG, SCEMBLIX FI...  Asciminib hydrochloride   \n",
            "4                     SALONPAS DICLOFENAC PATCH 15MG        Diclofenac Sodium   \n",
            "5  RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSIO...      Amivantamab 50mg/ml   \n",
            "6  TEPADINA POWDER FOR CONCENTRATE FOR SOLUTION F...                 Thiotepa   \n",
            "7  ROZEVON FILM-COATED TABLET 40MG/10MGROZEVON FI...        Active ingredient   \n",
            "8  PRIMOVIST SOLUTION FOR INJECTION IN VIAL 0.25 ...     Gadoxetate, disodium   \n",
            "\n",
            "                                               2  \\\n",
            "0    NDA-2: BiosimilarNDA-3: Subsequent strength   \n",
            "1              NDA-2: New dosage form/indication   \n",
            "2                     NDA-1: New chemical entity   \n",
            "3  NDA-1: New chemical entityNDA-3: New strength   \n",
            "4                         NDA-2: New dosage form   \n",
            "5                   NDA-1: New biological entity   \n",
            "6  NDA-1: New chemical entityNDA-3: New strength   \n",
            "7                         NDA-2: New combination   \n",
            "8                        NDA-2: New presentation   \n",
            "\n",
            "                                                   3            4  \\\n",
            "0                    MYLAN PHARMACEUTICALS PTE. LTD.   04/07/2022   \n",
            "1                                  Orient Europharma     5/7/2022   \n",
            "2                            GLAXOSMITHKLINE PTE LTD     5/7/2022   \n",
            "3                       NOVARTIS (SINGAPORE) PTE LTD   05/07/2022   \n",
            "4  Hisamitsu Pharmaceutical Co., Inc. Singapore B...  07/070/2022   \n",
            "5                        JOHNSON & JOHNSON PTE. LTD.   13/07/2022   \n",
            "6                                  AXXESSBIO PTE LID    18/7/2022   \n",
            "7                       NOVEM PHARMA PRIVATE LIMITED   04/07/2022   \n",
            "8                    BAYER (SOUTH EAST ASIA) PTE LTD   21/07/2022   \n",
            "\n",
            "                                      5  \n",
            "0           SIN16531PSIN16532PSIN16533P  \n",
            "1                             SIN16538P  \n",
            "2       SIN16541P, SIN16542P, SIN16543P  \n",
            "3                  SIN16539P, SIN16540P  \n",
            "4                             SIN16546P  \n",
            "5                             SIN16548P  \n",
            "6                    SIN16552PSIN16553P  \n",
            "7  SIN16534PSIN16535PSIN16536PSIN16537P  \n",
            "8                             SIN16559P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2022\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P', 'ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P', 'ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P', 'ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P', 'ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2', 'MYLAN PHARMACEUTICALS PTE. LTD.']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P', 'ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2', 'MYLAN PHARMACEUTICALS PTE. LTD.', '29/08/2022']\n",
            "['ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40MG/0.8 ML', 'Adalimumab', 'NDA-2/3', 'PFIZER PRIVATE LIMITED', '02/08/2022', 'SIN16561P, SIN16562P, SIN16563P', 'NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY', 'Nicotine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '06/08/2022', 'SIN16567P', 'REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJECTION 300MG/ML', 'Rilpivirine', 'NDA-2*: New dosage form', 'JOHNSON & JOHNSON PTE LTD', '11/08/2022', 'SIN16568P', 'AKLIEF CREAM 50 MCG/G', 'Trifarotene', 'NDA-1', 'GALDERMA SINGAPORE PRIVATE LIMITED', '17/08/2022', 'SIN16571P', 'ONUREG FILM-COATED TABLETS 200MGONUREG FILM-COATED TABLETS 300MG', 'Azacitidine', 'NDA-2/3', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '19/08/2022', 'SIN16572PSIN16573P', 'BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML', 'Vortioxetine', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16577P', 'KORSUVA SOLUTION FOR INJECTION 50 MCG/ML', 'Difelikefalin', 'NDA-1: New chemical entity', 'VIFOR PHARMA ASIA PACIFIC PTE. LTD.', '25/08/2022', 'SIN16582P', 'YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG', 'Abemaciclib', 'NDA-2 and NDA-3', 'DKSH SINGAPORE PTE. LTD.', '22/08/2022', 'SIN16574P, SIN16575P, SIN16576P', 'ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION 25MG/ML', 'Bevacizumab', 'NDA-2', 'MYLAN PHARMACEUTICALS PTE. LTD.', '29/08/2022', 'SIN16583P']\n",
            "                                                   0              1  \\\n",
            "0  ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE...     Adalimumab   \n",
            "1           NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY       Nicotine   \n",
            "2  REKAMBYS PROLONGED-RELEASE SUSPENSION FOR INJE...    Rilpivirine   \n",
            "3                              AKLIEF CREAM 50 MCG/G    Trifarotene   \n",
            "4  ONUREG FILM-COATED TABLETS 200MGONUREG FILM-CO...    Azacitidine   \n",
            "5            BRINTELLIX ORAL DROPS SOLUTION 20 MG/ML   Vortioxetine   \n",
            "6           KORSUVA SOLUTION FOR INJECTION 50 MCG/ML  Difelikefalin   \n",
            "7      YULAREB FILM-COATED TABLET 50MG, 100MG, 150MG    Abemaciclib   \n",
            "8  ABEVMY™ CONCENTRATE FOR SOLUTION FOR INFUSION ...    Bevacizumab   \n",
            "\n",
            "                            2                                           3  \\\n",
            "0                     NDA-2/3                      PFIZER PRIVATE LIMITED   \n",
            "1     NDA-2*: New dosage form                   JOHNSON & JOHNSON PTE LTD   \n",
            "2     NDA-2*: New dosage form                   JOHNSON & JOHNSON PTE LTD   \n",
            "3                       NDA-1          GALDERMA SINGAPORE PRIVATE LIMITED   \n",
            "4                     NDA-2/3  BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.   \n",
            "5      NDA-2: New dosage form                LUNDBECK SINGAPORE PTE. LTD.   \n",
            "6  NDA-1: New chemical entity         VIFOR PHARMA ASIA PACIFIC PTE. LTD.   \n",
            "7             NDA-2 and NDA-3                    DKSH SINGAPORE PTE. LTD.   \n",
            "8                       NDA-2             MYLAN PHARMACEUTICALS PTE. LTD.   \n",
            "\n",
            "            4                                5  \n",
            "0  02/08/2022  SIN16561P, SIN16562P, SIN16563P  \n",
            "1  06/08/2022                        SIN16567P  \n",
            "2  11/08/2022                        SIN16568P  \n",
            "3  17/08/2022                        SIN16571P  \n",
            "4  19/08/2022               SIN16572PSIN16573P  \n",
            "5  22/08/2022                        SIN16577P  \n",
            "6  25/08/2022                        SIN16582P  \n",
            "7  22/08/2022  SIN16574P, SIN16575P, SIN16576P  \n",
            "8  29/08/2022                        SIN16583P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---august-2022\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\"]\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE', 'Tozinameran']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE', 'Tozinameran', 'NDA-2: New formulation and patient population']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE', 'Tozinameran', 'NDA-2: New formulation and patient population', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE.LTD.']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE', 'Tozinameran', 'NDA-2: New formulation and patient population', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE.LTD.', '28 Sep 2022']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE', 'Tozinameran', 'NDA-2: New formulation and patient population', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE.LTD.', '28 Sep 2022', 'SIN16616P']\n",
            "['DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML', 'Dexamethasone sodium phosphate 1.32mg/mL (eqv to Dexamethasone 1.00mg/mL)Levofloxacin hemihydrate 5.12mg/mL (eqv to Levofloxacin 5.00mg/Ml)', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '07/09/2022', 'SIN16596P', 'BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG', 'Belantamab mafodotin', 'NDA-1', 'GLAXOSMITHKLINE PTE LTD', '21/09/2022', 'SIN16606P', 'JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG, 90MG/30MG', 'Tolvaptan', 'NDA-2/3: New indication/strength/dosing regimen', 'Otsuka Pharmaceuticals (Singapore) Pte. Ltd.', '23 Sep 22', 'SIN16607P, SIN16608P, SIN16609P, SIN16610P, SIN16611P', 'STAQUIS OINTMENT 2% W/W', 'Crisaborole', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '27/09/2022', 'SIN16613P', 'EQUFINA FILM-COATED TABLETS 50MG', 'Safinamide', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '28/09/2022', 'SIN16615P', \"Improvement of wearing-off phenomenon in idiopathic Parkinson's disease currently treated with levodopa-containing products\", 'INREBIC CAPSULES 100MG', 'Fedratinib', 'NDA-1: New chemical entity', 'Bristol-Myers Squibb (Singapore) Pte Ltd', '29 Sep 2022', 'SIN16617P', 'Inrebic is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.', 'COMIRNATY, CONCENTRATE FOR DISPERSION FOR\\xa0INJECTION, 3 MCG/DOSE', 'Tozinameran', 'NDA-2: New formulation and patient population', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE.LTD.', '28 Sep 2022', 'SIN16616P', 'COMIRNATY is indicated for active immunisation to prevent COVID-19 caused by SARS CoV- 2 virus, in individuals 6 months of age and older. The use of this vaccine should be in accordance with official recommendations.']\n",
            "                                                   0  \\\n",
            "0        DUCRESSA EYE DROPS SOLUTION 1MG/ML + 5MG/ML   \n",
            "1  BLENREP POWDER FOR CONCENTRATE FOR SOLUTION FO...   \n",
            "2  JINARC TABLET 15MG, 30MG, 45MG/15MG, 60MG/30MG...   \n",
            "3                            STAQUIS OINTMENT 2% W/W   \n",
            "4                   EQUFINA FILM-COATED TABLETS 50MG   \n",
            "5  Improvement of wearing-off phenomenon in idiop...   \n",
            "6                                          SIN16617P   \n",
            "7                                        28 Sep 2022   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Dexamethasone sodium phosphate 1.32mg/mL (eqv ...   \n",
            "1                               Belantamab mafodotin   \n",
            "2                                          Tolvaptan   \n",
            "3                                        Crisaborole   \n",
            "4                                         Safinamide   \n",
            "5                             INREBIC CAPSULES 100MG   \n",
            "6  Inrebic is indicated for the treatment of sple...   \n",
            "7                                          SIN16616P   \n",
            "\n",
            "                                                   2  \\\n",
            "0                             NDA-2: New combination   \n",
            "1                                              NDA-1   \n",
            "2    NDA-2/3: New indication/strength/dosing regimen   \n",
            "3                         NDA-1: New chemical entity   \n",
            "4                         NDA-1: New chemical entity   \n",
            "5                                         Fedratinib   \n",
            "6  COMIRNATY, CONCENTRATE FOR DISPERSION FOR INJE...   \n",
            "7  COMIRNATY is indicated for active immunisation...   \n",
            "\n",
            "                                              3  \\\n",
            "0            SANTEN PHARMACEUTICAL ASIA PTE LTD   \n",
            "1                       GLAXOSMITHKLINE PTE LTD   \n",
            "2  Otsuka Pharmaceuticals (Singapore) Pte. Ltd.   \n",
            "3                        PFIZER PRIVATE LIMITED   \n",
            "4                   EISAI (SINGAPORE) PTE. LTD.   \n",
            "5                    NDA-1: New chemical entity   \n",
            "6                                   Tozinameran   \n",
            "7                                          None   \n",
            "\n",
            "                                               4  \\\n",
            "0                                     07/09/2022   \n",
            "1                                     21/09/2022   \n",
            "2                                      23 Sep 22   \n",
            "3                                     27/09/2022   \n",
            "4                                     28/09/2022   \n",
            "5       Bristol-Myers Squibb (Singapore) Pte Ltd   \n",
            "6  NDA-2: New formulation and patient population   \n",
            "7                                           None   \n",
            "\n",
            "                                                   5  \n",
            "0                                          SIN16596P  \n",
            "1                                          SIN16606P  \n",
            "2  SIN16607P, SIN16608P, SIN16609P, SIN16610P, SI...  \n",
            "3                                          SIN16613P  \n",
            "4                                          SIN16615P  \n",
            "5                                        29 Sep 2022  \n",
            "6     BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE.LTD.  \n",
            "7                                               None  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---september-2022\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P', 'Trazher (trastuzumab) Powder for Concentrate for Solution for Infusion 150mg/vial']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P', 'Trazher (trastuzumab) Powder for Concentrate for Solution for Infusion 150mg/vial', 'Trastuzumab']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P', 'Trazher (trastuzumab) Powder for Concentrate for Solution for Infusion 150mg/vial', 'Trastuzumab', 'NDA-2']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P', 'Trazher (trastuzumab) Powder for Concentrate for Solution for Infusion 150mg/vial', 'Trastuzumab', 'NDA-2', 'INNOGENE KALBIOTECH PTE. LTD.']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P', 'Trazher (trastuzumab) Powder for Concentrate for Solution for Infusion 150mg/vial', 'Trastuzumab', 'NDA-2', 'INNOGENE KALBIOTECH PTE. LTD.', '09/10/2022']\n",
            "['JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/10ML', 'Dostarlimab', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '06/10/2022', 'SIN16623P', 'SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION20MG/ML', 'Isatuximab', 'NDA-1: New biological entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD', '17 OCT 2022', 'SIN16630P', 'Trazher (trastuzumab) Powder for Concentrate for Solution for Infusion 150mg/vial', 'Trastuzumab', 'NDA-2', 'INNOGENE KALBIOTECH PTE. LTD.', '09/10/2022', 'SIN16631P']\n",
            "                                                   0            1  \\\n",
            "0  JEMPERLI CONCENTRATE FOR SOLUTION FOR INFUSION...  Dostarlimab   \n",
            "1  SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION...   Isatuximab   \n",
            "2  Trazher (trastuzumab) Powder for Concentrate f...  Trastuzumab   \n",
            "\n",
            "                              2                                  3  \\\n",
            "0  NDA-1: New biological entity            GLAXOSMITHKLINE PTE LTD   \n",
            "1  NDA-1: New biological entity  SANOFI-AVENTIS SINGAPORE PTE. LTD   \n",
            "2                         NDA-2      INNOGENE KALBIOTECH PTE. LTD.   \n",
            "\n",
            "             4          5  \n",
            "0   06/10/2022  SIN16623P  \n",
            "1  17 OCT 2022  SIN16630P  \n",
            "2   09/10/2022  SIN16631P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---october-2022\n",
            "['ASADIN INJECTION 1 MG/ML']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P', 'APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P', 'APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'Pneumococcal polysaccharide of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F conjugated to CRM197carrier protein, adsorbed on aluminium phosphate.']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P', 'APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'Pneumococcal polysaccharide of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F conjugated to CRM197carrier protein, adsorbed on aluminium phosphate.', 'NDA-1: New biological entity']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P', 'APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'Pneumococcal polysaccharide of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F conjugated to CRM197carrier protein, adsorbed on aluminium phosphate.', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P', 'APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'Pneumococcal polysaccharide of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F conjugated to CRM197carrier protein, adsorbed on aluminium phosphate.', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '30/11/2022']\n",
            "['ASADIN INJECTION 1 MG/ML', 'Arsenic Trioxide', 'NDA-1: New chemical entity', 'PHARM-D SINGAPORE PTE LTD', '02/11/2022', 'SIN16634P', 'HIBRUKA TABLET 50 MG', 'Orelabrutinib', 'NDA-1: New chemical entity', 'LABCORP DEVELOPMENT (ASIA) PTE. LTD.', '22/11/2022', 'SIN16645P', 'APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML', 'Pneumococcal polysaccharide of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F conjugated to CRM197carrier protein, adsorbed on aluminium phosphate.', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '30/11/2022', 'SIN16648P']\n",
            "                                                   0  \\\n",
            "0                           ASADIN INJECTION 1 MG/ML   \n",
            "1                               HIBRUKA TABLET 50 MG   \n",
            "2  APEXXNAR SUSPENSION FOR INJECTION IN SINGLE-DO...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                   Arsenic Trioxide   \n",
            "1                                      Orelabrutinib   \n",
            "2  Pneumococcal polysaccharide of serotypes 1, 3,...   \n",
            "\n",
            "                              2                                     3  \\\n",
            "0    NDA-1: New chemical entity             PHARM-D SINGAPORE PTE LTD   \n",
            "1    NDA-1: New chemical entity  LABCORP DEVELOPMENT (ASIA) PTE. LTD.   \n",
            "2  NDA-1: New biological entity                PFIZER PRIVATE LIMITED   \n",
            "\n",
            "            4          5  \n",
            "0  02/11/2022  SIN16634P  \n",
            "1  22/11/2022  SIN16645P  \n",
            "2  30/11/2022  SIN16648P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---november-2022\n",
            "['LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG']\n",
            "['LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG', 'Rosuvastatin, ezetimibe']\n",
            "['LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG', 'Rosuvastatin, ezetimibe', 'NDA-2: New combination']\n",
            "['LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG', 'Rosuvastatin, ezetimibe', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED']\n",
            "['LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG', 'Rosuvastatin, ezetimibe', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '06/12/2022']\n",
            "['LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG', 'Rosuvastatin, ezetimibe', 'NDA-2: New combination', 'ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED', '06/12/2022', 'SIN16650P, SIN16651P']\n",
            "                                                   0                        1  \\\n",
            "0  LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/...  Rosuvastatin, ezetimibe   \n",
            "\n",
            "                        2                                                3  \\\n",
            "0  NDA-2: New combination  ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED   \n",
            "\n",
            "            4                     5  \n",
            "0  06/12/2022  SIN16650P, SIN16651P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---december-2022\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P', 'CALQUENCE FILM-COATED TABLET 100MG']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P', 'CALQUENCE FILM-COATED TABLET 100MG', 'Acalabrutinib']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P', 'CALQUENCE FILM-COATED TABLET 100MG', 'Acalabrutinib', 'NDA-2: New dosage form']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P', 'CALQUENCE FILM-COATED TABLET 100MG', 'Acalabrutinib', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P', 'CALQUENCE FILM-COATED TABLET 100MG', 'Acalabrutinib', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '29/09/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Tozinameran / Famtozinameran', 'NDA-1: New biological entityNDA-2: New dosage form', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '07/09/2023', 'SIN16855P, SIN16856P', 'ANDROGEL GEL 16.2MG/G', 'Testosterone', 'NDA-2: New formulation, strength', 'PHARMED IMPORT & EXPORT PTE LTD', '07/09/2023', 'SIN16857P', 'BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG', 'Doxylamine Succinate, Pyridoxine Hydrochloride', 'NDA-2: New formulation, dosing regimen', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '18/09/2023', 'SIN16865P', 'KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNITS/MLKIRSTY™ SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 UNITS/ML', 'Insulin aspart (rDNA origin)', 'NDA-2: Biosimilar', 'MYLAN PHARMACEUTICALS PTE. LTD.', '20/09/2023', 'SIN16867P, SIN16868P', 'SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION 600MG/10MLSKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED CARTRIDGE WITH ON-BODY INJECTOR 360MG/2.4ML', 'Risankizumab', 'NDA-2: New presentation, strength, indication, dosing regimen', 'ABBVIE PTE. LTD.', '27/09/2023', 'SIN16869P, SIN16870P', 'OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/10ML', 'Ocrelizumab', 'NDA-1: New chemical entity', 'ROCHE SINGAPORE PTE LTD', '28/09/2023', 'SIN16871P', 'CALQUENCE FILM-COATED TABLET 100MG', 'Acalabrutinib', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '29/09/2023', 'SIN16875P']\n",
            "                                                   0  \\\n",
            "0  COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION F...   \n",
            "1                              ANDROGEL GEL 16.2MG/G   \n",
            "2        BONJESTA EXTENDED-RELEASE TABLETS 20MG/20MG   \n",
            "3  KIRSTY™ SOLUTION FOR INJECTION IN VIAL 100 UNI...   \n",
            "4  SKYRIZI CONCENTRATE FOR SOLUTION FOR INFUSION ...   \n",
            "5  OCREVUS CONCENTRATE FOR SOLUTION FOR INFUSION ...   \n",
            "6                 CALQUENCE FILM-COATED TABLET 100MG   \n",
            "\n",
            "                                                1  \\\n",
            "0                    Tozinameran / Famtozinameran   \n",
            "1                                    Testosterone   \n",
            "2  Doxylamine Succinate, Pyridoxine Hydrochloride   \n",
            "3                    Insulin aspart (rDNA origin)   \n",
            "4                                    Risankizumab   \n",
            "5                                     Ocrelizumab   \n",
            "6                                   Acalabrutinib   \n",
            "\n",
            "                                                   2  \\\n",
            "0  NDA-1: New biological entityNDA-2: New dosage ...   \n",
            "1                   NDA-2: New formulation, strength   \n",
            "2             NDA-2: New formulation, dosing regimen   \n",
            "3                                  NDA-2: Biosimilar   \n",
            "4  NDA-2: New presentation, strength, indication,...   \n",
            "5                         NDA-1: New chemical entity   \n",
            "6                             NDA-2: New dosage form   \n",
            "\n",
            "                                                   3           4  \\\n",
            "0    BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.  07/09/2023   \n",
            "1                    PHARMED IMPORT & EXPORT PTE LTD  07/09/2023   \n",
            "2  UNITED ITALIAN TRADING CORPORATION (PRIVATE) L...  18/09/2023   \n",
            "3                    MYLAN PHARMACEUTICALS PTE. LTD.  20/09/2023   \n",
            "4                                   ABBVIE PTE. LTD.  27/09/2023   \n",
            "5                            ROCHE SINGAPORE PTE LTD  28/09/2023   \n",
            "6                      ASTRAZENECA SINGAPORE PTE LTD  29/09/2023   \n",
            "\n",
            "                      5  \n",
            "0  SIN16855P, SIN16856P  \n",
            "1             SIN16857P  \n",
            "2             SIN16865P  \n",
            "3  SIN16867P, SIN16868P  \n",
            "4  SIN16869P, SIN16870P  \n",
            "5             SIN16871P  \n",
            "6             SIN16875P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---sep-2023\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P', 'FESPIXON CREAM']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P', 'FESPIXON CREAM', 'Centella asiatica extract, Plectranthus amboinicusextract']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P', 'FESPIXON CREAM', 'Centella asiatica extract, Plectranthus amboinicusextract', 'NDA-1']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P', 'FESPIXON CREAM', 'Centella asiatica extract, Plectranthus amboinicusextract', 'NDA-1', 'PHARMENG TECHNOLOGY PTE. LTD.']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P', 'FESPIXON CREAM', 'Centella asiatica extract, Plectranthus amboinicusextract', 'NDA-1', 'PHARMENG TECHNOLOGY PTE. LTD.', '31/01/2023']\n",
            "['TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50MG, 100MG, 200MG', 'Topiramate', 'NDA-2: New dosage formNDA-3: New strength', 'ORIENT EUROPHARMA PTE LTD', '05/01/2023', 'SIN16662P, SIN16663P, SIN16664P, SIN16665P', 'SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN 20 MG/10 MG FILM-COATED TABLETS', 'Rosuvastatin, Ezetimibe', 'NDA-2: New dosage formNDA-3: New strength', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '05/01/2023', 'SIN16660P, SIN16661P', 'K-CAB FILM-COATED TABLETS 50MG', 'Tegoprazan', 'NDA-1: New chemical entity', 'UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED', '11/01/2023', 'SIN16672P', 'ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIAL', 'Vedolizumab', 'NDA-2: New dosage form /dosing regimen', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '11/01/2023', 'SIN16673P', 'NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL', 'Clostridium Botulinum Toxin Type A', 'NDA-2: New biological product', 'HYPHENS PHARMA PTE. LTD.', '20/01/2023', 'SIN16680P', 'FESPIXON CREAM', 'Centella asiatica extract, Plectranthus amboinicusextract', 'NDA-1', 'PHARMENG TECHNOLOGY PTE. LTD.', '31/01/2023', 'SIN16683P']\n",
            "                                                   0  \\\n",
            "0  TROKENDI XR EXTENDED-RELEASE CAPSULE 25MG, 50M...   \n",
            "1  SUVEZEN 10 MG/10 MG FILM-COATED TABLETSSUVEZEN...   \n",
            "2                     K-CAB FILM-COATED TABLETS 50MG   \n",
            "3  ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FO...   \n",
            "4  NABOTA POWDER FOR SOLUTION FOR INJECTION 100 U...   \n",
            "5                                     FESPIXON CREAM   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Topiramate   \n",
            "1                            Rosuvastatin, Ezetimibe   \n",
            "2                                         Tegoprazan   \n",
            "3                                        Vedolizumab   \n",
            "4                 Clostridium Botulinum Toxin Type A   \n",
            "5  Centella asiatica extract, Plectranthus amboin...   \n",
            "\n",
            "                                           2  \\\n",
            "0  NDA-2: New dosage formNDA-3: New strength   \n",
            "1  NDA-2: New dosage formNDA-3: New strength   \n",
            "2                 NDA-1: New chemical entity   \n",
            "3     NDA-2: New dosage form /dosing regimen   \n",
            "4              NDA-2: New biological product   \n",
            "5                                      NDA-1   \n",
            "\n",
            "                                                   3           4  \\\n",
            "0                          ORIENT EUROPHARMA PTE LTD  05/01/2023   \n",
            "1                 SANOFI-AVENTIS SINGAPORE PTE. LTD.  05/01/2023   \n",
            "2  UNITED ITALIAN TRADING CORPORATION (PRIVATE) L...  11/01/2023   \n",
            "3    TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.  11/01/2023   \n",
            "4                           HYPHENS PHARMA PTE. LTD.  20/01/2023   \n",
            "5                      PHARMENG TECHNOLOGY PTE. LTD.  31/01/2023   \n",
            "\n",
            "                                            5  \n",
            "0  SIN16662P, SIN16663P, SIN16664P, SIN16665P  \n",
            "1                        SIN16660P, SIN16661P  \n",
            "2                                   SIN16672P  \n",
            "3                                   SIN16673P  \n",
            "4                                   SIN16680P  \n",
            "5                                   SIN16683P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---january-2023\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P', 'NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR INJECTION 2000IU/VIAL']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P', 'NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR INJECTION 2000IU/VIAL', 'Turoctocog Alfa']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P', 'NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR INJECTION 2000IU/VIAL', 'Turoctocog Alfa', 'NDA-3: New strength']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P', 'NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR INJECTION 2000IU/VIAL', 'Turoctocog Alfa', 'NDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P', 'NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR INJECTION 2000IU/VIAL', 'Turoctocog Alfa', 'NDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24 Feb 2023']\n",
            "['RINVOQ EXTENDED-RELEASE TABLET 45MG', 'Upadacitinib Hemihydrate eqv Upadacitinib', 'NDA-3: New strength', 'ABBVIE PTE LTD', '10 Feb 2023', 'SIN16687P', 'MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED PEN 600 IU, 1200 IU', 'Menotrophin', 'NDA-2/3: New formulation, new strength', 'Ferring Pharmaceuticals Private Limited', '20 Feb 2023', 'SIN16699PSIN16700P', 'NURTEC ORALLY DISINTEGRATING TABLET 75MG', 'Rimegepant sulfate eqv Rimegepant', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '21 Feb 2023', 'SIN16702P', 'MAXIGESIC PE FILM-COATED TABLET', 'Paracetamol, phenylephrine hydrochloride, ibuprofen', 'NDA-2: New combination', 'APEX PHARMA MARKETING PTE. LTD.', '21 Feb 2023', 'SIN16703P', 'WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.5MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 0.25MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 1.7MG SOLUTION FOR INJECTION IN PRE-FILLED PENWEGOVY 2.4MG SOLUTION FOR INJECTION IN PRE-FILLED PEN', 'Semaglutide', 'NDA-2/3: New strength, new indication', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '22 Feb 2023', 'SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P', 'NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR INJECTION 2000IU/VIAL', 'Turoctocog Alfa', 'NDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24 Feb 2023', 'SIN16713P']\n",
            "                                                   0  \\\n",
            "0                RINVOQ EXTENDED-RELEASE TABLET 45MG   \n",
            "1  MENOPUR SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "2           NURTEC ORALLY DISINTEGRATING TABLET 75MG   \n",
            "3                    MAXIGESIC PE FILM-COATED TABLET   \n",
            "4  WEGOVY 1MG SOLUTION FOR INJECTION IN PRE-FILLE...   \n",
            "5  NOVOEIGHT POWDER AND SOLVENT FOR SOLUTIONFOR I...   \n",
            "\n",
            "                                                   1  \\\n",
            "0          Upadacitinib Hemihydrate eqv Upadacitinib   \n",
            "1                                        Menotrophin   \n",
            "2                  Rimegepant sulfate eqv Rimegepant   \n",
            "3  Paracetamol, phenylephrine hydrochloride, ibup...   \n",
            "4                                        Semaglutide   \n",
            "5                                    Turoctocog Alfa   \n",
            "\n",
            "                                        2  \\\n",
            "0                     NDA-3: New strength   \n",
            "1  NDA-2/3: New formulation, new strength   \n",
            "2              NDA-1: New chemical entity   \n",
            "3                  NDA-2: New combination   \n",
            "4   NDA-2/3: New strength, new indication   \n",
            "5                     NDA-3: New strength   \n",
            "\n",
            "                                         3            4  \\\n",
            "0                           ABBVIE PTE LTD  10 Feb 2023   \n",
            "1  Ferring Pharmaceuticals Private Limited  20 Feb 2023   \n",
            "2                   PFIZER PRIVATE LIMITED  21 Feb 2023   \n",
            "3          APEX PHARMA MARKETING PTE. LTD.  21 Feb 2023   \n",
            "4  NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  22 Feb 2023   \n",
            "5  NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  24 Feb 2023   \n",
            "\n",
            "                                               5  \n",
            "0                                      SIN16687P  \n",
            "1                             SIN16699PSIN16700P  \n",
            "2                                      SIN16702P  \n",
            "3                                      SIN16703P  \n",
            "4  SIN16704PSIN16705PSIN16706PSIN16707PSIN16708P  \n",
            "5                                      SIN16713P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---february-2023\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P', 'SPINRAZA SOLUTION FOR INJECTION 12MG/5ML']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P', 'SPINRAZA SOLUTION FOR INJECTION 12MG/5ML', 'Nusinersen sodium']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P', 'SPINRAZA SOLUTION FOR INJECTION 12MG/5ML', 'Nusinersen sodium', 'NDA-1: New chemical entity']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P', 'SPINRAZA SOLUTION FOR INJECTION 12MG/5ML', 'Nusinersen sodium', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P', 'SPINRAZA SOLUTION FOR INJECTION 12MG/5ML', 'Nusinersen sodium', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '31/03/2023']\n",
            "['MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5MG/0.5ML, 10MG/0.5ML, 12.5MG/0.5ML AND 15MG/0.5ML', 'Tirzepatide', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '01/03/2023', 'SIN16714P, SIN16716P, SIN16717P, SIN16718P, SIN16719P AND SIN16720P', 'BREZTRI AEROSPHERE PRESSURISED INHALATION SUSPENSION 160 MCG/7.2 MCG/5 MCG PER ACTUATION', 'Budesonide, glycopyrronium, formoterol', 'NDA-2: New combination', 'ASTRAZENECA SINGAPORE PTE LTD', '01/03/2023', 'SIN16723P', 'LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, 5 MG', 'Leuprorelin acetate eqv leuprorelin', 'NDA-2: New dosage formNDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/03/2023', 'SIN16740P, SIN16739P', 'WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG FLEXTOUCH SOLUTION FOR INJECTION in PRE-FILLED PEN', 'Semaglutide', 'NDA-2: New product containing registered entityNDA-3: New strength', 'NOVO NORDISK PHARMA (SINGAPORE) PTE LTD', '24/03/2023', 'SIN16744P, SIN16745P, SIN16746P, SIN16747P and SIN16748P', 'SPINRAZA SOLUTION FOR INJECTION 12MG/5ML', 'Nusinersen sodium', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '31/03/2023', 'SIN16751P']\n",
            "                                                   0  \\\n",
            "0  MOUNJARO INJECTION 2.5MG/0/5ML, 5MG/0.5ML, 7.5...   \n",
            "1  BREZTRI AEROSPHERE PRESSURISED INHALATION SUSP...   \n",
            "2  LEUPRORELIN SANDOZ IMPLANT IN SYRINGE 3.6 MG, ...   \n",
            "3  WEGOVY 0.25MG, 0.5MG, 1.0MG, 1.7MG and 2.4MG F...   \n",
            "4           SPINRAZA SOLUTION FOR INJECTION 12MG/5ML   \n",
            "\n",
            "                                        1  \\\n",
            "0                             Tirzepatide   \n",
            "1  Budesonide, glycopyrronium, formoterol   \n",
            "2     Leuprorelin acetate eqv leuprorelin   \n",
            "3                             Semaglutide   \n",
            "4                       Nusinersen sodium   \n",
            "\n",
            "                                                   2  \\\n",
            "0      NDA-1: New chemical entityNDA-3: New strength   \n",
            "1                             NDA-2: New combination   \n",
            "2          NDA-2: New dosage formNDA-3: New strength   \n",
            "3  NDA-2: New product containing registered entit...   \n",
            "4                         NDA-1: New chemical entity   \n",
            "\n",
            "                                         3           4  \\\n",
            "0                 DKSH SINGAPORE PTE. LTD.  01/03/2023   \n",
            "1            ASTRAZENECA SINGAPORE PTE LTD  01/03/2023   \n",
            "2             NOVARTIS (SINGAPORE) PTE LTD  21/03/2023   \n",
            "3  NOVO NORDISK PHARMA (SINGAPORE) PTE LTD  24/03/2023   \n",
            "4                 ZUELLIG PHARMA PTE. LTD.  31/03/2023   \n",
            "\n",
            "                                                   5  \n",
            "0  SIN16714P, SIN16716P, SIN16717P, SIN16718P, SI...  \n",
            "1                                          SIN16723P  \n",
            "2                               SIN16740P, SIN16739P  \n",
            "3  SIN16744P, SIN16745P, SIN16746P, SIN16747P and...  \n",
            "4                                          SIN16751P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---march-2023\n",
            "['GAVRETO HARD CAPSULE 100MG']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P', 'QINLOCK TABLET 50 MG']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P', 'QINLOCK TABLET 50 MG', 'Ripretinib']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P', 'QINLOCK TABLET 50 MG', 'Ripretinib', 'NDA-1']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P', 'QINLOCK TABLET 50 MG', 'Ripretinib', 'NDA-1', 'SPECIALISED THERAPEUTICS ASIA PTE LTD']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P', 'QINLOCK TABLET 50 MG', 'Ripretinib', 'NDA-1', 'SPECIALISED THERAPEUTICS ASIA PTE LTD', '28 April 2023']\n",
            "['GAVRETO HARD CAPSULE 100MG', 'Pralsetinib', 'NDA-1', 'ROCHE SINGAPORE PTE LTD', '06 April 2023', 'SIN16755P', 'ALBUMIN SG INJECTION 20%', 'Human serum albumin', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16765P', 'IMMUNOGLOBULIN SG INJECTION 50MG/ML', 'Human immunoglobulin G', 'NDA-2', 'THE REG CONSULTANTS PTE LTD', '20 April 2023', 'SIN16766P', 'DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MICROGRAMS/ML', 'Dexmedetomidine', 'NDA-2', 'ORION PHARMA (SG) PTE. LTD.', '25 April 2023', 'SIN16767P', 'ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR INJUSION 1MG/ML', 'Zinc gluconate equivalent to elemental zinc', 'NDA-2', 'AGUETTANT ASIA PACIFIC PTE LTD', '25 April 2023', 'SIN16768P', 'QINLOCK TABLET 50 MG', 'Ripretinib', 'NDA-1', 'SPECIALISED THERAPEUTICS ASIA PTE LTD', '28 April 2023', 'SIN16769P']\n",
            "                                                   0  \\\n",
            "0                         GAVRETO HARD CAPSULE 100MG   \n",
            "1                           ALBUMIN SG INJECTION 20%   \n",
            "2                IMMUNOGLOBULIN SG INJECTION 50MG/ML   \n",
            "3  DEXDOR CONCENTRATE FOR SOLUTION FOR INFUSION 1...   \n",
            "4  ZINC AGUETTANT CONCENTRATE FOR SOLUTION FOR IN...   \n",
            "5                               QINLOCK TABLET 50 MG   \n",
            "\n",
            "                                             1      2  \\\n",
            "0                                  Pralsetinib  NDA-1   \n",
            "1                          Human serum albumin  NDA-2   \n",
            "2                       Human immunoglobulin G  NDA-2   \n",
            "3                              Dexmedetomidine  NDA-2   \n",
            "4  Zinc gluconate equivalent to elemental zinc  NDA-2   \n",
            "5                                   Ripretinib  NDA-1   \n",
            "\n",
            "                                       3              4          5  \n",
            "0                ROCHE SINGAPORE PTE LTD  06 April 2023  SIN16755P  \n",
            "1            THE REG CONSULTANTS PTE LTD  20 April 2023  SIN16765P  \n",
            "2            THE REG CONSULTANTS PTE LTD  20 April 2023  SIN16766P  \n",
            "3            ORION PHARMA (SG) PTE. LTD.  25 April 2023  SIN16767P  \n",
            "4         AGUETTANT ASIA PACIFIC PTE LTD  25 April 2023  SIN16768P  \n",
            "5  SPECIALISED THERAPEUTICS ASIA PTE LTD  28 April 2023  SIN16769P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---april-2023\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P', 'BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR SEALANT 1.0ML, 3.0ML']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P', 'BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR SEALANT 1.0ML, 3.0ML', '1.0mlVial 1: Factor XIII 60IU/mLVial 1: Fibrinogen: 90mg/mLVial 2: Aprotinin solution 1000KIU/mLVial 3: Thrombin 500IU/mLVial 4: Calcium chloride dihydrate 5.9mg/mL3.0mlVial 1: Factor XIII 180IU/mLVial 1: Fibrinogen: 270mg/mLVial 2: Aprotinin solution 3000KIU/mLVial 3: Thrombin 1500IU/mLVial 4: Calcium chloride dihydrate 17.7mg/mL']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P', 'BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR SEALANT 1.0ML, 3.0ML', '1.0mlVial 1: Factor XIII 60IU/mLVial 1: Fibrinogen: 90mg/mLVial 2: Aprotinin solution 1000KIU/mLVial 3: Thrombin 500IU/mLVial 4: Calcium chloride dihydrate 5.9mg/mL3.0mlVial 1: Factor XIII 180IU/mLVial 1: Fibrinogen: 270mg/mLVial 2: Aprotinin solution 3000KIU/mLVial 3: Thrombin 1500IU/mLVial 4: Calcium chloride dihydrate 17.7mg/mL', 'NDA-2/3: New product containing a currently registered entity, new strength']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P', 'BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR SEALANT 1.0ML, 3.0ML', '1.0mlVial 1: Factor XIII 60IU/mLVial 1: Fibrinogen: 90mg/mLVial 2: Aprotinin solution 1000KIU/mLVial 3: Thrombin 500IU/mLVial 4: Calcium chloride dihydrate 5.9mg/mL3.0mlVial 1: Factor XIII 180IU/mLVial 1: Fibrinogen: 270mg/mLVial 2: Aprotinin solution 3000KIU/mLVial 3: Thrombin 1500IU/mLVial 4: Calcium chloride dihydrate 17.7mg/mL', 'NDA-2/3: New product containing a currently registered entity, new strength', 'CSL BEHRING PTE. LTD.']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P', 'BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR SEALANT 1.0ML, 3.0ML', '1.0mlVial 1: Factor XIII 60IU/mLVial 1: Fibrinogen: 90mg/mLVial 2: Aprotinin solution 1000KIU/mLVial 3: Thrombin 500IU/mLVial 4: Calcium chloride dihydrate 5.9mg/mL3.0mlVial 1: Factor XIII 180IU/mLVial 1: Fibrinogen: 270mg/mLVial 2: Aprotinin solution 3000KIU/mLVial 3: Thrombin 1500IU/mLVial 4: Calcium chloride dihydrate 17.7mg/mL', 'NDA-2/3: New product containing a currently registered entity, new strength', 'CSL BEHRING PTE. LTD.', '10/05/2023']\n",
            "['ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL', 'Taliglucerase alfa', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '03/05/2023', 'SIN16770P', 'ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATMENT INITIATION PACK', 'Ozanimod Hydrochloride', 'NDA-1: New chemical entityNDA-2: New strength', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD', '17 May 2023', 'SIN16785P, SIN16786P', 'BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR SEALANT 1.0ML, 3.0ML', '1.0mlVial 1: Factor XIII 60IU/mLVial 1: Fibrinogen: 90mg/mLVial 2: Aprotinin solution 1000KIU/mLVial 3: Thrombin 500IU/mLVial 4: Calcium chloride dihydrate 5.9mg/mL3.0mlVial 1: Factor XIII 180IU/mLVial 1: Fibrinogen: 270mg/mLVial 2: Aprotinin solution 3000KIU/mLVial 3: Thrombin 1500IU/mLVial 4: Calcium chloride dihydrate 17.7mg/mL', 'NDA-2/3: New product containing a currently registered entity, new strength', 'CSL BEHRING PTE. LTD.', '10/05/2023', 'SIN16775P, SIN16776P']\n",
            "                                                   0  \\\n",
            "0  ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FO...   \n",
            "1  ZEPOSIA CAPSULE 0.92MGZEPOSIA CAPSULES TREATME...   \n",
            "2  BERIPLAST P COMBI-SET POWDERS AND SOLVENTS FOR...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                 Taliglucerase alfa   \n",
            "1                             Ozanimod Hydrochloride   \n",
            "2  1.0mlVial 1: Factor XIII 60IU/mLVial 1: Fibrin...   \n",
            "\n",
            "                                                   2  \\\n",
            "0                       NDA-1: New biological entity   \n",
            "1      NDA-1: New chemical entityNDA-2: New strength   \n",
            "2  NDA-2/3: New product containing a currently re...   \n",
            "\n",
            "                                           3            4  \\\n",
            "0                     PFIZER PRIVATE LIMITED   03/05/2023   \n",
            "1  BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD  17 May 2023   \n",
            "2                      CSL BEHRING PTE. LTD.   10/05/2023   \n",
            "\n",
            "                      5  \n",
            "0             SIN16770P  \n",
            "1  SIN16785P, SIN16786P  \n",
            "2  SIN16775P, SIN16776P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---may-2023\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P', 'NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.4ML']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P', 'NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.4ML', 'Mepolizumab']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P', 'NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.4ML', 'Mepolizumab', 'NDA-2: New strength / indication / dosing regimen']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P', 'NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.4ML', 'Mepolizumab', 'NDA-2: New strength / indication / dosing regimen', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P', 'NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.4ML', 'Mepolizumab', 'NDA-2: New strength / indication / dosing regimen', 'GLAXOSMITHKLINE PTE LTD', '19/06/2023']\n",
            "['SONDELBAY INJECTION 20 MCG/80 MCL', 'Teriparatide', 'NDA-2: Biosimilar', 'ACCORD HEALTHCARE PRIVATE LIMITED', '01/06/2023', 'SIN16802P', 'CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZYOS CAPSULES 10MGCAMZYOS CAPSULES 15MG', 'Mavacamten', 'NDA-1: New chemicalNDA-3: New strength', 'LIANBIO DEVELOPMENT (SG) PTE. LTD.', '14/06/2023', 'SIN16804P, SIN16805P, SIN16806P, SIN16807P', 'VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML', 'Bevacizumab', 'NDA-2: Biosimilar', 'CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED', '16/06/2023', 'SIN16810P', 'NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.4ML', 'Mepolizumab', 'NDA-2: New strength / indication / dosing regimen', 'GLAXOSMITHKLINE PTE LTD', '19/06/2023', 'SIN16811P']\n",
            "                                                   0             1  \\\n",
            "0                  SONDELBAY INJECTION 20 MCG/80 MCL  Teriparatide   \n",
            "1  CAMZYOS CAPSULES 2.5MGCAMZYOS CAPSULES 5MGCAMZ...    Mavacamten   \n",
            "2  VEGZELMA CONCENTRATE FOR SOLUTION FOR INFUSION...   Bevacizumab   \n",
            "3  NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SY...   Mepolizumab   \n",
            "\n",
            "                                                   2  \\\n",
            "0                                  NDA-2: Biosimilar   \n",
            "1             NDA-1: New chemicalNDA-3: New strength   \n",
            "2                                  NDA-2: Biosimilar   \n",
            "3  NDA-2: New strength / indication / dosing regimen   \n",
            "\n",
            "                                                3           4  \\\n",
            "0               ACCORD HEALTHCARE PRIVATE LIMITED  01/06/2023   \n",
            "1              LIANBIO DEVELOPMENT (SG) PTE. LTD.  14/06/2023   \n",
            "2  CELLTRION HEALTHCARE SINGAPORE PRIVATE LIMITED  16/06/2023   \n",
            "3                         GLAXOSMITHKLINE PTE LTD  19/06/2023   \n",
            "\n",
            "                                            5  \n",
            "0                                   SIN16802P  \n",
            "1  SIN16804P, SIN16805P, SIN16806P, SIN16807P  \n",
            "2                                   SIN16810P  \n",
            "3                                   SIN16811P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---june-2023\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P', 'VITRAKVI ORAL SOLUTION 20MG/ML']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P', 'VITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib sulfate eqv Larotrectinib']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P', 'VITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib sulfate eqv Larotrectinib', 'NDA-2: New formulation']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P', 'VITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib sulfate eqv Larotrectinib', 'NDA-2: New formulation', 'Bayer (South East Asia) Pte Ltd']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P', 'VITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib sulfate eqv Larotrectinib', 'NDA-2: New formulation', 'Bayer (South East Asia) Pte Ltd', '28/7/2023']\n",
            "['RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%', 'Netarsudil mesylate', 'NDA-1: New chemical entity', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16816P', 'ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0.005%', 'Netarsudil mesylate/Latanoprost', 'NDA-2: New combination', 'SANTEN PHARMACEUTICAL ASIA PTE LTD', '4/7/2023', 'SIN16818P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED SYRINGE)', 'Tezepelumab', 'NDA-1: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16815P', 'TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FILLED PEN)', 'Tezepelumab', 'NDA-2: New presentation', 'ASTRAZENECA SINGAPORE PTE LTD', '4/7/2023', 'SIN16817P', 'BRAFTOVI HARD CAPSULE 50 MG AND 75 MG', 'Encorafenib', 'NDA-1/3: New chemical entity and strength', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16824P and SIN16825P', 'MEKTOVI FILM-COATED TABLET 15MG', 'Binimetinib', 'NDA-1: New chemical entity', 'ZUELLIG PHARMA PTE. LTD.', '19/7/2023', 'SIN16826P', 'VITRAKVI ORAL SOLUTION 20MG/ML', 'Larotrectinib sulfate eqv Larotrectinib', 'NDA-2: New formulation', 'Bayer (South East Asia) Pte Ltd', '28/7/2023', 'SIN16827P']\n",
            "                                                   0  \\\n",
            "0       RHOPRESSA OPHTHALMIC SOLUTION, STERILE 0.02%   \n",
            "1  ROCKLATAN OPHTHALMIC SOLUTION, STERILE 0.02%/0...   \n",
            "2  TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FIL...   \n",
            "3  TEZSPIRE SOLUTION FOR INJECTION 210MG (PRE-FIL...   \n",
            "4              BRAFTOVI HARD CAPSULE 50 MG AND 75 MG   \n",
            "5                    MEKTOVI FILM-COATED TABLET 15MG   \n",
            "6                     VITRAKVI ORAL SOLUTION 20MG/ML   \n",
            "\n",
            "                                         1  \\\n",
            "0                      Netarsudil mesylate   \n",
            "1          Netarsudil mesylate/Latanoprost   \n",
            "2                              Tezepelumab   \n",
            "3                              Tezepelumab   \n",
            "4                              Encorafenib   \n",
            "5                              Binimetinib   \n",
            "6  Larotrectinib sulfate eqv Larotrectinib   \n",
            "\n",
            "                                           2  \\\n",
            "0                 NDA-1: New chemical entity   \n",
            "1                     NDA-2: New combination   \n",
            "2                 NDA-1: New chemical entity   \n",
            "3                    NDA-2: New presentation   \n",
            "4  NDA-1/3: New chemical entity and strength   \n",
            "5                 NDA-1: New chemical entity   \n",
            "6                     NDA-2: New formulation   \n",
            "\n",
            "                                    3          4                        5  \n",
            "0  SANTEN PHARMACEUTICAL ASIA PTE LTD   4/7/2023                SIN16816P  \n",
            "1  SANTEN PHARMACEUTICAL ASIA PTE LTD   4/7/2023                SIN16818P  \n",
            "2       ASTRAZENECA SINGAPORE PTE LTD   4/7/2023                SIN16815P  \n",
            "3       ASTRAZENECA SINGAPORE PTE LTD   4/7/2023                SIN16817P  \n",
            "4            ZUELLIG PHARMA PTE. LTD.  19/7/2023  SIN16824P and SIN16825P  \n",
            "5            ZUELLIG PHARMA PTE. LTD.  19/7/2023                SIN16826P  \n",
            "6     Bayer (South East Asia) Pte Ltd  28/7/2023                SIN16827P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2023\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P', 'OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P', 'OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG', 'Nivolumab/relatlimab']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P', 'OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG', 'Nivolumab/relatlimab', 'NDA-1: New biological entity']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P', 'OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG', 'Nivolumab/relatlimab', 'NDA-1: New biological entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P', 'OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG', 'Nivolumab/relatlimab', 'NDA-1: New biological entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '31/08/2023']\n",
            "['NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION', 'Galsulfase', 'NDA-1: New biological entity', 'PHARM-D SINGAPORE PRIVATE LIMITED', '11/08/2023', 'SIN16831P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION IN PFS 400 MG', 'Aripiprazole', 'NDA-2: New dosage form', 'LUNDBECK SINGAPORE PTE LTD', '14/08/2023', 'SIN16832P', 'SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-1: New biological entity(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16834P', 'SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION', 'Elasomeran', 'NDA-2: New strength(Transition from PSAR to marketing authorisation)', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '17/08/2023', 'SIN16835P', 'GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85 GBq', 'Germanium (68Ge) chloride; Gallium (68Ga) chloride', 'NDA-1: New chemical entity', 'LABGISTICS ASIA PTE LTD', '23/08/2023', 'SIN16844P', 'IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML', 'Tremelimumab', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '25/08/2023', 'SIN16845P', 'SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 10 MCG/ML', 'Sodium Selenite', 'NDA-2: New presentation', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '27/08/2023', 'SIN16847P', 'OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG', 'Nivolumab/relatlimab', 'NDA-1: New biological entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '31/08/2023', 'SIN16852P']\n",
            "                                                   0  \\\n",
            "0    NAGLAZYME CONCENTRATE FOR SOLUTION FOR INFUSION   \n",
            "1  ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLON...   \n",
            "2  ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLON...   \n",
            "3        SPIKEVAX 0.2 mg/mL DISPERSION FOR INJECTION   \n",
            "4        SPIKEVAX 0.1 mg/mL DISPERSION FOR INJECTION   \n",
            "5  GALLIAPHARM RADIONUCLIDE GENERATOR 0.74 – 1.85...   \n",
            "6  IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 2...   \n",
            "7  SELENIUM AGUETTANT CONCENTRATE FOR SOLUTION FO...   \n",
            "8  OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Galsulfase   \n",
            "1                                       Aripiprazole   \n",
            "2                                       Aripiprazole   \n",
            "3                                         Elasomeran   \n",
            "4                                         Elasomeran   \n",
            "5  Germanium (68Ge) chloride; Gallium (68Ga) chlo...   \n",
            "6                                       Tremelimumab   \n",
            "7                                    Sodium Selenite   \n",
            "8                               Nivolumab/relatlimab   \n",
            "\n",
            "                                                   2  \\\n",
            "0                       NDA-1: New biological entity   \n",
            "1                             NDA-2: New dosage form   \n",
            "2                             NDA-2: New dosage form   \n",
            "3  NDA-1: New biological entity(Transition from P...   \n",
            "4  NDA-2: New strength(Transition from PSAR to ma...   \n",
            "5                         NDA-1: New chemical entity   \n",
            "6                       NDA-1: New biological entity   \n",
            "7                            NDA-2: New presentation   \n",
            "8                       NDA-1: New biological entity   \n",
            "\n",
            "                                            3           4          5  \n",
            "0           PHARM-D SINGAPORE PRIVATE LIMITED  11/08/2023  SIN16831P  \n",
            "1                  LUNDBECK SINGAPORE PTE LTD  14/08/2023  SIN16832P  \n",
            "2                  LUNDBECK SINGAPORE PTE LTD  14/08/2023  SIN16832P  \n",
            "3         MODERNA BIOTECH SINGAPORE PTE. LTD.  17/08/2023  SIN16834P  \n",
            "4         MODERNA BIOTECH SINGAPORE PTE. LTD.  17/08/2023  SIN16835P  \n",
            "5                     LABGISTICS ASIA PTE LTD  23/08/2023  SIN16844P  \n",
            "6               ASTRAZENECA SINGAPORE PTE LTD  25/08/2023  SIN16845P  \n",
            "7            AGUETTANT ASIA PACIFIC PTE. LTD.  27/08/2023  SIN16847P  \n",
            "8  BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.  31/08/2023  SIN16852P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---august-2023\n",
            "Empty DataFrame\n",
            "Columns: []\n",
            "Index: []\n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---september-2023\n",
            "['GOOFICE FILM-COATED TABLET 5MG']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P', 'SKIIP NICOTINE MINI LOZENGE 2MG (MINT)']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P', 'SKIIP NICOTINE MINI LOZENGE 2MG (MINT)', 'Nicotine Polacrilex']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P', 'SKIIP NICOTINE MINI LOZENGE 2MG (MINT)', 'Nicotine Polacrilex', 'NDA-2: New salt /dosage form']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P', 'SKIIP NICOTINE MINI LOZENGE 2MG (MINT)', 'Nicotine Polacrilex', 'NDA-2: New salt /dosage form', 'RUBICON RESEARCH PRIVATE LIMITED']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P', 'SKIIP NICOTINE MINI LOZENGE 2MG (MINT)', 'Nicotine Polacrilex', 'NDA-2: New salt /dosage form', 'RUBICON RESEARCH PRIVATE LIMITED', '30/10/2023']\n",
            "['GOOFICE FILM-COATED TABLET 5MG', 'Elobixibat', 'NDA-1: New chemical entity', 'EISAI (SINGAPORE) PTE. LTD.', '02/10/2023', 'SIN16878P', 'PAXLOVID FILM-COATED TABLETS', 'Nirmatrelvir, Ritonavir', 'NDA-1: New chemical entity(Transition from PSAR to marketing authorisation)', 'PFIZER PRIVATE LIMITED', '02/10/2023', 'SIN16877P', 'SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 MICROGRAMS/50 MICROGRAMS)/ML DISPERSION FOR INJECTION', 'Elasomeran, Davesomeran', 'NDA-1: New biological entity', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '11/10/2023', 'SIN16881P', 'SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 450 MG/7.5 ML', 'Spesolimab', 'NDA-1: New biological entity', 'BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.', '12/10/2023', 'SIN16883P', 'NUVAXOVID DISPERSION FOR INJECTION COVID-19 VACCINE 5µG/DOSE (RECOMBINANT, ADJUVANTED)', 'SARS-CoV-2 recombinant Spike Protein (rS)', 'NDA-1: New biological entity', 'PHARMENG TECHNOLOGY PTE LTD', '17/10/2023', 'SIN16886P', 'PERIOLIMEL N4E EMULSION FOR INFUSION', '(Compartment 1) Alanine 3.66g/L(Compartment 1) Arginine 2.48g/L(Compartment 1) Aspartic Acid 0.73g/L(Compartment 1) Glutamic Acid 1.26g/L(Compartment 1) Glycine 1.76g/L(Compartment 1) Histidine 1.51g/L(Compartment 1) Isoleucine 1.26g/L(Compartment 1) Leucine 1.76g/L(Compartment 1) Lysine Acetate eqv Lysine 1.99g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.45g/L(Compartment 1) Methionine 1.26g/L(Compartment 1) Phenylalanine 1.76g/L(Compartment 1) Potassium Chloride 1.19g/L(Compartment 1) Proline 1.51g/L(Compartment 1) Serine 1.00g/L(Compartment 1) Sodium Acetate Trihydrate 1.16g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 1.91g/L(Compartment 1) Threonine 1.26g/L(Compartment 1) Tryptophan 0.42g/L(Compartment 1) Tyrosine 0.06g/L(Compartment 1) Valine 1.62g/L(Compartment 2) Calcium Chloride Dihydrate 0.30g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 75.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 30g/L', 'NDA-2: New combination', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16888P', 'OLIMEL N7E EMULSION FOR INFUSION', '(Compartment 1) Alanine 6.41g/L(Compartment 1) Arginine 4.34g/L(Compartment 1) Aspartic Acid 1.28g/L(Compartment 1) Glutamic Acid 2.21g/L(Compartment 1) Glycine 3.07g/L(Compartment 1) Histidine 2.64g/L(Compartment 1) Isoleucine 2.21g/L(Compartment 1) Leucine 3.07g/L(Compartment 1) Lysine Acetate eqv Lysine 3.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.21g/L(Compartment 1) Phenylalanine 3.07g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 2.64g/L(Compartment 1) Serine 1.75g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.21g/L(Compartment 1) Tryptophan 0.74g/L(Compartment 1) Tyrosine 0.11g/L(Compartment 1) Valine 2.83g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 140g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16889P', 'OLIMEL N9E EMULSION FOR INFUSION', '(Compartment 1) Alanine 8.24g/L(Compartment 1) Arginine 5.58g/L(Compartment 1) Aspartic Acid 1.65g/L(Compartment 1) Glutamic Acid 2.84g/L(Compartment 1) Glycine 3.95g/L(Compartment 1) Histidine 3.40g/L(Compartment 1) Isoleucine 2.84g/L(Compartment 1) Leucine 3.95g/L(Compartment 1) Lysine Acetate eqv Lysine 4.48g/L(Compartment 1) Magnesium Chloride Hexahydrate 0.81g/L(Compartment 1) Methionine 2.84g/L(Compartment 1) Phenylalanine 3.95g/L(Compartment 1) Potassium Chloride 2.24g/L(Compartment 1) Proline 3.40g/L(Compartment 1) Serine 2.25g/L(Compartment 1) Sodium Acetate Trihydrate 1.50g/L(Compartment 1) Sodium Glycerophosphate, Hydrated 3.67g/L(Compartment 1) Threonine 2.84g/L(Compartment 1) Tryptophan 0.95g/L(Compartment 1) Tyrosine 0.15g/L(Compartment 1) Valine 3.64g/L(Compartment 2) Calcium Chloride Dihydrate 0.52g/L(Compartment 2) Glucose Monohydrate eqv Glucose Anhydrous 110.0g/L(Compartment 3) Refined Olive Oil + Soya-bean Oil (80:20) 40g/L', 'NDA-3: Line extension', 'BAXTER HEALTHCARE (ASIA) PTE LTD', '20/10/2023', 'SIN16890P', 'SKIIP NICOTINE MINI LOZENGE 2MG (MINT)', 'Nicotine Polacrilex', 'NDA-2: New salt /dosage form', 'RUBICON RESEARCH PRIVATE LIMITED', '30/10/2023', 'SIN16895P']\n",
            "                                                   0  \\\n",
            "0                     GOOFICE FILM-COATED TABLET 5MG   \n",
            "1                       PAXLOVID FILM-COATED TABLETS   \n",
            "2  SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5(50 M...   \n",
            "3  SPEVIGOCONCENTRATE FOR SOLUTION FOR INFUSION 4...   \n",
            "4  NUVAXOVID DISPERSION FOR INJECTION COVID-19 VA...   \n",
            "5               PERIOLIMEL N4E EMULSION FOR INFUSION   \n",
            "6                   OLIMEL N7E EMULSION FOR INFUSION   \n",
            "7                   OLIMEL N9E EMULSION FOR INFUSION   \n",
            "8             SKIIP NICOTINE MINI LOZENGE 2MG (MINT)   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                         Elobixibat   \n",
            "1                            Nirmatrelvir, Ritonavir   \n",
            "2                            Elasomeran, Davesomeran   \n",
            "3                                         Spesolimab   \n",
            "4          SARS-CoV-2 recombinant Spike Protein (rS)   \n",
            "5  (Compartment 1) Alanine 3.66g/L(Compartment 1)...   \n",
            "6  (Compartment 1) Alanine 6.41g/L(Compartment 1)...   \n",
            "7  (Compartment 1) Alanine 8.24g/L(Compartment 1)...   \n",
            "8                                Nicotine Polacrilex   \n",
            "\n",
            "                                                   2  \\\n",
            "0                         NDA-1: New chemical entity   \n",
            "1  NDA-1: New chemical entity(Transition from PSA...   \n",
            "2                       NDA-1: New biological entity   \n",
            "3                       NDA-1: New biological entity   \n",
            "4                       NDA-1: New biological entity   \n",
            "5                             NDA-2: New combination   \n",
            "6                              NDA-3: Line extension   \n",
            "7                              NDA-3: Line extension   \n",
            "8                       NDA-2: New salt /dosage form   \n",
            "\n",
            "                                          3           4          5  \n",
            "0               EISAI (SINGAPORE) PTE. LTD.  02/10/2023  SIN16878P  \n",
            "1                    PFIZER PRIVATE LIMITED  02/10/2023  SIN16877P  \n",
            "2       MODERNA BIOTECH SINGAPORE PTE. LTD.  11/10/2023  SIN16881P  \n",
            "3  BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.  12/10/2023  SIN16883P  \n",
            "4               PHARMENG TECHNOLOGY PTE LTD  17/10/2023  SIN16886P  \n",
            "5          BAXTER HEALTHCARE (ASIA) PTE LTD  20/10/2023  SIN16888P  \n",
            "6          BAXTER HEALTHCARE (ASIA) PTE LTD  20/10/2023  SIN16889P  \n",
            "7          BAXTER HEALTHCARE (ASIA) PTE LTD  20/10/2023  SIN16890P  \n",
            "8          RUBICON RESEARCH PRIVATE LIMITED  30/10/2023  SIN16895P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---october-2023\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P', 'TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P', 'TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL', 'Trastuzumab (420 mg/vial)']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P', 'TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL', 'Trastuzumab (420 mg/vial)', 'NDA-3: New pack size']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P', 'TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL', 'Trastuzumab (420 mg/vial)', 'NDA-3: New pack size', 'INNOGENE KALBIOTECH PTE. LTD.']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P', 'TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL', 'Trastuzumab (420 mg/vial)', 'NDA-3: New pack size', 'INNOGENE KALBIOTECH PTE. LTD.', '22/11/2023']\n",
            "['ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 0.1 MG/ML', 'Adrenaline tartrate equivalent to adrenaline (0.1 mg/ml)', 'NDA-2: New formulation / strength', 'AGUETTANT ASIA PACIFIC PTE. LTD.', '07/11/2023', 'SIN16897P', 'AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUSION 235 MG/0.25 MG/VIAL', 'Fosnetupitant Chloride Hydrochloride equivalent to Fosnetupitant (235mg/vial), Palonosetron hydrochloride equivalent to Palonosetron (0.25 mg/vial)', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '28/11/2023', 'SIN16899P', 'LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEUTICAL PREPARATION OF GALLIUM (68GA) GOZETOTIDE SOLUTION', 'Gozetotide (25μg/vial)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '30/11/2023', 'SIN16904P', 'TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/VIAL', 'Trastuzumab (420 mg/vial)', 'NDA-3: New pack size', 'INNOGENE KALBIOTECH PTE. LTD.', '22/11/2023', 'SIN16898P']\n",
            "                                                   0  \\\n",
            "0  ADRENALINE AGUETTANT SOLUTION FOR INJECTION IN...   \n",
            "1  AKYNZEO® IV CONCENTRATE FOR SOLUTION FOR INFUS...   \n",
            "2  LOCAMETZ 25 MICROGRAMS, KIT FOR RADIOPHARMACEU...   \n",
            "3  TRAZHER (TRASTUZUMAB) POWDER FOR CONCENTRATE F...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Adrenaline tartrate equivalent to adrenaline (...   \n",
            "1  Fosnetupitant Chloride Hydrochloride equivalen...   \n",
            "2                             Gozetotide (25μg/vial)   \n",
            "3                          Trastuzumab (420 mg/vial)   \n",
            "\n",
            "                                   2                                 3  \\\n",
            "0  NDA-2: New formulation / strength  AGUETTANT ASIA PACIFIC PTE. LTD.   \n",
            "1         NDA-1: New chemical entity         JUNIPER BIOLOGICS PTE LTD   \n",
            "2         NDA-1: New chemical entity      NOVARTIS (SINGAPORE) PTE LTD   \n",
            "3               NDA-3: New pack size     INNOGENE KALBIOTECH PTE. LTD.   \n",
            "\n",
            "            4          5  \n",
            "0  07/11/2023  SIN16897P  \n",
            "1  28/11/2023  SIN16899P  \n",
            "2  30/11/2023  SIN16904P  \n",
            "3  22/11/2023  SIN16898P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---november-2023\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P', 'TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P', 'TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG', 'FLUTICASONE FUROATE (MICRONISED)(200 MCG),UMECLIDINIUM BROMIDE (MICRONISED) EQV TO UMECLIDINIUM(62.5 MCG),VILANTEROL TRIFENATATE (MICRONISED) EQV TO VILANTEROL(25 MCG)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P', 'TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG', 'FLUTICASONE FUROATE (MICRONISED)(200 MCG),UMECLIDINIUM BROMIDE (MICRONISED) EQV TO UMECLIDINIUM(62.5 MCG),VILANTEROL TRIFENATATE (MICRONISED) EQV TO VILANTEROL(25 MCG)', 'NDA-2: New presentation']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P', 'TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG', 'FLUTICASONE FUROATE (MICRONISED)(200 MCG),UMECLIDINIUM BROMIDE (MICRONISED) EQV TO UMECLIDINIUM(62.5 MCG),VILANTEROL TRIFENATATE (MICRONISED) EQV TO VILANTEROL(25 MCG)', 'NDA-2: New presentation', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P', 'TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG', 'FLUTICASONE FUROATE (MICRONISED)(200 MCG),UMECLIDINIUM BROMIDE (MICRONISED) EQV TO UMECLIDINIUM(62.5 MCG),VILANTEROL TRIFENATATE (MICRONISED) EQV TO VILANTEROL(25 MCG)', 'NDA-2: New presentation', 'GLAXOSMITHKLINE PTE LTD', '15/12/2023']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (MDV)', 'Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)', 'NDA-2: New combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '18/12/2023', 'SIN16915P', 'LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD CAPSULE 10MG/10MG', 'EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (20.00mg),EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROSUVASTATIN (10.00mg)', 'NDA-2: New combination', 'SERVIER (S) PTE LTD', '21/12/2023', 'SIN16919P, SIN16920P', 'NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 24 MG/1.2ML,NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 60 MG/1.2ML', 'Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)', 'NDA-1: New biological entityNDA-3: Subsequent strength', 'PFIZER PRIVATE LIMITED', '14/12/2023', 'SIN16911P, SIN16912P', 'PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBQ/ML', 'Lutetium (177 Lu) vipivotide tetraxetan (1000 MBq/mL)', 'NDA-1: New chemical entity', 'NOVARTIS (SINGAPORE) PTE LTD', '18/12/2023', 'SIN16917P', 'TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G PER VIAL,TRECONDI POWDER FOR SOLUTION FOR INFUSION 1 G PER VIAL', 'Treosulfan (5 g / vial),Treosulfan (1 g / vial)', 'NDA-1: New chemical entityNDA-3: Subsequent strength', 'LINK HEALTHCARE SINGAPORE PTE LTD', '26/12/2023', 'SIN16922P, SIN16923P', 'TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5 MCG/25 MCG', 'FLUTICASONE FUROATE (MICRONISED)(200 MCG),UMECLIDINIUM BROMIDE (MICRONISED) EQV TO UMECLIDINIUM(62.5 MCG),VILANTEROL TRIFENATATE (MICRONISED) EQV TO VILANTEROL(25 MCG)', 'NDA-2: New presentation', 'GLAXOSMITHKLINE PTE LTD', '15/12/2023', 'SIN16914P']\n",
            "                                                   0  \\\n",
            "0  COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE ...   \n",
            "1  LIPOCOMB HARD CAPSULE 20MG/10MG,LIPOCOMB HARD ...   \n",
            "2  NGENLA SOLUTION FOR INJECTION IN A PRE-FILLED ...   \n",
            "3  PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 ...   \n",
            "4  TRECONDI POWDER FOR SOLUTION FOR INFUSION 5 G ...   \n",
            "5  TRELEGY ELLIPTA INHALATION POWDER 200 MCG/62.5...   \n",
            "\n",
            "                                                   1  \\\n",
            "0   Famtozinameran(5 μg/dose),Tozinameran(5 μg/dose)   \n",
            "1  EZETIMIBE (10.00mg), ROSUVASTATIN ZINC EQV ROS...   \n",
            "2      Somatrogon(24mg/1.2ml),Somatrogon(60mg/1.2ml)   \n",
            "3  Lutetium (177 Lu) vipivotide tetraxetan (1000 ...   \n",
            "4    Treosulfan (5 g / vial),Treosulfan (1 g / vial)   \n",
            "5  FLUTICASONE FUROATE (MICRONISED)(200 MCG),UMEC...   \n",
            "\n",
            "                                                   2  \\\n",
            "0                             NDA-2: New combination   \n",
            "1                             NDA-2: New combination   \n",
            "2  NDA-1: New biological entityNDA-3: Subsequent ...   \n",
            "3                         NDA-1: New chemical entity   \n",
            "4  NDA-1: New chemical entityNDA-3: Subsequent st...   \n",
            "5                            NDA-2: New presentation   \n",
            "\n",
            "                                                 3           4  \\\n",
            "0  BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.  18/12/2023   \n",
            "1                              SERVIER (S) PTE LTD  21/12/2023   \n",
            "2                           PFIZER PRIVATE LIMITED  14/12/2023   \n",
            "3                     NOVARTIS (SINGAPORE) PTE LTD  18/12/2023   \n",
            "4                LINK HEALTHCARE SINGAPORE PTE LTD  26/12/2023   \n",
            "5                          GLAXOSMITHKLINE PTE LTD  15/12/2023   \n",
            "\n",
            "                      5  \n",
            "0             SIN16915P  \n",
            "1  SIN16919P, SIN16920P  \n",
            "2  SIN16911P, SIN16912P  \n",
            "3             SIN16917P  \n",
            "4  SIN16922P, SIN16923P  \n",
            "5             SIN16914P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---december-2023\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P', 'LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P', 'LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%', 'Bimatoprost(0.3 mg/mL)']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P', 'LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%', 'Bimatoprost(0.3 mg/mL)', 'NDA-2']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P', 'LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%', 'Bimatoprost(0.3 mg/mL)', 'NDA-2', 'ABBVIE PTE. LTD.']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P', 'LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%', 'Bimatoprost(0.3 mg/mL)', 'NDA-2', 'ABBVIE PTE. LTD.', '30/01/2024']\n",
            "['GENCEBOK SOLUTION FOR INFUSION 10MG/ML', 'Caffeine Citrate(10.00mg/ml)', 'NDA-2', 'AXXESSBIO PTE. LTD.', '16/01/2024', 'SIN16929P', 'LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%', 'Bimatoprost(0.3 mg/mL)', 'NDA-2', 'ABBVIE PTE. LTD.', '30/01/2024', 'SIN16938P']\n",
            "                                                   0  \\\n",
            "0             GENCEBOK SOLUTION FOR INFUSION 10MG/ML   \n",
            "1  LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0...   \n",
            "\n",
            "                              1      2                    3           4  \\\n",
            "0  Caffeine Citrate(10.00mg/ml)  NDA-2  AXXESSBIO PTE. LTD.  16/01/2024   \n",
            "1        Bimatoprost(0.3 mg/mL)  NDA-2     ABBVIE PTE. LTD.  30/01/2024   \n",
            "\n",
            "           5  \n",
            "0  SIN16929P  \n",
            "1  SIN16938P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---january-2024\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P', 'VAXNEUVANCE® SUSPENSION FOR INJECTION']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P', 'VAXNEUVANCE® SUSPENSION FOR INJECTION', '(MBC) Pneumococcal Polysaccharide Serotype 1 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 14 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 18C conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 23F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 4 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 5 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6B conjugated to CRM197(4μg),(MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 9V conjugated to CRM197(2μg)']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P', 'VAXNEUVANCE® SUSPENSION FOR INJECTION', '(MBC) Pneumococcal Polysaccharide Serotype 1 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 14 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 18C conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 23F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 4 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 5 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6B conjugated to CRM197(4μg),(MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 9V conjugated to CRM197(2μg)', 'NDA-1: New biological entity']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P', 'VAXNEUVANCE® SUSPENSION FOR INJECTION', '(MBC) Pneumococcal Polysaccharide Serotype 1 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 14 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 18C conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 23F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 4 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 5 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6B conjugated to CRM197(4μg),(MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 9V conjugated to CRM197(2μg)', 'NDA-1: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P', 'VAXNEUVANCE® SUSPENSION FOR INJECTION', '(MBC) Pneumococcal Polysaccharide Serotype 1 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 14 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 18C conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 23F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 4 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 5 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6B conjugated to CRM197(4μg),(MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 9V conjugated to CRM197(2μg)', 'NDA-1: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '07/02/2024']\n",
            "['EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V', 'Omidenepag isopropyl(0.02 mg/mL)', 'NDA-2: New formulation', 'SANTEN PHARMACEUTICAL ASIA PTE. LTD.', '19/02/2024', 'SIN16951P', 'SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/100 MG', 'Dapagliflozin propanediol monohydrate eqv Dapagliflozin(10mg), Sitagliptin phosphate monohydrate eqv Sitagliptin(100mg)', 'NDA-2: New dosage form', 'ASTRAZENECA SINGAPORE PTE LTD', '20/02/2024', 'SIN16958P', 'SOTYKTU FILM-COATED TABLETS 6 MG', 'Deucravacitinib(6.00 mg)', 'NDA-1: New chemical entity', 'BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.', '04/02/2024', 'SIN16939P', 'TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAYLI SOLUTION FOR INJECTION 90MG/ML', 'Teclistamab(10mg/mL),Teclistamab(90mg/mL)', 'NDA-1: New biological entityNDA-3: New strength', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '16/02/2024', 'SIN16948P,SIN16949P', 'VAXNEUVANCE® SUSPENSION FOR INJECTION', '(MBC) Pneumococcal Polysaccharide Serotype 1 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 14 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 18C conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 19F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 23F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 4 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 5 conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 6B conjugated to CRM197(4μg),(MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197(2μg),(MBC) Pneumococcal Polysaccharide Serotype 9V conjugated to CRM197(2μg)', 'NDA-1: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '07/02/2024', 'SIN16944P']\n",
            "                                                   0  \\\n",
            "0            EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V   \n",
            "1  SIDAPVIA FIXED DOSE COMBINATION TABLET 10 MG/1...   \n",
            "2                   SOTYKTU FILM-COATED TABLETS 6 MG   \n",
            "3  TECVAYLI SOLUTION FOR INJECTION 10MG/ML,TECVAY...   \n",
            "4              VAXNEUVANCE® SUSPENSION FOR INJECTION   \n",
            "\n",
            "                                                   1  \\\n",
            "0                   Omidenepag isopropyl(0.02 mg/mL)   \n",
            "1  Dapagliflozin propanediol monohydrate eqv Dapa...   \n",
            "2                           Deucravacitinib(6.00 mg)   \n",
            "3          Teclistamab(10mg/mL),Teclistamab(90mg/mL)   \n",
            "4  (MBC) Pneumococcal Polysaccharide Serotype 1 c...   \n",
            "\n",
            "                                                 2  \\\n",
            "0                           NDA-2: New formulation   \n",
            "1                           NDA-2: New dosage form   \n",
            "2                       NDA-1: New chemical entity   \n",
            "3  NDA-1: New biological entityNDA-3: New strength   \n",
            "4                     NDA-1: New biological entity   \n",
            "\n",
            "                                                   3           4  \\\n",
            "0               SANTEN PHARMACEUTICAL ASIA PTE. LTD.  19/02/2024   \n",
            "1                      ASTRAZENECA SINGAPORE PTE LTD  20/02/2024   \n",
            "2         BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.  04/02/2024   \n",
            "3  JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PT...  16/02/2024   \n",
            "4                   MSD PHARMA (SINGAPORE) PTE. LTD.  07/02/2024   \n",
            "\n",
            "                     5  \n",
            "0            SIN16951P  \n",
            "1            SIN16958P  \n",
            "2            SIN16939P  \n",
            "3  SIN16948P,SIN16949P  \n",
            "4            SIN16944P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---february-2024\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P', 'SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P', 'SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)', 'Nicotine Polacrilex eqv to Nicotine(4.00 mg)']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P', 'SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)', 'Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-3: New strength']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P', 'SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)', 'Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-3: New strength', 'RUBICON RESEARCH PRIVATE LIMITED']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P', 'SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)', 'Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-3: New strength', 'RUBICON RESEARCH PRIVATE LIMITED', '13/03/2024']\n",
            "['COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML', 'Glofitamab(1 mg/ml)', 'NDA-1: New biological entity', 'ROCHE SINGAPORE PTE. LTD.', '05/03/2024', 'SIN16968P', 'JYSELECA FILM-COATED TABLET 100MG,JYSELECA FILM-COATED TABLET 200MG', 'Filgotinib maleate eqv filgotinib(100 mg),Filgotinib maleate eqv filgotinib(200 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'EISAI (SINGAPORE) PTE. LTD.', '27/03/2024', 'SIN16980P,SIN16981P', 'NEFEGAN MODIFIED RELEASE CAPSULE 4MG', 'Budesonide(4.00 mg)', 'NDA-2: New formulation', 'EVEREST MEDICINES (SINGAPORE) PTE. LTD.', '19/03/2024', 'SIN16972P', 'SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)', 'Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-3: New strength', 'RUBICON RESEARCH PRIVATE LIMITED', '13/03/2024', 'SIN16971P']\n",
            "                                                   0  \\\n",
            "0  COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION ...   \n",
            "1  JYSELECA FILM-COATED TABLET 100MG,JYSELECA FIL...   \n",
            "2               NEFEGAN MODIFIED RELEASE CAPSULE 4MG   \n",
            "3            SKIIP NICOTINE MINI LOZENGE 4 MG (MINT)   \n",
            "\n",
            "                                                   1  \\\n",
            "0                                Glofitamab(1 mg/ml)   \n",
            "1  Filgotinib maleate eqv filgotinib(100 mg),Filg...   \n",
            "2                                Budesonide(4.00 mg)   \n",
            "3       Nicotine Polacrilex eqv to Nicotine(4.00 mg)   \n",
            "\n",
            "                                               2  \\\n",
            "0                   NDA-1: New biological entity   \n",
            "1  NDA-1: New chemical entityNDA-3: New strength   \n",
            "2                         NDA-2: New formulation   \n",
            "3                            NDA-3: New strength   \n",
            "\n",
            "                                         3           4                    5  \n",
            "0                ROCHE SINGAPORE PTE. LTD.  05/03/2024            SIN16968P  \n",
            "1              EISAI (SINGAPORE) PTE. LTD.  27/03/2024  SIN16980P,SIN16981P  \n",
            "2  EVEREST MEDICINES (SINGAPORE) PTE. LTD.  19/03/2024            SIN16972P  \n",
            "3         RUBICON RESEARCH PRIVATE LIMITED  13/03/2024            SIN16971P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---march-2024\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P', 'TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CAPSULES 80MG']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P', 'TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CAPSULES 80MG', 'Selpercatinib(40.0mg),Selpercatinib(80.0mg)']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P', 'TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CAPSULES 80MG', 'Selpercatinib(40.0mg),Selpercatinib(80.0mg)', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P', 'TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CAPSULES 80MG', 'Selpercatinib(40.0mg),Selpercatinib(80.0mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P', 'TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CAPSULES 80MG', 'Selpercatinib(40.0mg),Selpercatinib(80.0mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '24/04/2024']\n",
            "['IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 ML PRE-FILLED SYRINGE', 'Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Purified Tetanus Toxoid(≥ 20   IU/ 0.5mL)', 'NDA-2: New strength/combination', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '30/04/2024', 'SIN16995P', 'LEDAGA TOPICAL GEL 160 ΜG /G', 'Chlormethine hydrochloride equivalent to Chlormethine(160 μg /g )', 'NDA-1: New chemical entity', 'JUNIPER BIOLOGICS PTE LTD', '15/04/2024', 'SIN16986P', 'NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL', 'AVALGLUCOSIDASE ALFA(100mg/vial)', 'NDA-1: New chemical entity', 'SANOFI-AVENTIS SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16989P', 'TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CAPSULES 80MG', 'Selpercatinib(40.0mg),Selpercatinib(80.0mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'DKSH SINGAPORE PTE. LTD.', '24/04/2024', 'SIN16990P,SIN16991P']\n",
            "                                                   0  \\\n",
            "0  IMOVAX D.T., SUSPENSION FOR INJECTION IN 0.5 M...   \n",
            "1                       LEDAGA TOPICAL GEL 160 ΜG /G   \n",
            "2  NEXVIAZYME POWDER FOR CONCENTRATE FOR SOLUTION...   \n",
            "3  TANSTRIVE HARD CAPSULES 40MG,TANSTRIVE HARD CA...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Purified Diphtheria Toxoid(≥ 2 IU/ 0.5 mL),Pur...   \n",
            "1  Chlormethine hydrochloride equivalent to Chlor...   \n",
            "2                   AVALGLUCOSIDASE ALFA(100mg/vial)   \n",
            "3        Selpercatinib(40.0mg),Selpercatinib(80.0mg)   \n",
            "\n",
            "                                               2  \\\n",
            "0                NDA-2: New strength/combination   \n",
            "1                     NDA-1: New chemical entity   \n",
            "2                     NDA-1: New chemical entity   \n",
            "3  NDA-1: New chemical entityNDA-3: New strength   \n",
            "\n",
            "                                    3           4                    5  \n",
            "0  SANOFI-AVENTIS SINGAPORE PTE. LTD.  30/04/2024            SIN16995P  \n",
            "1           JUNIPER BIOLOGICS PTE LTD  15/04/2024            SIN16986P  \n",
            "2  SANOFI-AVENTIS SINGAPORE PTE. LTD.  24/04/2024            SIN16989P  \n",
            "3            DKSH SINGAPORE PTE. LTD.  24/04/2024  SIN16990P,SIN16991P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---april-2024\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P', 'VELSIPITY FILM-COATED TABLET 2 MG']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P', 'VELSIPITY FILM-COATED TABLET 2 MG', 'Etrasimod L-arginine eqv Etrasimod(2 mg)']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P', 'VELSIPITY FILM-COATED TABLET 2 MG', 'Etrasimod L-arginine eqv Etrasimod(2 mg)', 'NDA-1: New chemical entity']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P', 'VELSIPITY FILM-COATED TABLET 2 MG', 'Etrasimod L-arginine eqv Etrasimod(2 mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P', 'VELSIPITY FILM-COATED TABLET 2 MG', 'Etrasimod L-arginine eqv Etrasimod(2 mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '30/05/2024']\n",
            "['AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 120MCG/0.5ML', 'RSVPreF3 antigen(120mcg/0.5mL)', 'NDA-1: New biological entity', 'GLAXOSMITHKLINE PTE LTD', '10/05/2024', 'SIN17008P', 'BESREMI SOLUTION FOR INJECTION IN PREFILLED SYRINGE 500 MICROGRAMS/ML', 'Ropeginterferon alfa-2b(500 µg/mL)', 'NDA-1: New biological entity', 'PHARMAESSENTIA SINGAPORE PTE. LTD', '29/05/2024', 'SIN17014P', 'COMIRNATY, DISPERSION FOR INJECTION, 10 MICROGRAMS/DOSE (SINGLE-DOSE VIAL),COMIRNATY, DISPERSION FOR INJECTION, 30 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Raxtozinameran(10 μg/dose),Raxtozinameran(30 mcg/dose)', 'NDA-2: New presentation', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '31/05/2024', 'SIN17017P,SIN17016P', 'INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU (60MG)/0.6ML,INHIXA SOLUTION FOR INJECTION 4000 ANTI-XA IU (40MG)/0.4ML,INHIXA SOLUTION FOR INJECTION 2000 ANTI-XA IU (20MG)/0.2ML', 'Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enoxaparin Sodium(4000 IU (40 MG)/0.4 ML),Enoxaparin Sodium(2000 IU (20 MG)/0.2 ML)', 'NDA-3: New strength', 'PHARMAZEN MEDICALS PTE LTD', '07/05/2024', 'SIN16997P,SIN16998P,SIN16999P', 'LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML,LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 30MG/30ML', 'Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)', 'NDA-1: New biological entityNDA-3: new strengths', 'ROCHE SINGAPORE PTE. LTD.', '08/05/2024', 'SIN17001P,SIN17002P', 'VELSIPITY FILM-COATED TABLET 2 MG', 'Etrasimod L-arginine eqv Etrasimod(2 mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '30/05/2024', 'SIN17015P']\n",
            "                                                   0  \\\n",
            "0  AREXVY POWDER AND SUSPENSION FOR SUSPENSION FO...   \n",
            "1  BESREMI SOLUTION FOR INJECTION IN PREFILLED SY...   \n",
            "2  COMIRNATY, DISPERSION FOR INJECTION, 10 MICROG...   \n",
            "3  INHIXA SOLUTION FOR INJECTION 6000 ANTI-XA IU ...   \n",
            "4  LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "5                  VELSIPITY FILM-COATED TABLET 2 MG   \n",
            "\n",
            "                                                   1  \\\n",
            "0                     RSVPreF3 antigen(120mcg/0.5mL)   \n",
            "1                 Ropeginterferon alfa-2b(500 µg/mL)   \n",
            "2  Raxtozinameran(10 μg/dose),Raxtozinameran(30 m...   \n",
            "3  Enoxaparin Sodium(6000 IU (60 MG)/0.6 ML),Enox...   \n",
            "4  Mosunetuzumab(1 mg/ml),Mosunetuzumab(30 mg/30 ml)   \n",
            "5           Etrasimod L-arginine eqv Etrasimod(2 mg)   \n",
            "\n",
            "                                                  2  \\\n",
            "0                      NDA-1: New biological entity   \n",
            "1                      NDA-1: New biological entity   \n",
            "2                           NDA-2: New presentation   \n",
            "3                               NDA-3: New strength   \n",
            "4  NDA-1: New biological entityNDA-3: new strengths   \n",
            "5                        NDA-1: New chemical entity   \n",
            "\n",
            "                                                 3           4  \\\n",
            "0                          GLAXOSMITHKLINE PTE LTD  10/05/2024   \n",
            "1                PHARMAESSENTIA SINGAPORE PTE. LTD  29/05/2024   \n",
            "2  BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.  31/05/2024   \n",
            "3                       PHARMAZEN MEDICALS PTE LTD  07/05/2024   \n",
            "4                        ROCHE SINGAPORE PTE. LTD.  08/05/2024   \n",
            "5                           PFIZER PRIVATE LIMITED  30/05/2024   \n",
            "\n",
            "                               5  \n",
            "0                      SIN17008P  \n",
            "1                      SIN17014P  \n",
            "2            SIN17017P,SIN17016P  \n",
            "3  SIN16997P,SIN16998P,SIN16999P  \n",
            "4            SIN17001P,SIN17002P  \n",
            "5                      SIN17015P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---may-2024\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML', 'Omalizumab(300.00 mg/2.0 mL)']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML', 'Omalizumab(300.00 mg/2.0 mL)', 'NDA-3: New strength']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML', 'Omalizumab(300.00 mg/2.0 mL)', 'NDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML', 'Omalizumab(300.00 mg/2.0 mL)', 'NDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024']\n",
            "['MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG', 'Trametinib dimethylsulfoxide 5.30 mg eqv trametinib(4.7 mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17018P', 'TAFINLAR DISPERSIBLE TABLET 10MG', 'Dabrafenib mesylate eqv Dabrafenib(10mg)', 'NDA-2: New presentation', 'NOVARTIS (SINGAPORE) PTE LTD', '03/06/2024', 'SIN17019P', 'TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML', 'Atezolizumab(1875 mg/15ml)', 'NDA-2: New formulation', 'ROCHE SINGAPORE PTE. LTD.', '27/06/2024', 'SIN17033P', 'ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML', 'Ravulizumab(100 mg/mL)', 'NDA-1: New biologcal entity', 'ASTRAZENECA SINGAPORE PTE LTD', '19/06/2024', 'SIN17026P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/1.0ML,XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 300MG/2.0ML', 'Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 mg/1.0 mL),Omalizumab(300.00 mg / 2.0 mL)', 'NDA-2: New presentationNDA-3: New strengths', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17030P,SIN17031P,SIN17032P', 'XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 300MG/2.0ML', 'Omalizumab(300.00 mg/2.0 mL)', 'NDA-3: New strength', 'NOVARTIS (SINGAPORE) PTE LTD', '21/06/2024', 'SIN17029P']\n",
            "                                                   0  \\\n",
            "0          MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG   \n",
            "1                   TAFINLAR DISPERSIBLE TABLET 10MG   \n",
            "2       TECENTRIQ SOLUTION FOR INJECTION 1875MG/15ML   \n",
            "3  ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSIO...   \n",
            "4  XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PE...   \n",
            "5  XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SY...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Trametinib dimethylsulfoxide 5.30 mg eqv trame...   \n",
            "1           Dabrafenib mesylate eqv Dabrafenib(10mg)   \n",
            "2                         Atezolizumab(1875 mg/15ml)   \n",
            "3                             Ravulizumab(100 mg/mL)   \n",
            "4  Omalizumab(75.00 mg/0.5 mL),Omalizumab(150.00 ...   \n",
            "5                       Omalizumab(300.00 mg/2.0 mL)   \n",
            "\n",
            "                                             2                              3  \\\n",
            "0                      NDA-2: New presentation   NOVARTIS (SINGAPORE) PTE LTD   \n",
            "1                      NDA-2: New presentation   NOVARTIS (SINGAPORE) PTE LTD   \n",
            "2                       NDA-2: New formulation      ROCHE SINGAPORE PTE. LTD.   \n",
            "3                  NDA-1: New biologcal entity  ASTRAZENECA SINGAPORE PTE LTD   \n",
            "4  NDA-2: New presentationNDA-3: New strengths   NOVARTIS (SINGAPORE) PTE LTD   \n",
            "5                          NDA-3: New strength   NOVARTIS (SINGAPORE) PTE LTD   \n",
            "\n",
            "            4                              5  \n",
            "0  03/06/2024                      SIN17018P  \n",
            "1  03/06/2024                      SIN17019P  \n",
            "2  27/06/2024                      SIN17033P  \n",
            "3  19/06/2024                      SIN17026P  \n",
            "4  21/06/2024  SIN17030P,SIN17031P,SIN17032P  \n",
            "5  21/06/2024                      SIN17029P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---june-2024\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P', 'PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG,PEMAZYRE TABLETS 4.5 MG']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P', 'PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG,PEMAZYRE TABLETS 4.5 MG', 'Pemigatinib(13.50 mg),Pemigatinib(9.00 mg),Pemigatinib(4.50 mg)']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P', 'PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG,PEMAZYRE TABLETS 4.5 MG', 'Pemigatinib(13.50 mg),Pemigatinib(9.00 mg),Pemigatinib(4.50 mg)', 'NDA-1: New chemical entityNDA-3: New strength']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P', 'PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG,PEMAZYRE TABLETS 4.5 MG', 'Pemigatinib(13.50 mg),Pemigatinib(9.00 mg),Pemigatinib(4.50 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'SPECIALISED THERAPEUTICS ASIA PTE LTD']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P', 'PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG,PEMAZYRE TABLETS 4.5 MG', 'Pemigatinib(13.50 mg),Pemigatinib(9.00 mg),Pemigatinib(4.50 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'SPECIALISED THERAPEUTICS ASIA PTE LTD', '09/07/2024']\n",
            "['ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR INJECTION', '(Powder) RSV subgroup A stabilized prefusion F protein(0.06 mg/vial),(Powder) RSV subgroup B stabilized prefusion F protein(0.06 mg/vial)', 'NDA-1: New biological entity', 'PFIZER PRIVATE LIMITED', '23/07/2024', 'SIN17049P', 'COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE FOR DISPERSION FOR INJECTION 1.5/1.5 MICROGRAMS/DOSE', 'Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg/dose)', 'NDA-2: New dosage form, strength, combination', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '25/07/2024', 'SIN17053P', 'EYLEA SOLUTION FOR INJECTION 114.3 MG/ML', 'Aflibercept(114.3mg/ml)', 'NDA-2: New strength, dosing regimen', 'BAYER (SOUTH EAST ASIA) PTE LTD', '05/07/2024', 'SIN17040P', 'LITFULO CAPSULE 50MG', 'Ritlecitinib Tosylate equivalent to Ritlecitinib(50mg)', 'NDA-1: New chemical entity', 'PFIZER PRIVATE LIMITED', '05/07/2024', 'SIN17041P', 'MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL CARTRIDGE PACK,MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL PEN + CARTRIDGE PACK', 'Teriparatide(20 mcg/80 mcl)', 'NDA-2: biosimilar', 'GOLDPLUS UNIVERSAL PTE LTD', '24/07/2024', 'SIN17051P,SIN17052P', 'PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG,PEMAZYRE TABLETS 4.5 MG', 'Pemigatinib(13.50 mg),Pemigatinib(9.00 mg),Pemigatinib(4.50 mg)', 'NDA-1: New chemical entityNDA-3: New strength', 'SPECIALISED THERAPEUTICS ASIA PTE LTD', '09/07/2024', 'SIN17044P,SIN17043P,SIN17042P']\n",
            "                                                   0  \\\n",
            "0  ABRYSVO POWDER AND SOLVENT FOR SOLUTION FOR IN...   \n",
            "1  COMIRNATY ORIGINAL/OMICRON BA.4-5 CONCENTRATE ...   \n",
            "2           EYLEA SOLUTION FOR INJECTION 114.3 MG/ML   \n",
            "3                               LITFULO CAPSULE 50MG   \n",
            "4  MEGAPTH-G SOLUTION FOR INJECTION 20 MCG/80MCL ...   \n",
            "5  PEMAZYRE TABLETS 13.5 MG,PEMAZYRE TABLETS 9 MG...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  (Powder) RSV subgroup A stabilized prefusion F...   \n",
            "1  Famtozinameran(1.5 μg/dose),Tozinameran(1.5 μg...   \n",
            "2                            Aflibercept(114.3mg/ml)   \n",
            "3  Ritlecitinib Tosylate equivalent to Ritlecitin...   \n",
            "4                        Teriparatide(20 mcg/80 mcl)   \n",
            "5  Pemigatinib(13.50 mg),Pemigatinib(9.00 mg),Pem...   \n",
            "\n",
            "                                               2  \\\n",
            "0                   NDA-1: New biological entity   \n",
            "1  NDA-2: New dosage form, strength, combination   \n",
            "2            NDA-2: New strength, dosing regimen   \n",
            "3                     NDA-1: New chemical entity   \n",
            "4                              NDA-2: biosimilar   \n",
            "5  NDA-1: New chemical entityNDA-3: New strength   \n",
            "\n",
            "                                                 3           4  \\\n",
            "0                           PFIZER PRIVATE LIMITED  23/07/2024   \n",
            "1  BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.  25/07/2024   \n",
            "2                  BAYER (SOUTH EAST ASIA) PTE LTD  05/07/2024   \n",
            "3                           PFIZER PRIVATE LIMITED  05/07/2024   \n",
            "4                       GOLDPLUS UNIVERSAL PTE LTD  24/07/2024   \n",
            "5            SPECIALISED THERAPEUTICS ASIA PTE LTD  09/07/2024   \n",
            "\n",
            "                               5  \n",
            "0                      SIN17049P  \n",
            "1                      SIN17053P  \n",
            "2                      SIN17040P  \n",
            "3                      SIN17041P  \n",
            "4            SIN17051P,SIN17052P  \n",
            "5  SIN17044P,SIN17043P,SIN17042P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---july-2024\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P', 'WINLEVI CREAM 1% W/W']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P', 'WINLEVI CREAM 1% W/W', 'Clascoterone (1% w/w)']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P', 'WINLEVI CREAM 1% W/W', 'Clascoterone (1% w/w)', 'NDA-1: New chemical entity']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P', 'WINLEVI CREAM 1% W/W', 'Clascoterone (1% w/w)', 'NDA-1: New chemical entity', 'HYPHENS PHARMA PTE. LTD.']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P', 'WINLEVI CREAM 1% W/W', 'Clascoterone (1% w/w)', 'NDA-1: New chemical entity', 'HYPHENS PHARMA PTE. LTD.', '28/08/2024']\n",
            "['COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 5/5 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)', 'Famtozinameran (5 μg/dose), Tozinameran (5 μg/dose)', 'NDA-2: New presentation, strength', 'BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.', '01/08/2024', 'SIN17058P', 'ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML', 'TAGRAXOFUSP (1.0 MG/mL)', 'NDA-1: New biological entity', 'A. MENARINI SINGAPORE PTE. LTD.', '05/08/2024', 'SIN17059P', 'JYNNEOS SUSPENSION FOR INJECTION', 'Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN, live,   non-replicating) (0.5 x 10^8 to 3.95 x 10^8 Inf. U /dose)', 'NDA-1: New biological entity', 'AENON PHARMACEUTICALS SEA PTE. LTD.', '23/08/2024', 'SIN17067P', 'SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 4 MG (CHERRY),SKIIP NICOTINE MINI LOZENGE 2 MG (CINNAMON),SKIIP NICOTINE MINI LOZENGE 4 MG (CINNAMON)', 'Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg),Nicotine Polacrilex eqv to Nicotine(2.00 mg),Nicotine Polacrilex eqv to Nicotine(4.00 mg)', 'NDA-2/3: New flavours', 'RUBICON RESEARCH PRIVATE LIMITED', '14/08/2024', 'SIN17060P,SIN17061P,SIN17062P,SIN17063P', 'WINLEVI CREAM 1% W/W', 'Clascoterone (1% w/w)', 'NDA-1: New chemical entity', 'HYPHENS PHARMA PTE. LTD.', '28/08/2024', 'SIN17072P']\n",
            "                                                   0  \\\n",
            "0  COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION F...   \n",
            "1  ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "2                   JYNNEOS SUSPENSION FOR INJECTION   \n",
            "3  SKIIP NICOTINE MINI LOZENGE 2 MG (CHERRY),SKII...   \n",
            "4                               WINLEVI CREAM 1% W/W   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Famtozinameran (5 μg/dose), Tozinameran (5 μg/...   \n",
            "1                            TAGRAXOFUSP (1.0 MG/mL)   \n",
            "2  Modified Vaccinia Ankara - Bavarian Nordic (MV...   \n",
            "3  Nicotine Polacrilex eqv to Nicotine(2.00 mg),N...   \n",
            "4                              Clascoterone (1% w/w)   \n",
            "\n",
            "                                   2  \\\n",
            "0  NDA-2: New presentation, strength   \n",
            "1       NDA-1: New biological entity   \n",
            "2       NDA-1: New biological entity   \n",
            "3              NDA-2/3: New flavours   \n",
            "4         NDA-1: New chemical entity   \n",
            "\n",
            "                                                 3           4  \\\n",
            "0  BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.  01/08/2024   \n",
            "1                  A. MENARINI SINGAPORE PTE. LTD.  05/08/2024   \n",
            "2              AENON PHARMACEUTICALS SEA PTE. LTD.  23/08/2024   \n",
            "3                 RUBICON RESEARCH PRIVATE LIMITED  14/08/2024   \n",
            "4                         HYPHENS PHARMA PTE. LTD.  28/08/2024   \n",
            "\n",
            "                                         5  \n",
            "0                                SIN17058P  \n",
            "1                                SIN17059P  \n",
            "2                                SIN17067P  \n",
            "3  SIN17060P,SIN17061P,SIN17062P,SIN17063P  \n",
            "4                                SIN17072P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---august-2024\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P', 'ZYNLONTA® FOR INJECTION 10MG/VIAL']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P', 'ZYNLONTA® FOR INJECTION 10MG/VIAL', 'Loncastuximab tesirine(10mg/vial)']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P', 'ZYNLONTA® FOR INJECTION 10MG/VIAL', 'Loncastuximab tesirine(10mg/vial)', 'NDA-1: New biological entity']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P', 'ZYNLONTA® FOR INJECTION 10MG/VIAL', 'Loncastuximab tesirine(10mg/vial)', 'NDA-1: New biological entity', 'ORIENT EUROPHARMA PTE LTD']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P', 'ZYNLONTA® FOR INJECTION 10MG/VIAL', 'Loncastuximab tesirine(10mg/vial)', 'NDA-1: New biological entity', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024']\n",
            "['ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FOR INJECTION 40 MG/ML', 'Triamcinolone acetonide(40MG/ML)', 'NDA-2: New dosage form', 'ARCTIC VISION SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17090P', 'AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/4ML,AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/16ML', 'Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)', 'NDA-2: New biosimilar', 'INNOGENE KALBIOTECH PTE. LTD.', '25/09/2024', 'SIN17101P,SIN17102P', 'ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 8,000 IU (80 MG)/ 0.8 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6,000 IU (60 MG)/ 0.6 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 4,000 IU (40 MG)/ 0.4 ML,ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 2,000 IU (20 MG)/ 0.2 ML', 'Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),Enoxaparin Sodium(6,000 IU (60 MG) /0.6 ML),Enoxaparin Sodium(4,000 IU (40 MG) /0.4 ML),Enoxaparin Sodium(2,000 IU (20 MG) /0.2 ML)', 'NDA-2/3: New biosimilar', 'SANDOZ SINGAPORE PTE. LTD.', '11/09/2024', 'SIN17084P,SIN17086P,SIN17085P,SIN17083P', 'FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 MCG PER DOSE,FOSTER PRESSURISED INHALATION SOLUTION 200MCG/6MCG PER ACTUATION', 'Beclometasone dipropionate(0.200mg/dose),Formoterol   fumarate dihydrate(0.006mg/dose),Beclometasone dipropionate(0.200mg/actuation),Formoterol fumarate   dihydrate(0.006mg/actuation)', 'NDA-2: New presentation', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17099P,SIN17100P', 'ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML', 'Tildrakizumab(100mg/mL)', 'NDA-1: New biological entity', 'RANBAXY (MALAYSIA) SDN. BHD.', '04/09/2024', 'SIN17076P', 'ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM-COATED TABLET 86 MG', 'ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(345 MG),ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(86 MG)', 'NDA-1/3: New chemical entity', 'A. MENARINI SINGAPORE PTE. LTD.', '25/09/2024', 'SIN17096P,SIN17097P', 'STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML', 'Ustekinumab(90mg/1ml)', 'NDA-2: New presentation', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '26/09/2024', 'SIN17103P', 'TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR INFUSION 400MG', 'Thiotepa(400mg)', 'NDA-2: New presentation', 'AXXESSBIO PTE. LTD.', '20/09/2024', 'SIN17095P', 'TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML', 'Tislelizumab(100mg/10mL )', 'NDA-1: New biological entity', 'BEIGENE SINGAPORE PTE. LTD.', '19/09/2024', 'SIN17089P', 'WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG,WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY),WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)', '(Powder vial) sotatercept(45mg),(Powder vial) sotatercept(60mg),Sotatercept(45mg),Sotatercept(60mg)', 'NDA-1/3: New biological entity', 'MSD PHARMA (SINGAPORE) PTE. LTD.', '20/09/2024', 'SIN17091P,SIN17092P,SIN17093P,SIN17094P', 'ZYNLONTA® FOR INJECTION 10MG/VIAL', 'Loncastuximab tesirine(10mg/vial)', 'NDA-1: New biological entity', 'ORIENT EUROPHARMA PTE LTD', '25/09/2024', 'SIN17098P']\n",
            "                                                    0  \\\n",
            "0   ARCATUS® TRIAMCINOLONE ACETONIDE SUSPENSION FO...   \n",
            "1   AVAMAB CONCENTRATE FOR SOLUTION FOR INFUSION 1...   \n",
            "2   ENOXAPARIN SANDOZ SOLUTION FOR INJECTION IN PR...   \n",
            "3   FOSTER NEXTHALER INHALATION POWDER 200 MCG/6 M...   \n",
            "4   ILUMYA SOLUTION FOR INJECTION IN PRE-FILLED SY...   \n",
            "5   ORSERDU FILM-COATED TABLET 345 MG,ORSERDU FILM...   \n",
            "6   STELARA SOLUTION FOR INJECTION IN PRE-FILLED P...   \n",
            "7   TEPADINA POWDER AND SOLVENT FOR SOLUTION FOR I...   \n",
            "8   TEVIMBRA CONCENTRATE FOR SOLUTION FOR INFUSION...   \n",
            "9   WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 4...   \n",
            "10                  ZYNLONTA® FOR INJECTION 10MG/VIAL   \n",
            "\n",
            "                                                    1  \\\n",
            "0                    Triamcinolone acetonide(40MG/ML)   \n",
            "1      Bevacizumab(100mg/4ml),Bevacizumab(400mg/16ml)   \n",
            "2   Enoxaparin Sodium(8,000 IU (80 MG) /0.8 ML),En...   \n",
            "3   Beclometasone dipropionate(0.200mg/dose),Formo...   \n",
            "4                             Tildrakizumab(100mg/mL)   \n",
            "5   ELACESTRANT DIHYDROCHLORIDE eqv ELACESTRANT(34...   \n",
            "6                               Ustekinumab(90mg/1ml)   \n",
            "7                                     Thiotepa(400mg)   \n",
            "8                           Tislelizumab(100mg/10mL )   \n",
            "9   (Powder vial) sotatercept(45mg),(Powder vial) ...   \n",
            "10                  Loncastuximab tesirine(10mg/vial)   \n",
            "\n",
            "                                 2  \\\n",
            "0           NDA-2: New dosage form   \n",
            "1            NDA-2: New biosimilar   \n",
            "2          NDA-2/3: New biosimilar   \n",
            "3          NDA-2: New presentation   \n",
            "4     NDA-1: New biological entity   \n",
            "5     NDA-1/3: New chemical entity   \n",
            "6          NDA-2: New presentation   \n",
            "7          NDA-2: New presentation   \n",
            "8     NDA-1: New biological entity   \n",
            "9   NDA-1/3: New biological entity   \n",
            "10    NDA-1: New biological entity   \n",
            "\n",
            "                                                    3           4  \\\n",
            "0                   ARCTIC VISION SINGAPORE PTE. LTD.  19/09/2024   \n",
            "1                       INNOGENE KALBIOTECH PTE. LTD.  25/09/2024   \n",
            "2                          SANDOZ SINGAPORE PTE. LTD.  11/09/2024   \n",
            "3                           ORIENT EUROPHARMA PTE LTD  25/09/2024   \n",
            "4                        RANBAXY (MALAYSIA) SDN. BHD.  04/09/2024   \n",
            "5                     A. MENARINI SINGAPORE PTE. LTD.  25/09/2024   \n",
            "6   JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PT...  26/09/2024   \n",
            "7                                 AXXESSBIO PTE. LTD.  20/09/2024   \n",
            "8                         BEIGENE SINGAPORE PTE. LTD.  19/09/2024   \n",
            "9                    MSD PHARMA (SINGAPORE) PTE. LTD.  20/09/2024   \n",
            "10                          ORIENT EUROPHARMA PTE LTD  25/09/2024   \n",
            "\n",
            "                                          5  \n",
            "0                                 SIN17090P  \n",
            "1                       SIN17101P,SIN17102P  \n",
            "2   SIN17084P,SIN17086P,SIN17085P,SIN17083P  \n",
            "3                       SIN17099P,SIN17100P  \n",
            "4                                 SIN17076P  \n",
            "5                       SIN17096P,SIN17097P  \n",
            "6                                 SIN17103P  \n",
            "7                                 SIN17095P  \n",
            "8                                 SIN17089P  \n",
            "9   SIN17091P,SIN17092P,SIN17093P,SIN17094P  \n",
            "10                                SIN17098P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---september-2024\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P', 'TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-COATED TABLETS 160MG']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P', 'TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-COATED TABLETS 160MG', 'Capivasertib(200mg),Capivasertib(160mg)']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P', 'TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-COATED TABLETS 160MG', 'Capivasertib(200mg),Capivasertib(160mg)', 'NDA-1 and NDA-3: New chemical entity']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P', 'TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-COATED TABLETS 160MG', 'Capivasertib(200mg),Capivasertib(160mg)', 'NDA-1 and NDA-3: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P', 'TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-COATED TABLETS 160MG', 'Capivasertib(200mg),Capivasertib(160mg)', 'NDA-1 and NDA-3: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '14/10/2024']\n",
            "['AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA FILM-COATED TABLETS 100MG/500MG', 'Abiraterone acetate(500mg),Niraparib tosylate monohydrate   eqv niraparib(50mg),Abiraterone acetate(500mg),Niraparib tosylate monohydrate eqv   niraparib(100mg)', 'NDA-2: New combination', 'JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD', '14/10/2024', 'SIN17109P,SIN17110P', 'AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 25MG', 'Vutrisiran (as vutrisiran sodium)(25mg)', 'NDA-1: New chemical entity', 'NYPRAX PHARMA PTE. LTD.', '25/10/2024', 'SIN17124P', 'BILAXTEN TABLET 20 MG (PHARMACY ONLY)', 'BILASTINE(20.00 mg)', 'NDA-2: New forensic classification', 'A. MENARINI SINGAPORE PTE. LTD.', '02/10/2024', 'SIN17104P', 'EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML,EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION 4MG/0.8ML,EPKINLY SOLUTION FOR INJECTION 48MG/0.8ML', 'Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL),Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8mL)', 'NDA-1 and NDA-2: New biological entity', 'ABBVIE PTE. LTD.', '02/10/2024', 'SIN17105P,SIN17106P,SIN17105P,SIN17106P', 'FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG', 'Fruquintinib(5mg),Fruquintinib(1mg)', 'NDA-1 and NDA-3: New chemical entity', 'TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.', '17/10/2024', 'SIN17113P,SIN17114P', 'HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE   20MG/0.4ML', 'Adalimumab(20 mg/0.4 mL)', 'NDA-2: New presentation', 'SANDOZ SINGAPORE PTE. LTD.', '17/10/2024', 'SIN17117P', 'SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN PRE‐FILLED   SYRINGE,SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML IN SINGLE-DOSE VIAL', 'Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg / 0.5ml)', 'NDA-2: New presentation', 'MODERNA BIOTECH SINGAPORE PTE. LTD.', '30/10/2024', 'SIN17128P,SIN17129P', 'STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRENSIQ SOLUTION FOR INJECTION 40 MG/ML', 'Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)', 'NDA-1: New biological entity', 'ASTRAZENECA SINGAPORE PTE LTD', '29/10/2024', 'SIN17126P,SIN17127P', 'TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-COATED TABLETS 160MG', 'Capivasertib(200mg),Capivasertib(160mg)', 'NDA-1 and NDA-3: New chemical entity', 'ASTRAZENECA SINGAPORE PTE LTD', '14/10/2024', 'SIN17111P,SIN17112P']\n",
            "                                                   0  \\\n",
            "0  AKEEGA FILM-COATED TABLETS 50MG/500MG,AKEEGA F...   \n",
            "1  AMVUTTRA SOLUTION FOR INJECTION IN PRE-FILLED ...   \n",
            "2              BILAXTEN TABLET 20 MG (PHARMACY ONLY)   \n",
            "3  EPKINLY CONCENTRATE FOR SOLUTION FOR INJECTION...   \n",
            "4          FRUZAQLA CAPSULE 5MG,FRUZAQLA CAPSULE 1MG   \n",
            "5  HYRIMOZ SOLUTION FOR INJECTION IN PRE-FILLED S...   \n",
            "6  SPIKEVAX DISPERSION FOR INJECTION 50MCG/0.5ML ...   \n",
            "7  STRENSIQ SOLUTION FOR INJECTION 100 MG/ML,STRE...   \n",
            "8  TRUQAP FILM-COATED TABLETS 200MG,TRUQAP FILM-C...   \n",
            "\n",
            "                                                   1  \\\n",
            "0  Abiraterone acetate(500mg),Niraparib tosylate ...   \n",
            "1            Vutrisiran (as vutrisiran sodium)(25mg)   \n",
            "2                                BILASTINE(20.00 mg)   \n",
            "3  Epcoritamab(4.0mg/0.8mL),Epcoritamab(48mg/0.8m...   \n",
            "4                Fruquintinib(5mg),Fruquintinib(1mg)   \n",
            "5                           Adalimumab(20 mg/0.4 mL)   \n",
            "6  Andusomeran(0.05mg/0.5ml),Andusomeran(0.05mg /...   \n",
            "7     Asfotase alfa(100mg/mL),Asfotase alfa(40mg/mL)   \n",
            "8            Capivasertib(200mg),Capivasertib(160mg)   \n",
            "\n",
            "                                        2  \\\n",
            "0                  NDA-2: New combination   \n",
            "1              NDA-1: New chemical entity   \n",
            "2      NDA-2: New forensic classification   \n",
            "3  NDA-1 and NDA-2: New biological entity   \n",
            "4    NDA-1 and NDA-3: New chemical entity   \n",
            "5                 NDA-2: New presentation   \n",
            "6                 NDA-2: New presentation   \n",
            "7            NDA-1: New biological entity   \n",
            "8    NDA-1 and NDA-3: New chemical entity   \n",
            "\n",
            "                                                   3           4  \\\n",
            "0  JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PT...  14/10/2024   \n",
            "1                            NYPRAX PHARMA PTE. LTD.  25/10/2024   \n",
            "2                    A. MENARINI SINGAPORE PTE. LTD.  02/10/2024   \n",
            "3                                   ABBVIE PTE. LTD.  02/10/2024   \n",
            "4    TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.  17/10/2024   \n",
            "5                         SANDOZ SINGAPORE PTE. LTD.  17/10/2024   \n",
            "6                MODERNA BIOTECH SINGAPORE PTE. LTD.  30/10/2024   \n",
            "7                      ASTRAZENECA SINGAPORE PTE LTD  29/10/2024   \n",
            "8                      ASTRAZENECA SINGAPORE PTE LTD  14/10/2024   \n",
            "\n",
            "                                         5  \n",
            "0                      SIN17109P,SIN17110P  \n",
            "1                                SIN17124P  \n",
            "2                                SIN17104P  \n",
            "3  SIN17105P,SIN17106P,SIN17105P,SIN17106P  \n",
            "4                      SIN17113P,SIN17114P  \n",
            "5                                SIN17117P  \n",
            "6                      SIN17128P,SIN17129P  \n",
            "7                      SIN17126P,SIN17127P  \n",
            "8                      SIN17111P,SIN17112P  \n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---october-2024\n",
            "Empty DataFrame\n",
            "Columns: []\n",
            "Index: []\n",
            "https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---november-2024\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "KeyboardInterrupt",
          "evalue": "",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-1-01741e9883d9>\u001b[0m in \u001b[0;36m<cell line: 195>\u001b[0;34m()\u001b[0m\n\u001b[1;32m    194\u001b[0m \u001b[0;31m# Main function trigger\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    195\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0m__name__\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m'__main__'\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 196\u001b[0;31m     \u001b[0mmain\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
            "\u001b[0;32m<ipython-input-1-01741e9883d9>\u001b[0m in \u001b[0;36mmain\u001b[0;34m()\u001b[0m\n\u001b[1;32m    173\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    174\u001b[0m             \u001b[0;31m# Get the dataframes from scraping\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 175\u001b[0;31m             \u001b[0mdf\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mscraping\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    176\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    177\u001b[0m             \u001b[0;31m# Append the returned dataframe into the list\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-1-01741e9883d9>\u001b[0m in \u001b[0;36mscraping\u001b[0;34m(url)\u001b[0m\n\u001b[1;32m    130\u001b[0m \u001b[0;32mdef\u001b[0m \u001b[0mscraping\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    131\u001b[0m     \u001b[0;31m# Get response from the url\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 132\u001b[0;31m     \u001b[0mr\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mrequests\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mheaders\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mheaders\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    133\u001b[0m     \u001b[0;31m# Initialize soup\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    134\u001b[0m     \u001b[0msoup\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mBeautifulSoup\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mr\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcontent\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"html.parser\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/api.py\u001b[0m in \u001b[0;36mget\u001b[0;34m(url, params, **kwargs)\u001b[0m\n\u001b[1;32m     71\u001b[0m     \"\"\"\n\u001b[1;32m     72\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 73\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0mrequest\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"get\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mparams\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mparams\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     74\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     75\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/api.py\u001b[0m in \u001b[0;36mrequest\u001b[0;34m(method, url, **kwargs)\u001b[0m\n\u001b[1;32m     57\u001b[0m     \u001b[0;31m# cases, and look like a memory leak in others.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     58\u001b[0m     \u001b[0;32mwith\u001b[0m \u001b[0msessions\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mSession\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0msession\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 59\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0msession\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     60\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     61\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/sessions.py\u001b[0m in \u001b[0;36mrequest\u001b[0;34m(self, method, url, params, data, headers, cookies, files, auth, timeout, allow_redirects, proxies, hooks, stream, verify, cert, json)\u001b[0m\n\u001b[1;32m    587\u001b[0m         }\n\u001b[1;32m    588\u001b[0m         \u001b[0msend_kwargs\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mupdate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msettings\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 589\u001b[0;31m         \u001b[0mresp\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mprep\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0msend_kwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    590\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    591\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/sessions.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, request, **kwargs)\u001b[0m\n\u001b[1;32m    701\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    702\u001b[0m         \u001b[0;31m# Send the request\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 703\u001b[0;31m         \u001b[0mr\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0madapter\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    704\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    705\u001b[0m         \u001b[0;31m# Total elapsed time of the request (approximately)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/adapters.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[1;32m    665\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    666\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 667\u001b[0;31m             resp = conn.urlopen(\n\u001b[0m\u001b[1;32m    668\u001b[0m                 \u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    669\u001b[0m                 \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/urllib3/connectionpool.py\u001b[0m in \u001b[0;36murlopen\u001b[0;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, preload_content, decode_content, **response_kw)\u001b[0m\n\u001b[1;32m    787\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    788\u001b[0m             \u001b[0;31m# Make the request on the HTTPConnection object\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 789\u001b[0;31m             response = self._make_request(\n\u001b[0m\u001b[1;32m    790\u001b[0m                 \u001b[0mconn\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    791\u001b[0m                 \u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/urllib3/connectionpool.py\u001b[0m in \u001b[0;36m_make_request\u001b[0;34m(self, conn, method, url, body, headers, retries, timeout, chunked, response_conn, preload_content, decode_content, enforce_content_length)\u001b[0m\n\u001b[1;32m    534\u001b[0m         \u001b[0;31m# Receive the response from the server\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    535\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 536\u001b[0;31m             \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mconn\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mgetresponse\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    537\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mBaseSSLError\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mOSError\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    538\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_raise_timeout\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0merr\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0me\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtimeout_value\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mread_timeout\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/urllib3/connection.py\u001b[0m in \u001b[0;36mgetresponse\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    505\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    506\u001b[0m         \u001b[0;31m# Get the response from http.client.HTTPConnection\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 507\u001b[0;31m         \u001b[0mhttplib_response\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mgetresponse\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    508\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    509\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/http/client.py\u001b[0m in \u001b[0;36mgetresponse\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1373\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1374\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1375\u001b[0;31m                 \u001b[0mresponse\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbegin\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1376\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mConnectionError\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1377\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mclose\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/http/client.py\u001b[0m in \u001b[0;36mbegin\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    316\u001b[0m         \u001b[0;31m# read until we get a non-100 response\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    317\u001b[0m         \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 318\u001b[0;31m             \u001b[0mversion\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstatus\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mreason\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_read_status\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    319\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mstatus\u001b[0m \u001b[0;34m!=\u001b[0m \u001b[0mCONTINUE\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    320\u001b[0m                 \u001b[0;32mbreak\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/http/client.py\u001b[0m in \u001b[0;36m_read_status\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    277\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    278\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_read_status\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 279\u001b[0;31m         \u001b[0mline\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreadline\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0m_MAXLINE\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"iso-8859-1\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    280\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mline\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0m_MAXLINE\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    281\u001b[0m             \u001b[0;32mraise\u001b[0m \u001b[0mLineTooLong\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"status line\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/socket.py\u001b[0m in \u001b[0;36mreadinto\u001b[0;34m(self, b)\u001b[0m\n\u001b[1;32m    703\u001b[0m         \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    704\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 705\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sock\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    706\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    707\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_timeout_occurred\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/ssl.py\u001b[0m in \u001b[0;36mrecv_into\u001b[0;34m(self, buffer, nbytes, flags)\u001b[0m\n\u001b[1;32m   1301\u001b[0m                   \u001b[0;34m\"non-zero flags not allowed in calls to recv_into() on %s\"\u001b[0m \u001b[0;34m%\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1302\u001b[0m                   self.__class__)\n\u001b[0;32m-> 1303\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnbytes\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbuffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1304\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1305\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbuffer\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnbytes\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mflags\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/ssl.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, len, buffer)\u001b[0m\n\u001b[1;32m   1157\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1158\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mbuffer\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1159\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbuffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1160\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1161\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "For Scraping GDA"
      ],
      "metadata": {
        "id": "0loobOQKWfG4"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "logging.basicConfig(level=logging.INFO, format='%(asctime)s - %(levelname)s - %(message)s')\n",
        "\n",
        "# Swap the path to web driver in the executable_path\n",
        "service = Service(executable_path='C:/Users/Aiman/geckodriver-v0.35.0-win64/geckodriver.exe')\n",
        "# URL path\n",
        "url = 'https://www.hsa.gov.sg/therapeutic-products/approvals-and-post-reg-actions'\n",
        "\n",
        "# Set up the Selenium WebDriver\n",
        "logging.info('Setting up the WebDriver')\n",
        "driver = webdriver.Firefox(service=service)\n",
        "\n",
        "# create action chain object\n",
        "action = ActionChains(driver)\n",
        "\n",
        "# Load the website\n",
        "driver.get(url)\n",
        "logging.info('Navigated to the website')\n",
        "\n",
        "# Create a DataFrame to store the data\n",
        "df = pd.DataFrame(\n",
        "    columns=[\n",
        "    'Approval Date',\n",
        "    'Product Name',\n",
        "    'Active Ingredient(s)',\n",
        "    'Application Type',\n",
        "    'Product Registrant',\n",
        "    'Registration Number'\n",
        "    ]\n",
        ")\n",
        "\n",
        "# Define dictionary for the different components\n",
        "gda_dict = {\n",
        "    'year': [2024, 2023, 2022, 2021],\n",
        "\n",
        "    'accordion': [\n",
        "        '//*[@id=\"main_C187_Col00\"]',\n",
        "        '//*[@id=\"main_C166_Col00\"]',\n",
        "        '//*[@id=\"main_C123_Col00\"]',\n",
        "        '//*[@id=\"main_C124_Col00\"]'\n",
        "    ],\n",
        "\n",
        "    'button': [\n",
        "        '/html/body/form/main/div/div[2]/div/div[1]/div/div[5]/div[1]/div/div[2]/div/div/div/div[3]/div[2]/span[5]',\n",
        "        '/html/body/form/main/div/div[2]/div/div[1]/div/div[5]/div[2]/div/div[2]/div/div/div/div/div/div[3]/div[2]/span[6]',\n",
        "        '/html/body/form/main/div/div[2]/div/div[1]/div/div[5]/div[3]/div/div[2]/div/div/div/div/div/div[3]/div[2]/span[5]',\n",
        "        '/html/body/form/main/div/div[2]/div/div[1]/div/div[5]/div[4]/div/div[2]/div/div/div/div/div/div[3]/div[2]/span[7]'\n",
        "    ]\n",
        "}\n",
        "\n",
        "# Define index for the years\n",
        "u = 0\n",
        "\n",
        "# Start loop — each year in gda_list from 2024 to 2021\n",
        "for year in gda_dict['year']:\n",
        "    print(year)\n",
        "    time.sleep(1)\n",
        "\n",
        "    # Move cursor to the accordian\n",
        "    logging.info('Located Accordian button')\n",
        "    menu_trigger = driver.find_element(\n",
        "        By.XPATH,\n",
        "        f'//*[@id=\"togglepanel-{year}\"]'\n",
        "    )\n",
        "\n",
        "    # Scrolling the accordian into view\n",
        "    time.sleep(1)\n",
        "    logging.info('Scrolling the Accordian element into view')\n",
        "    driver.execute_script(\n",
        "        \"arguments[0].scrollIntoView();\",\n",
        "        menu_trigger\n",
        "    )\n",
        "\n",
        "    # Click the Accordian\n",
        "    time.sleep(1)\n",
        "    logging.info('Clicking the accordian')\n",
        "    ActionChains(driver).click(\n",
        "        on_element=menu_trigger\n",
        "    ).perform()\n",
        "\n",
        "    # Wait for the accordian to be loaded\n",
        "    logging.info('Waiting for the Accordian content to be loaded')\n",
        "    acn = gda_dict['accordion'][u]\n",
        "    WebDriverWait(driver, 10).until(\n",
        "    EC.presence_of_element_located((\n",
        "            By.XPATH,\n",
        "            f'{acn}'\n",
        "        ))\n",
        "    )\n",
        "    logging.info('Accordian loaded\\n')\n",
        "\n",
        "    print(u)\n",
        "\n",
        "    # initialize index for pages\n",
        "    i=0\n",
        "\n",
        "    # Assign the maximum pages according to the year\n",
        "    if year == 2024:\n",
        "        v=3\n",
        "    elif year == 2023:\n",
        "        v=4\n",
        "    elif year == 2022:\n",
        "        v=3\n",
        "    elif year == 2021:\n",
        "        v=5\n",
        "\n",
        "    # While page number is below page max\n",
        "    while i < v:\n",
        "        time.sleep(1)\n",
        "        print(f'Page: {i}')\n",
        "\n",
        "        # Find the accordian component\n",
        "        list_element = driver.find_element(\n",
        "            By.XPATH,\n",
        "            f'{acn}'\n",
        "        )\n",
        "\n",
        "        # Get the html content from the accordian\n",
        "        list_html = list_element.get_attribute('outerHTML')\n",
        "\n",
        "        # Parse the HTML content with BeautifulSoup\n",
        "        soup = BeautifulSoup(list_html, \"html.parser\")\n",
        "\n",
        "        # Find the table\n",
        "        div = soup.find(\n",
        "            'table',\n",
        "            attrs={\n",
        "                'class' :\n",
        "                \"hsa-datatable status--done dataTable-table\"\n",
        "            }\n",
        "        )\n",
        "\n",
        "        time.sleep(5)\n",
        "\n",
        "        # Array to store data from each row\n",
        "        row_data = []\n",
        "\n",
        "        # Start loop — find each column\n",
        "        for idx, cols in enumerate(div.find_all('td')):\n",
        "\n",
        "            # print(idx)\n",
        "\n",
        "            # Grab the text in the column\n",
        "            selected_column = cols.get_text(strip=True)\n",
        "\n",
        "            # Append the text into row_data\n",
        "            row_data.append(selected_column)\n",
        "\n",
        "            # Since there are 6 columns for every row\n",
        "            # when len(row_data) is 6\n",
        "            # it will be dataframed as one row\n",
        "            if len(row_data) == 6:\n",
        "                row_df = pd.DataFrame(\n",
        "                    [row_data],\n",
        "                    columns=df.columns\n",
        "                )\n",
        "                # print(row_df)\n",
        "\n",
        "                # Concatenate all the row df into one table df\n",
        "                df = pd.concat(\n",
        "                    [df, row_df],\n",
        "                    ignore_index=True,\n",
        "                    sort=False\n",
        "                )\n",
        "\n",
        "                # Reset the row_data\n",
        "                row_data = []\n",
        "                # print(row_data)\n",
        "\n",
        "        # End loop\n",
        "\n",
        "        # Find next page element\n",
        "        btn = gda_dict['button'][u]\n",
        "        next_button = driver.find_element(\n",
        "            By.XPATH,\n",
        "            f'{btn}'\n",
        "        )\n",
        "        logging.info('Found the next page button')\n",
        "\n",
        "        # Scroll next page element into view\n",
        "        logging.info('Scrolling the header element into view')\n",
        "        driver.execute_script(\n",
        "            \"arguments[0].scrollIntoView();\",\n",
        "            next_button\n",
        "        )\n",
        "\n",
        "        time.sleep(1)\n",
        "\n",
        "        # Click on the next page button\n",
        "        ActionChains(driver).click(\n",
        "            on_element=next_button\n",
        "        ).perform()\n",
        "        logging.info('Clicked on the next page button\\n')\n",
        "\n",
        "        # Add increment to the page index\n",
        "        i=i+1\n",
        "\n",
        "        # Scrolling the accordian into view\n",
        "        time.sleep(1)\n",
        "        logging.info('Scrolling the Accordian element into view')\n",
        "        driver.execute_script(\n",
        "            \"arguments[0].scrollIntoView();\",\n",
        "            menu_trigger\n",
        "        )\n",
        "\n",
        "\n",
        "    logging.info('Finished Extraction')\n",
        "\n",
        "    # Add increment to the yeat index\n",
        "    u=u+1\n",
        "    print(df.info())\n",
        "\n",
        "# Add regs admin and country column\n",
        "df.insert(0, 'Regulatory Admin', 'HSA')\n",
        "df.insert(1, 'Country Name', 'Singapore')\n",
        "df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "# Save dataframe to csv\n",
        "df.to_csv('all_gda.csv', index=False)\n"
      ],
      "metadata": {
        "id": "o8oS68l_v7Jh"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "To concatenate NDA and GDA datasets"
      ],
      "metadata": {
        "id": "PXTqBVieWbDz"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df1 = pd.read_csv('hsa_combined_nda.csv')\n",
        "df2 = pd.read_csv('all_gda.csv')\n",
        "\n",
        "dfA = pd.concat([df1, df2])\n",
        "dfA.to_csv('full_hsa.csv', index = False)"
      ],
      "metadata": {
        "id": "IJr-TnSLh12E"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "One-time scraping for NDA, change the URL"
      ],
      "metadata": {
        "id": "0K01kZ4DWS1Q"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# One-by-one manually insert link\n",
        "from bs4 import BeautifulSoup\n",
        "import requests\n",
        "import pandas as pd\n",
        "\n",
        "URL = \"https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals---october-2024\"\n",
        "headers = {'User-Agent' : \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/42.0.2311.135 Safari/537.36 Edge/12.246\"}\n",
        "r = requests.get(url=URL, headers=headers)\n",
        "\n",
        "soup = BeautifulSoup(r.content, \"html.parser\")\n",
        "output_list = []\n",
        "\n",
        "for table_element in soup.findAll('tbody'):\n",
        "    for row in table_element.findAll('tr'):\n",
        "        columns = row.findAll('td')\n",
        "        if len(columns) > 1:\n",
        "            selected_column = columns[1].get_text(strip=True)\n",
        "            output_list.append(selected_column)\n",
        "\n",
        "\n",
        "print(output_list)\n",
        "\n",
        "# Calculate the number of columns needed\n",
        "num_columns = (len(output_list) + 5) // 6\n",
        "reshaped_list = [\n",
        "    output_list[i:i + 6] for i in range(0, len(output_list), 6)\n",
        "]\n",
        "df = pd.DataFrame(reshaped_list) #.transpose()\n",
        "\n",
        "# Add regs admin and country column\n",
        "df.insert(0, 'Regulatory Admin', 'HSA')\n",
        "df.insert(1, 'Country Name', 'Singapore')\n",
        "df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "print(df)\n",
        "df.to_csv('hsa_october_2024.csv', index=False)"
      ],
      "metadata": {
        "id": "h5E-7XFiZHDy"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "One-time scraping for GDA (this is set to scrape 2024)."
      ],
      "metadata": {
        "id": "gjUqHQjoWDPh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# 2024\n",
        "\n",
        "logging.basicConfig(level=logging.INFO, format='%(asctime)s - %(levelname)s - %(message)s')\n",
        "\n",
        "service = Service(executable_path='C:/Users/Aiman/geckodriver-v0.35.0-win64/geckodriver.exe')\n",
        "url = 'https://www.hsa.gov.sg/therapeutic-products/approvals-and-post-reg-actions'\n",
        "\n",
        "# Set up the Selenium WebDriver\n",
        "logging.info('Setting up the WebDriver')\n",
        "driver = webdriver.Firefox(service=service)\n",
        "\n",
        "driver.get(url)\n",
        "logging.info('Navigated to the website')\n",
        "\n",
        "# create action chain object\n",
        "action = ActionChains(driver)\n",
        "\n",
        "# Create a DataFrame to store the data\n",
        "df = pd.DataFrame(\n",
        "    columns=[\n",
        "    'Approval Date',\n",
        "    'Product Name',\n",
        "    'Active Ingredient(s)',\n",
        "    'Application Type',\n",
        "    'Product Registrant',\n",
        "    'Registration Number'\n",
        "    ]\n",
        ")\n",
        "\n",
        "# Move cursor to the accordian\n",
        "time.sleep(1)\n",
        "logging.info('Located Accordian button')\n",
        "\n",
        "# ============= Find the accordion button/element according to year ============\n",
        "menu_trigger = driver.find_element(\n",
        "    By.XPATH, '//*[@id=\"togglepanel-2024\"]'\n",
        ")\n",
        "\n",
        "# Scrolling the accordian into view\n",
        "time.sleep(1)\n",
        "logging.info('Scrolling the Accordian element into view')\n",
        "driver.execute_script(\n",
        "    \"arguments[0].scrollIntoView();\", menu_trigger\n",
        ")\n",
        "\n",
        "# Click the Accordian\n",
        "time.sleep(1)\n",
        "logging.info('Clicking the accordian')\n",
        "ActionChains(driver).click(on_element=menu_trigger).perform()\n",
        "\n",
        "# Wait for the modal to be present and the table to be loaded\n",
        "logging.info('Waiting for the Accordian content to be loaded')\n",
        "WebDriverWait(driver, 10).until(\n",
        "    # ==================== Find the table in the accordion =====================\n",
        "    EC.presence_of_element_located((\n",
        "        By.XPATH, '//*[@id=\"main_C187_Col00\"]'\n",
        "    ))\n",
        ")\n",
        "logging.info('Accordian loaded\\n')\n",
        "# logging.info('Start of Row 1')\n",
        "\n",
        "i=1\n",
        "\n",
        "while i < 4:\n",
        "    time.sleep(1)\n",
        "    print(f'Page: {i}')\n",
        "    # ==================== Find the table in the accordion =====================\n",
        "    list_element = driver.find_element(\n",
        "        By.XPATH, '//*[@id=\"main_C187_Col00\"]'\n",
        "    )\n",
        "    list_html = list_element.get_attribute('outerHTML')\n",
        "\n",
        "    # Parse the HTML content with BeautifulSoup\n",
        "    soup = BeautifulSoup(list_html, \"html.parser\")\n",
        "    div = soup.find(\n",
        "        'table',\n",
        "        attrs={'class' :\"hsa-datatable status--done dataTable-table\"}\n",
        "    )\n",
        "\n",
        "    time.sleep(5)\n",
        "    row_data = []\n",
        "\n",
        "    for idx, cols in enumerate(div.find_all('td')):\n",
        "        # print(idx)\n",
        "        selected_column = cols.get_text(strip=True)\n",
        "        row_data.append(selected_column)\n",
        "\n",
        "        if len(row_data) == 6:\n",
        "            row_df = pd.DataFrame(\n",
        "                [row_data], columns=df.columns\n",
        "            )\n",
        "            # print(row_df)\n",
        "            df = pd.concat(\n",
        "                [df, row_df], ignore_index=True, sort=False\n",
        "            )\n",
        "            row_data = []\n",
        "            # print(row_data)\n",
        "\n",
        "    # ========================= Find next page button ==========================\n",
        "    next_button = driver.find_element(\n",
        "        By.XPATH, '/html/body/form/main/div/div[2]/div/div[1]/div/div[5]/div[1]/div/div[2]/div/div/div/div[3]/div[2]/span[5]'\n",
        "    )\n",
        "    logging.info('Found the next page button')\n",
        "\n",
        "    # Scroll next page element into view\n",
        "    logging.info('Scrolling the header element into view')\n",
        "    driver.execute_script(\n",
        "        \"arguments[0].scrollIntoView();\", next_button\n",
        "    )\n",
        "\n",
        "    time.sleep(1)\n",
        "    # Click on the next page button\n",
        "    ActionChains(driver).click(on_element=next_button).perform()\n",
        "    logging.info('Clicked on the next page button\\n')\n",
        "    i=i+1\n",
        "\n",
        "    # Scrolling the accordian into view\n",
        "    time.sleep(1)\n",
        "    logging.info('Scrolling the Accordian element into view')\n",
        "    driver.execute_script(\n",
        "        \"arguments[0].scrollIntoView();\", menu_trigger\n",
        "    )\n",
        "\n",
        "df.insert(0, 'Regulatory Admin', 'HSA')\n",
        "df.insert(1, 'Country Name', 'Singapore')\n",
        "df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "df.to_csv('gda_hsa_2024.csv')\n",
        "\n",
        "logging.info('Finished Extraction')\n",
        "print(df.info())\n"
      ],
      "metadata": {
        "id": "7AUkZxKFcWu-"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **BPOM**"
      ],
      "metadata": {
        "id": "gMi8GO0ZT3vc"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "**This code does not work now unfortunately.**"
      ],
      "metadata": {
        "id": "tyz1INUIVyeu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Array to store multiple dataframes\n",
        "output_list = []\n",
        "\n",
        "# Set up logging\n",
        "logging.basicConfig(\n",
        "    level=logging.INFO,\n",
        "    format='%(asctime)s - %(levelname)s - %(message)s'\n",
        "    )\n",
        "\n",
        "# Path to Web Driver\n",
        "service = Service(executable_path='C:/Users/Aiman/geckodriver-v0.35.0-win64/geckodriver.exe')\n",
        "\n",
        "# Set up the Selenium Web Driver\n",
        "logging.info('Setting up the WebDriver')\n",
        "driver = webdriver.Firefox(service=service)\n",
        "\n",
        "# Open the website in browser\n",
        "driver.get(\"https://cekbpom.pom.go.id/obat\")\n",
        "logging.info('Navigated to the website')\n",
        "\n",
        "# Create action chain object\n",
        "action = ActionChains(driver)\n",
        "\n",
        "# Create a DataFrame to store the data\n",
        "df = pd.DataFrame(\n",
        "    columns=[\n",
        "        'Nomor Registrasi',\n",
        "        'Tanggal Terbit',\n",
        "        'Masa Berlaku s/d',\n",
        "        'Diterbitkan Oleh (1)',\n",
        "        'Diterbitkan Oleh (2)',\n",
        "        'Produk',\n",
        "        'Nama Produk',\n",
        "        'Bentuk Sediaan',\n",
        "        'Komposisi',\n",
        "        'Merk',\n",
        "        'Kemasan',\n",
        "        'Pendaftar',\n",
        "        'Diproduksi Oleh'\n",
        "    ]\n",
        ")\n",
        "\n",
        "# Important index to declare the first page for scraping\n",
        "page_start = 1\n",
        "\n",
        "# Important to change when website updates the list\n",
        "total_data = 28493\n",
        "\n",
        "# Start loop\n",
        "'''Only starts scraping when web driver is on the correct page\n",
        "Will skip the earlier pages without scraping them\n",
        "Change the if-else statements when you\n",
        "want the code to start scraping from an advanced page\n",
        "or when the total number of data changes'''\n",
        "# It will only loop when page_start isnt 1\n",
        "if page_start == 1:\n",
        "    pass\n",
        "else:\n",
        "    # Loop will stop when \"start\" is False\n",
        "    while start:\n",
        "        # Wait until next button is loaded completely\n",
        "        WebDriverWait(driver, 10).until(\n",
        "            EC.presence_of_element_located(\n",
        "                (\n",
        "                    By.XPATH,\n",
        "                '//*[@id=\"next\"]'\n",
        "                )\n",
        "            )\n",
        "        )\n",
        "\n",
        "        # Find the header element\n",
        "        header_element = driver.find_element(\n",
        "            By.XPATH,\n",
        "            '/html/body/div[2]/div/div/div[2]/div/div[1]/div/div/div[1]/div/div[3]'\n",
        "        )\n",
        "\n",
        "        # Get the outer HTML script for Beautiful Soup to parse\n",
        "        header_html = header_element.get_attribute(\n",
        "            'outerHTML'\n",
        "        )\n",
        "\n",
        "        # Parse the HTML content with BeautifulSoup\n",
        "        soup = BeautifulSoup(\n",
        "            header_html,\n",
        "            \"html.parser\"\n",
        "        )\n",
        "\n",
        "        # Find the component that details the page contents\n",
        "        # \"1 - 10 dari 28493 Data\" for example\n",
        "        div = soup.find(\n",
        "            'div',\n",
        "            attrs={\n",
        "                'class':\n",
        "                \"kt-inbox__pages paginggall\"\n",
        "            }\n",
        "        ).get_text(strip=True)\n",
        "\n",
        "        # Break the loop when web driver reaches the desired page\n",
        "        logging.info(div)\n",
        "        # Change the page detail below\n",
        "        if div == f'{page_start} - {page_start+9} dari {total_data} Data':\n",
        "            print(div)\n",
        "            print('Loop Break')\n",
        "            start = False\n",
        "            break\n",
        "\n",
        "        else:\n",
        "            # Search for header element\n",
        "            header = driver.find_element(\n",
        "                By.XPATH,\n",
        "                '/html/body/div[2]/div/div/div[2]/div/div[1]/div/div/div[1]/div'\n",
        "            )\n",
        "\n",
        "            # Scroll the element into view\n",
        "            driver.execute_script(\n",
        "                \"arguments[0].scrollIntoView();\",\n",
        "                header\n",
        "            )\n",
        "\n",
        "            # time.sleep(2)\n",
        "            # Click on the next page button\n",
        "            next_button = driver.find_element(\n",
        "                By.XPATH,\n",
        "                '//*[@id=\"next\"]'\n",
        "            )\n",
        "            ActionChains(driver).click(\n",
        "                on_element=next_button\n",
        "            ).perform()\n",
        "    # End loop\n",
        "\n",
        "\n",
        "# Start loop\n",
        "# When u>=0 and u<200\n",
        "# this means that it will only scrape 20 pages\n",
        "while 0 < page_start < 201:\n",
        "\n",
        "    print(\"Start of New Loop\")\n",
        "    # time.sleep(5)\n",
        "\n",
        "    # Wait for the modal to be present\n",
        "    # and the list to be loaded\n",
        "    # logging.info('Waiting for the list to be loaded')\n",
        "    WebDriverWait(driver, 10).until(\n",
        "        EC.presence_of_element_located(\n",
        "            (\n",
        "                By.XPATH,\n",
        "             '//*[@id=\"detailobat\"]'\n",
        "            )\n",
        "        )\n",
        "    )\n",
        "    logging.info('Table loaded\\n')\n",
        "    logging.info('Start of Row 1')\n",
        "\n",
        "    # Find the list element\n",
        "    list_element = driver.find_element(\n",
        "        By.XPATH,\n",
        "        '//*[@id=\"inbox-list\"]'\n",
        "    )\n",
        "\n",
        "    # Get the HTML script of the list element\n",
        "    list_html = list_element.get_attribute(\n",
        "        'outerHTML'\n",
        "    )\n",
        "\n",
        "    # Parse the HTML content with BeautifulSoup\n",
        "    soup = BeautifulSoup(\n",
        "        list_html,\n",
        "        \"html.parser\"\n",
        "    )\n",
        "\n",
        "    # Find the list element in HTML\n",
        "    div = soup.find(\n",
        "        'div',\n",
        "        attrs={\n",
        "            'class':'kt-inbox__items',\n",
        "            'id':\"inbox-list\",\n",
        "            'data-type':\"inbox\",\n",
        "            'style':\n",
        "            \"margin-top: -0.8rem; z-index: 0;\"\n",
        "        }\n",
        "    )\n",
        "\n",
        "    # Index for the number of rows\n",
        "    i=1\n",
        "\n",
        "    # Start Loop\n",
        "    # Find all the rows within the list\n",
        "    for row in div.find_all(\n",
        "        'div',\n",
        "        attrs={\n",
        "            'class':\n",
        "            'kt-inbox__item kt-inbox__item--unread'\n",
        "        }):\n",
        "\n",
        "        time.sleep(2)\n",
        "\n",
        "        # Wait for the element to be present\n",
        "        WebDriverWait(driver, 10).until(\n",
        "            EC.presence_of_element_located(\n",
        "                (\n",
        "                    By.XPATH,\n",
        "                    f'/html/body/div[2]/div/div/div[2]/div/div[1]/div/div/div[2]/div/div[{i}]'\n",
        "                )\n",
        "            )\n",
        "        )\n",
        "        logging.info(\n",
        "            'Menu trigger element loaded'\n",
        "        )\n",
        "\n",
        "        # Find the element\n",
        "        time.sleep(2)\n",
        "        logging.info(\n",
        "            'Finding the menu trigger element'\n",
        "        )\n",
        "        menu_trigger = driver.find_element(\n",
        "            By.XPATH,\n",
        "            f'/html/body/div[2]/div/div/div[2]/div/div[1]/div/div/div[2]/div/div[{i}]'\n",
        "        )\n",
        "\n",
        "        # Scroll the element into view\n",
        "        logging.info(\n",
        "            'Scrolling the menu trigger element into view'\n",
        "        )\n",
        "        time.sleep(2)\n",
        "        action.move_to_element(\n",
        "            menu_trigger\n",
        "        ).perform()\n",
        "\n",
        "        # Click on the element\n",
        "        time.sleep(2)\n",
        "        logging.info(\n",
        "            'Clicking on the menu trigger element'\n",
        "        )\n",
        "        ActionChains(driver).click(\n",
        "            on_element=menu_trigger\n",
        "        ).perform()\n",
        "\n",
        "        # Wait for the menu popup to become visible\n",
        "        time.sleep(1)\n",
        "        logging.info(\n",
        "            'Waiting for the menu popup to become visible'\n",
        "        )\n",
        "        WebDriverWait(driver, 30).until(\n",
        "            EC.visibility_of_element_located(\n",
        "                (\n",
        "                    By.XPATH,\n",
        "                    '//*[@id=\"exampleModal2\"]'\n",
        "                )\n",
        "            )\n",
        "        )\n",
        "        logging.info('Menu popup is visible')\n",
        "\n",
        "        # Find the menu popup element\n",
        "        # time.sleep(1)\n",
        "        menu_popup = driver.find_element(\n",
        "            By.XPATH,\n",
        "            '//*[@id=\"exampleModal2\"]'\n",
        "        )\n",
        "\n",
        "        # Get the HTML content of the menu popup element\n",
        "        # time.sleep(1)\n",
        "        menu_html = menu_popup.get_attribute('outerHTML')\n",
        "\n",
        "        # Parse the HTML content with BeautifulSoup\n",
        "        # time.sleep(1)\n",
        "        soup = BeautifulSoup(menu_html, \"html.parser\")\n",
        "        div = soup.find(\n",
        "            'div',\n",
        "            attrs={\n",
        "                'class': 'modal fade show',\n",
        "                'id': \"exampleModal2\"\n",
        "            }\n",
        "        )\n",
        "\n",
        "        # Extract the row\n",
        "        time.sleep(1)\n",
        "        row_data = []\n",
        "\n",
        "        # Start Loop\n",
        "        for idx, cols in enumerate(\n",
        "            div.find_all(\n",
        "                'td',\n",
        "                attrs={\n",
        "                    'class':\n",
        "                    'form-field-input'\n",
        "                })):\n",
        "\n",
        "            if idx<13:\n",
        "                selected_column = cols.find(\n",
        "                    'span',\n",
        "                    attrs={\n",
        "                        'class':\n",
        "                        'stepper-number label label-primary label-inline mr-2 font-weight-bold'\n",
        "                    }\n",
        "                ).get_text(strip=True)\n",
        "                row_data.append(selected_column)\n",
        "        # End Loop\n",
        "\n",
        "        # time.sleep(5)\n",
        "        logging.info('Finished Extraction')\n",
        "        # print(row_data)\n",
        "\n",
        "        # Create temporary dataframe for the row data\n",
        "        row_df = pd.DataFrame(\n",
        "            [row_data],\n",
        "            columns=df.columns\n",
        "        )\n",
        "        print(row_df)\n",
        "\n",
        "        # Concatenate row df to encompassing df\n",
        "        df = pd.concat(\n",
        "            [df, row_df],\n",
        "            ignore_index=True, sort=False\n",
        "            )\n",
        "\n",
        "        # Find close button element\n",
        "        # time.sleep(1)\n",
        "        logging.info(\n",
        "            'Finding the menu close element'\n",
        "        )\n",
        "        close = driver.find_element(\n",
        "            By.XPATH,\n",
        "            '/html/body/div[2]/div/div/div[2]/div/div[3]/div/div/div[3]/button'\n",
        "        )\n",
        "        logging.info(\n",
        "            'Clicking on the menu close element'\n",
        "        )\n",
        "        ActionChains(driver).click(\n",
        "            on_element=close\n",
        "        ).perform()\n",
        "\n",
        "        # Wait for menu popup to close\n",
        "        # time.sleep(1)\n",
        "        WebDriverWait(driver, 30).until(\n",
        "            EC.presence_of_element_located(\n",
        "                (\n",
        "                    By.XPATH,\n",
        "                    '//*[@id=\"inbox-list\"]/div[1]'\n",
        "                )\n",
        "            )\n",
        "        )\n",
        "        logging.info('Menu popup closed')\n",
        "        logging.info(f'End of row {i}\\n')\n",
        "        # time.sleep(5)\n",
        "\n",
        "\n",
        "        i+=1\n",
        "\n",
        "\n",
        "        if i == 4:\n",
        "            # Scroll the element into view\n",
        "            # time.sleep(1)\n",
        "            logging.info(\n",
        "                'Scrolling the menu trigger element into view'\n",
        "            )\n",
        "            driver.execute_script(\n",
        "                \"arguments[0].scrollIntoView();\",\n",
        "                menu_trigger\n",
        "            )\n",
        "\n",
        "\n",
        "        elif i == 8:\n",
        "            # time.sleep(1)\n",
        "            # Scroll the element into view\n",
        "            logging.info(\n",
        "                'Scrolling the menu trigger element into view'\n",
        "            )\n",
        "            driver.execute_script(\n",
        "                \"arguments[0].scrollIntoView();\",\n",
        "                menu_trigger\n",
        "            )\n",
        "\n",
        "\n",
        "        elif i == 11:\n",
        "            # time.sleep(1)\n",
        "            logging.info(f'End of Page {u}\\n')\n",
        "            reenter_loop = False\n",
        "            print('Exiting Loop')\n",
        "            i = 1\n",
        "            break\n",
        "    # End Loop\n",
        "\n",
        "    # Search for header element\n",
        "    header = driver.find_element(\n",
        "        By.XPATH,\n",
        "        '/html/body/div[2]/div/div/div[2]/div/div[1]/div/div/div[1]/div'\n",
        "    )\n",
        "    logging.info('Found the header element')\n",
        "\n",
        "    # Scroll the element into view\n",
        "    logging.info(\n",
        "        'Scrolling the header element into view'\n",
        "    )\n",
        "    driver.execute_script(\n",
        "        \"arguments[0].scrollIntoView();\",\n",
        "        header\n",
        "    )\n",
        "\n",
        "    time.sleep(3)\n",
        "\n",
        "    # Click on the next page button\n",
        "    next_button = driver.find_element(\n",
        "        By.XPATH, '//*[@id=\"next\"]'\n",
        "    )\n",
        "    logging.info(\n",
        "        'Found the next page button'\n",
        "    )\n",
        "    ActionChains(driver).click(\n",
        "        on_element=next_button\n",
        "    ).perform()\n",
        "    logging.info(\n",
        "        'Clicked on the next page button\\n'\n",
        "    )\n",
        "\n",
        "\n",
        "    # Parse the HTML content with BeautifulSoup\n",
        "    soup = BeautifulSoup(header_html, \"html.parser\")\n",
        "    div = soup.find(\n",
        "        'div',\n",
        "        attrs={'class':\"kt-inbox__pages paginggall\"}\n",
        "    ).get_text(strip=True)\n",
        "\n",
        "    page_start+=1\n",
        "    logging.info(f'Start of Page {u}\\n')\n",
        "    # End Loop\n",
        "# End Loop\n",
        "\n",
        "# Add regs admin and country column\n",
        "df.insert(0, 'Regulatory Admin', 'BPOM')\n",
        "df.insert(1, 'Country Name', 'Indonesia')\n",
        "df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "# Save to csv\n",
        "df.to_csv('bpom_1.csv')\n",
        "\n",
        "# Close the WebDriver\n",
        "# logging.info('Closing the WebDriver')\n",
        "# driver.quit()\n",
        "df.head()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 408
        },
        "id": "dp7zinQUHTRz",
        "outputId": "56b3fc36-b3c9-4096-e0ef-769712dd0758"
      },
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "error",
          "ename": "NoSuchDriverException",
          "evalue": "Message: Unable to obtain driver for firefox; For documentation on this error, please visit: https://www.selenium.dev/documentation/webdriver/troubleshooting/errors/driver_location\n",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/selenium/webdriver/common/driver_finder.py\u001b[0m in \u001b[0;36m_binary_paths\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m     63\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mPath\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mpath\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mis_file\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 64\u001b[0;31m                     \u001b[0;32mraise\u001b[0m \u001b[0mValueError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34mf\"The path is not a valid file: {path}\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     65\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_paths\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m\"driver_path\"\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpath\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mValueError\u001b[0m: The path is not a valid file: C:/Users/Aiman/geckodriver-v0.35.0-win64/geckodriver.exe",
            "\nThe above exception was the direct cause of the following exception:\n",
            "\u001b[0;31mNoSuchDriverException\u001b[0m                     Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-3-7b7874fe85bc>\u001b[0m in \u001b[0;36m<cell line: 15>\u001b[0;34m()\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[0;31m# Set up the Selenium Web Driver\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     14\u001b[0m \u001b[0mlogging\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0minfo\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Setting up the WebDriver'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 15\u001b[0;31m \u001b[0mdriver\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mwebdriver\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mFirefox\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mservice\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mservice\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     16\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     17\u001b[0m \u001b[0;31m# Open the website in browser\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/selenium/webdriver/firefox/webdriver.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, options, service, keep_alive)\u001b[0m\n\u001b[1;32m     55\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     56\u001b[0m         \u001b[0mfinder\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mDriverFinder\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mservice\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0moptions\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 57\u001b[0;31m         \u001b[0;32mif\u001b[0m \u001b[0mfinder\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_browser_path\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     58\u001b[0m             \u001b[0moptions\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbinary_location\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mfinder\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_browser_path\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     59\u001b[0m             \u001b[0moptions\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbrowser_version\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/selenium/webdriver/common/driver_finder.py\u001b[0m in \u001b[0;36mget_browser_path\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m     45\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     46\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mget_browser_path\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m->\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 47\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_binary_paths\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m\"browser_path\"\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     48\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     49\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mget_driver_path\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m->\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/selenium/webdriver/common/driver_finder.py\u001b[0m in \u001b[0;36m_binary_paths\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m     76\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mException\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     77\u001b[0m             \u001b[0mmsg\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34mf\"Unable to obtain driver for {browser}\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 78\u001b[0;31m             \u001b[0;32mraise\u001b[0m \u001b[0mNoSuchDriverException\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmsg\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfrom\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     79\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_paths\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     80\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mNoSuchDriverException\u001b[0m: Message: Unable to obtain driver for firefox; For documentation on this error, please visit: https://www.selenium.dev/documentation/webdriver/troubleshooting/errors/driver_location\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **PH FDA**"
      ],
      "metadata": {
        "id": "GB3ySdvKT764"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import requests\n",
        "from bs4 import BeautifulSoup\n",
        "import pandas as pd\n",
        "\n",
        "# initialize index\n",
        "i=1\n",
        "\n",
        "# initialize URL path\n",
        "URL = \"https://verification.fda.gov.ph/drug_productslist.php?start=\"+str(i)\n",
        "# URL = 'https://verification.fda.gov.ph/DRUGS_NEW_APPLICATIONSlist.php?start='+str(i)\n",
        "print(URL)\n",
        "\n",
        "# Define user-agent for beautiful soup\n",
        "headers = {'User-Agent' : \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/42.0.2311.135 Safari/537.36 Edge/12.246\"}\n",
        "\n",
        "# Define dataframe\n",
        "df = pd.DataFrame(\n",
        "    columns=[\n",
        "        'Registration Number',\n",
        "        'Generic Name',\n",
        "        'Brand Name',\n",
        "        'Dosage Strength',\n",
        "        'Dosage Form',\n",
        "        'Pharmaceutical Category',\n",
        "        'Manufacturer',\n",
        "        'Country of Origin',\n",
        "        'Application Type',\n",
        "        'Issuance Date',\n",
        "        'Expiry Date',\n",
        "        ]\n",
        "    )\n",
        "\n",
        "# Array to save list of dataframes\n",
        "output_list = []\n",
        "\n",
        "# initialize row count for debugging\n",
        "row_count = 0\n",
        "\n",
        "\n",
        "while i <= 32881:\n",
        "    # Load the website and get response\n",
        "    r = requests.get(url=URL, headers=headers)\n",
        "\n",
        "    # Initialize soup\n",
        "    soup = BeautifulSoup(r.content, \"html.parser\")\n",
        "\n",
        "    # Find the table to scrape\n",
        "    table = soup.find(\n",
        "        'table',\n",
        "        attrs ={'class':'table ew-table'}\n",
        "    )\n",
        "\n",
        "    # Start loop\n",
        "    # For every row in the table\n",
        "    for row in table.tbody.find_all('tr'):\n",
        "\n",
        "        # Find all data for each column\n",
        "        columns = row.find_all('td')\n",
        "\n",
        "        # Ensure the row has the expected number of columns\n",
        "        if len(columns) != []:\n",
        "\n",
        "            # Scrape the data based on the columns\n",
        "            noReg = columns[2].get_text(strip=True)\n",
        "            generic = columns[3].get_text(strip=True)\n",
        "            brand = columns[4].get_text(strip=True)\n",
        "            dosageStrength = columns[5].get_text(strip=True)\n",
        "            dosageForm = columns[6].get_text(strip=True)\n",
        "            category = columns[7].get_text(strip=True)\n",
        "            manufacturer = columns[8].get_text(strip=True)\n",
        "            country = columns[9].get_text(strip=True)\n",
        "            appType = columns[10].get_text(strip=True)\n",
        "            dateIssued = columns[11].get_text(strip=True)\n",
        "            dateExpire = columns[12].get_text(strip=True)\n",
        "\n",
        "\n",
        "            # Create a temporary DataFrame for the current row\n",
        "            temp_df = pd.DataFrame(\n",
        "                {\n",
        "                    'Registration Number': [noReg],\n",
        "                    'Generic Name': [generic],\n",
        "                    'Brand Name': [brand],\n",
        "                    'Dosage Strength': [dosageStrength],\n",
        "                    'Dosage Form': [dosageForm],\n",
        "                    'Pharmaceutical Category': [category],\n",
        "                    'Manufacturer': [manufacturer],\n",
        "                    'Country of Origin': [country],\n",
        "                    'Application Type': [appType],\n",
        "                    'Issuance Date': [dateIssued],\n",
        "                    'Expiry Date': [dateExpire]\n",
        "                }\n",
        "            )\n",
        "\n",
        "            # Concatenate the temporary DataFrame with\n",
        "            # the main DataFrame\n",
        "            df = pd.concat([df, temp_df], ignore_index=True)\n",
        "\n",
        "            # Log the row data for debugging\n",
        "            print(f\"Row {row_count}: {temp_df}\")\n",
        "            row_count += 1\n",
        "            print(URL)\n",
        "\n",
        "    # End loop\n",
        "\n",
        "    # Add 20 increment to url\n",
        "    i+=20\n",
        "    URL = \"https://verification.fda.gov.ph/drug_productslist.php?start=\"+str(i)\n",
        "\n",
        "\n",
        "# print(df.head())\n",
        "# print(df.info())\n",
        "\n",
        "# Remove duplcates from df\n",
        "df.drop_duplicates()\n",
        "\n",
        "# Copy df and read df for merging\n",
        "df1 = df.copy()\n",
        "df2 = pd.read_csv('drug_products.csv')\n",
        "\n",
        "# print(df1.head())\n",
        "# print(df2.head())\n",
        "\n",
        "# Merge the two df\n",
        "merged_df = pd.concat([df1, df2], ignore_index=True)\n",
        "# print(merged_df.info())\n",
        "\n",
        "# Key column for row merging\n",
        "column_merge = ['Registration Number']\n",
        "\n",
        "# Function for row merging\n",
        "def merge_rows(group):\n",
        "    merged = group.ffill().bfill().iloc[0]\n",
        "    return merged.infer_objects(copy=False)\n",
        "\n",
        "# Apply the function\n",
        "result_df = merged_df.groupby(column_merge).apply(merge_rows).reset_index(drop=True)\n",
        "# print(result_df.info())\n",
        "\n",
        "# Filter df for only appropriate data\n",
        "result_df = result_df[[\n",
        "    'Registration Number',\n",
        "    'Generic Name',\n",
        "    'Brand Name',\n",
        "    'Dosage Strength',\n",
        "    'Dosage Form',\n",
        "    'Pharmaceutical Category',\n",
        "    'Manufacturer',\n",
        "    'Country of Origin',\n",
        "    'Application Type',\n",
        "    'Classification',\n",
        "    'Packaging',\n",
        "    'Trader',\n",
        "    'Importer',\n",
        "    'Distributor',\n",
        "    'Issuance Date',\n",
        "    'Expiry Date'\n",
        "]]\n",
        "\n",
        "# Add regs admin and country column\n",
        "result_df.insert(0, 'Regulatory Admin', 'PH FDA')\n",
        "result_df.insert(1, 'Country Name', 'Philippines')\n",
        "result_df['Region'] = 'South East Asia (SEA)'\n",
        "\n",
        "# Save to CSV\n",
        "result_df.to_csv('ph_merge.csv', index=False)\n",
        "# result_df.to_csv('ph_new.csv', index=False)\n"
      ],
      "metadata": {
        "id": "nJKuhPrPWKri"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "4MxOjvm-ZTjX"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}